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Decidualisation of the endometrium is essential for successful implantation and pregnancy. 
Central to this is the progesterone-driven differentiation of human endometrial stromal cells 
(hESC) to secretory decidual cells which is dependent on the up-regulation of the Forkhead 
box O1 (FOXO1) transcription factor. Vascular endothelial growth factor-A (VEGF) is 
essential for vascular remodelling in the endometrium and perturbation of VEGF activity 
can lead to infertility, recurrent miscarriage and preeclampsia. However, little is known 
about the factors that regulate VEGF activity during ESC decidualisation. To investigate 
this, primary hESC and the St-T1b cell line were differentiated in vitro to decidual cells, 
confirmed by the up-regulation of decidual markers including FOXO1. VEGF mRNA and 
protein production was strongly induced with decidualisation leading to increased 
angiogenic activity. Interestingly, secretion of soluble Flt-1 receptor (sFlt-1), the 
physiological inhibitor of VEGF, decreased significantly upon hESC decidualisation. FOXO 
knock-down or over-expression in hESC showed that FOXO1 up-regulates VEGF, whilst 
FOXO3A inhibits its expression. FOXO1 increased VEGF promoter activity and in 
chromatin immunoprecipitation assays bound directly to three sites identified in the VEGF 
gene promoter in decidual hESC. In contrast, FOXO3A bound the same regions in the VEGF 
promoter in proliferative and decidual hESC. The Flt-1 receptor was detected on the surface 
of hESC and maintained during decidualisation. VEGF induced Akt and MAPK kinase 
signalling and promoted hESC migration and invasion. Collectively, these findings 
demonstrate that the increased VEGF activity of decidual hESC is a result of FOXO1-driven 
VEGF expression and concomitant decrease in sFlt-1 secretion. They also highlight an 
antagonist relationship between FOXO1 and FOXO3A in the control of VEGF expression 
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1.1 Introduction 
Pregnancy is a complex process that requires decidualisation of the maternal endometrium, 
blastocyst implantation, and placentation (Okada et al., 2017). The endometrium is the most 
crucial determinant of successful embryo implantation (Gellersen & Brosens, 2014). 
Decidualisation is one of the most critical events occurring within the human endometrium 
throughout the pregnancy. Failure of this process results in infertility (Lee et al., 2007). 
Whereas, impairment of decidualisation alters embryo-maternal interactions, which may 
lead to recurrent pregnancy loss, preeclampsia, and poor embryo selection (Salker et al., 
2010; Macklon & Brosens, 2014). Although many anatomical, endocrine, immunological, 
and genetic perturbations have been associated with pregnancy complications like recurrent 
miscarriage, none of these are specific to the condition. The limitation of IVF is largely due 
to the endometrial function and receptivity which lead to lower implantation rates (Shapiro 
et al., 2011; Penzias, 2012). An improved understanding of normal endometrial-receptivity 
and the molecular mechanisms involved should enhance embryo implantation and therefore 
increase pregnancy to successful delivery rates (Aplin, 2006). It may also lead to a greater 
understanding of other pathologies of pregnancy like recurrent miscarriage, early pregnancy 
loss, preeclampsia, intrauterine growth restriction (IUGR), preterm birth and ectopic 
pregnancy (Venners et al., 2004; Brosens et al., 2011).  
Menstrual pre-conditioning and the repeated inflammatory activities associated with each 
cycle may be crucial to sensitize the endometrium to environmental signals and coordinate 
a specific spatial-temporal decidual response (Brosens et al., 2009). Understanding the 
regulation of gene expression during decidualisation as well as their specific function is 
important to overcome various pregnancy complications. Vascular endothelial growth factor 
A (VEGF) is a potent stimulator of vascular remodelling of the maternal blood supply to 
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support the conceptus, but the precise role(s) of VEGF on the route to successful pregnancy 
is still unknown.  
 
1.2 The endometrium and the menstrual cycle 
1.2.1 The human endometrium 
The human uterus consists of three layers: the outer perimetrial layer which is composed of 
epithelial cells covering the uterus; the middle myometrial muscular layer which contains a 
highly organised network of arteries and veins; and the inner endometrial layer (Figure 1.1). 
The endometrial lining of the uterus is a unique and dynamic multi-layered tissue consisting 
of functional and basal layers overlaying the myometrium (Johnson and Everitt, 2007) 
(Figure 1.1). The endometrium is composed of a single layer of luminal epithelium which 
overlies a network of connective tissue and a multicellular stromal compartment (Gilbert, 
2010). The endometrial blood supply enters via the arteries arising from the myometrium, 
which then split to form basal arteries and spiral arterioles to supply the functional and basal 
layers (Rogers, 1996) (Figure 1.1). A new functional layer regenerates each month from the 
permanent basal layer and is shed during menstruation if implantation does not occur. 
Studies have identified epithelial progenitor cells (Chan et al., 2004; Verdi et al., 2014) and 
mesenchymal stem cells in the human endometrium, which are thought to play a role in the 
regeneration and maintenance of the endometrium (Masuda et al., 2010).  
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1.2.2 Cyclical changes of the endometrium 
The endometrium undergoes phases of proliferation, differentiation, tissue degeneration and 
regeneration with an average full cycle spanning 28 days under the control of ovarian steroid 
hormones (Gellersen and Brosens, 2014). The ovaries undergo a monthly cycle concurrent 
with the endometrial cycle to coordinate the release an oocyte with the preparation of the 
endometrium for implantation of an embryo. The ovarian cycle consists of the follicular and 
luteal phases. During the follicular phase, follicular granulosa cells produce a large amount 
of oestrogen initiated by the stimulation of follicle stimulating hormone (FSH), reaching a 
peak of circulating oestrogen prior to ovulation which induces positive feedback to trigger 
Figure 1.1: The structure of the human endometrium. The functional layer is composed 
of endometrial luminal and glandular epithelium and stromal cells receiving a blood supply from the 
spiral arterioles. The basal layer contains stem and progenitor cells which are important for 
regeneration of the functional layer during the menstrual cycle (adapted from 
https://www.grepmed.com/images/2497).  
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the luteinizing hormone (LH) surge and ovulation (Johnson and Everitt, 2007). During the 
luteal phase (day 14-28), the corpus luteum forms and becomes highly vascularised and 
begins to secrete high levels of progesterone. If pregnancy occurs, human chorionic 
gonadotrophin (hCG) secreted by the syncytiotrophoblast of an implanting blastocyst 
maintains the corpus luteum. Otherwise, the corpus luteum degenerates at the end of luteal 
phase leading to a decline in both oestrogen and progesterone levels (Critchley and Saunders, 
2009) (Figure 1.2). The length of the menstrual cycle is variable ranging from 26 to 34 days 
(Mihm et al., 2011) and a typical woman has more than 400 cycles during their reproductive 
life. 
During days 1-5 of the menstrual cycle, the endometrium breaks down and is sloughed off 
in menses. During the proliferative phase (days 5-13) under the influence of oestrogen, there 
is growth of the endometrial functional layer through rapid epithelial and stromal cell 
proliferation. The secretory phase (days 15-28) begins following the onset of progesterone 
production from corpus luteum. During the mid-secretory phase (days 20-23), the 
endometrium becomes receptive (Figure 1.2). With the rising levels of progesterone, the 
endometrium stops proliferating and the endometrial stromal cells (ESC) undergo 
differentiation, via a process called decidualisation (Gellersen and Brosens, 2014; Gellersen 
et al., 2007) (Figure 1.2).  
The process of decidualisation is marked by the transformation of elongated spindle-like 
stromal cells into rounded, enlarged epithelial-like decidual cells (Wynn, 1974; Gellersen et 
al., 2007). Decidualisation begins around day six post-ovulation in the humans, independent 
of the presence of a blastocyst (de Ziegler et al., 1998, Gellersen and Brosens, 2014) which 
is at the onset of the window of implantation (Figure 1.2). Decidualisation in the human is 
very pronounced and includes changes in all compartments of the uterus such as junctional 
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zone monocytes, local immune cells, spiral arteries, epithelial and major changes in the 
stromal compartment (Gellersen et al., 2007). 
 
Figure 1.2: Hormone levels through the menstrual cycle.  A series of degenerative and 
regenerative endometrial changes occur on a monthly basis in response to the influence of ovarian 
hormones. Following ovulation (day 14), progesterone is produced by the newly formed corpus 
luteum. In the absence of pregnancy, the corpus luteum breaks leading to withdrawal of ovarian 
hormones resulting in menstruation. The cyclical changes involve transformation of the endometrium 
into a state where it is most receptive to embryo implantation termed the ‘window of implantation’ 
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1.3 Decidualisation of human endometrial stromal cells 
Decidualisation of human endometrial stromal cells (hESC) is an example of mesenchymal-
to-epithelial transition (MET). The interconversion between epithelial and mesenchymal 
phenotype through MET and the epithelial-mesenchymal transition (EMT) processes is 
essential for embryogenesis and wound healing during differentiation (Micalizzi et al., 2010; 
Choi and Diehl, 2009). Undifferentiated hESC are mesenchymal cells with an elongated 
spindle-shaped fibroblastic appearance (Gellersen & Brosens, 2003; Gellersen et al., 2007). 
Decidualised hESC are characterised by a marked cell enlargement, rounded nucleus with 
an increase of nucleoli, expansion of the secretory machinery consisting rough endoplasmic 
reticulum and the Golgi complex, and cytoplasmic accumulation of glycogen and lipid 
droplets (Oliver et al., 1999; Christian et al., 2002). This transformation is accompanied by 
profound biochemical changes. Microarray studies have reported that decidualisation 
involves sequential reprogramming of functionally related genes involved in extracellular 
matrix organisation, metabolism, stress response, cell cycle progression, differentiation and 
apoptosis (Figure 1.3) (Giudice, 2004). Therefore, through decidualisation, hESC acquire 
new biochemical functions that are critical for embryo implantation and successful 
pregnancy. Upon decidualisation, hESC acquire a secretory phenotype releasing various 
cytokines, growth factors and proteins that are important for maintaining the decidual 
phenotype and regulating trophoblast invasion and placental formation (Giudice, 2004). 
Decidual prolactin (dPRL) and insulin-like growth factor binding protein-1 (IGFBP-1) are 
the most commonly used markers of decidualisation (Gellersen et al., 2007; Oliver et al., 
1999; Tseng et al., 1992). 




1.3.1 The importance of hESC decidualisation in embryo implantation 
Pregnancy relies upon dynamic cross-talk between the embryo and receptive endometrium. 
In order for successful implantation to occur the endometrium has to undergo changes which 
optimise the environment to receive and support the developing blastocyst (Hannan et al., 
2010; Lee and DeMayo, 2004; Dey et al., 2004). The implantation process can be divided 
Figure 1.3: Functions of decidualised hESC. Decidualised hESC acquire a secretory 
phenotype and become specialised epithelioid cells that regulate various biological functions for 
successful pregnancy: (A) Blastocyst/ embryo invasion; (B) Selection of high-quality embryos; (C) 
Immune responses to protect the fetal-maternal interface; (D) Angiogenesis and vascular 
remodelling of endometrial spiral arteries to support the growing conceptus; (E) Increased 
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into three main steps: apposition, attachment and invasion (Figure 1.4) (Lee et al., 2011; 
Norwitz et al., 2001). There are many factors that can lead to implantation failure such as 
uterine abnormalities, hormonal disorders, immunological factors and infections (Timeva et 
al., 2014). Recently, changes in the levels of autocrine and paracrine factors during the 
menstrual cycle have been identified as critical to uterine function (Dimitriadis et al., 2010; 
Singh et al., 2011; Okada et al., 2014). 
 
 
1.3.1.1 The window of implantation 
It is now well-established that endometrial receptivity is a vital part of successful 
implantation. The receptive period is known as the ‘window of implantation’ and usually 
occurs at around day 20-23 of the menstrual cycle, coinciding with the mid-secretory phase 
(Figure 1.2) (Harper, 1992; Achache and Revel, 2006). Deficiencies of endometrial 
receptivity or the failure of a blastocyst to attach to the endometrium at the right time can 
cause infertility and there is a strong correlation between implantation occurring beyond the 
Figure 1.4: Human embryo implantation. The embryo enters the uterus approximately 4 
days after fertilisation as a morula. Apposition begins when the blastocyst hatches from the zona 
pellucida and associates with the endometrial epithelial layer to form an unstable adhesion. This is 
followed by the firm attachment of blastocyst to the endometrium. Invasion occurs when the embryo 
invades through the luminal epithelium (LE) and basal lamina deeper into the stroma of uterine lining 
to reach maternal blood vessels (adapted from Greening et al., 2016). 
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normal receptivity period and early pregnancy loss (Wilcox et al., 1999). Many studies have 
attempted to find the useful biomarkers which signify endometrial receptivity including 
histological dating, immunohistochemistry, and microarray analysis, several genes have 
been found but the number of common genes that were identified was minimal (Haouzi et 
al., 2012; Sugawara et al., 2014). However, it was shown that local factors produced during 
the receptive period including cytokines, growth factors and transcription factors serve to 
specify endometrial receptivity. 
 
1.3.1.2 Embryo invasion 
As discussed earlier, embryo implantation involves embryo apposition and attachment to the 
endometrial surface, breaching of the luminal epithelium and invasion into the ESC (Loke 
et al., 1995). Understanding of this process in the human is somewhat limited as it is 
restricted to the use of animal models and in vitro co-culture systems for ethical and practical 
reasons. Decidualised hESC secrete a number of matrix metalloproteases (MMPs), 
transforming growth factor b (TGFb) on the trophoblast (Anacker et al., 2011), which are 
able to promote embryo invasion due to the chemoattractant ability of their secreted 
leukocytes (Salamonsen et al., 2007).  
 
1.3.1.3 Embryo selection  
It has been reported that secretion of cytokines, chemokines and growth factors from the 
supernatants of decidualised hESC co-cultured with blastocysts are different if the blastocyst 
displays signs of developmental arrest and inhibition of interleukins and growth factors 
(Teklenburg et al., 2010). A few studies have reported that decidual hESC can act as 
biosensors in recognising compromised embryos and prevent their implantation (Salker et 
al., 2010; Teklenburg et al., 2010). Decidualised hESC have been shown to migrate more in 
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the presence of high-quality embryos compared to low-quality embryos using the time-lapse 
microscopy (Gonzalez et al., 2011; Weimar et al., 2012). However, a mechanism of how 




Pregnancy is an inflammatory-related process which requires complex immunoregulation to 
prevent the fetal antigens being recognised by cytotoxic T-cells and to protect the fetal-
maternal interface (Cloke et al., 2010). During decidualisation, an influx of innate immune 
cells (uNK) takes place to tolerate the semi-allogenic embryo and these cells also regulate 
trophoblast invasion and vascular remodelling through the expression of angiogenic factors, 
endothelial cell mitogens and chemokines (Koopman et al., 2003; Ledee et al., 2008). 
Decidualised ESC also modulate the immune responses at the fetal-maternal interface. 
Decidual cells play a critical role to ensure sufficient balance of specialised macrophages 
and uNK to prevent the priming of maternal T cells to paternal anti-allogens (Hanna et al., 
2006; Lash et al., 2006). The importance of uNK cells in angiogenesis has also been 
highlighted by studies in mice lacking uNK cells which show impaired angiogenesis 
(Greenwood et al., 2000) and develop conditions such as preeclampsia and fetal growth 
restriction (Zhang et al., 2011). 
 
1.3.1.5 Oxidative stress responses 
During early pregnancy, there is vascular remodelling and as a consequence oxygen 
concentrations fluctuate profoundly at the fetal-maternal interface (Burton et al., 1999; 
Brosens et al., 2009). Due to these changes and inflammatory responses, reactive oxygen 
species (ROS) including hydroxy radicals, superoxide anions and hydrogen peroxide are 
produced. ROS, when not attenuated by antioxidative defences, cause nucleic acid and 
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protein damage and subsequent cell death (Valko et al., 2007). Decidualised hESC acquire 
resistance to oxidative cell death by producing ROS scavengers such as superoxide 
dismutase 2 (SOD2), which is up-regulated by the forkhead box protein O1 (FOXO1) 
transcription factor (Takano et al., 2007). In contrast, ROS are reported to up-regulate 
forkhead box protein O3A (FOXO3A) in undifferentiated cells which triggers apoptosis 
under oxidative stress (Kajihara et al., 2006). Silencing of FOXO3A in ESC can prevent 
apoptosis (Kajihara et al., 2006). Therefore, ESC only adopt pro-survival behaviour upon 
decidualisation. 
 
1.4 Use of hESC in vitro to model decidualisation and its ethical limitations 
A failure or impairment of decidualisation can result in infertility or altered embryo-maternal 
interactions which can cause poor embryo selection, recurrent pregnancy loss and 
preeclampsia (Salker et al., 2010; Macklon & Brosens, 2014). Determining the regulation 
and roles of differentially expressed genes during decidualisation may be important to 
overcome these conditions. Human ESC (hESC) obtained from endometrial biopsies or after 
hysterectomy for gynaecology disorders are used widely to study decidualisation (Gellersen 
and Brosens, 2003). However, ethical restrictions and the limited proliferation of primary 
hESC in vitro has led to the establishment of various immortalised hESC lines through 
retroviral transduction of telomerase (Krikun et al., 2004; Samalecos et al., 2009; Yuhki et 
al., 2011) or SV40 large T antigen (Chapdelaine et al., 2006) which provide good models 
for decidualisation (Samalecos et al., 2009). Moreover, using hESC in vitro has greatly 
advanced our understanding of implantation. Mouse models have also been widely utilised 
to investigate the process of decidualisation in vivo. Non-primate mammals have an oestrus 
cycle and, in the species, decidualisation of the endometrium only occurs following a signal 
from an implanting blastocyst. Despite this, the regulation of murine uterine function is 
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sufficiently similar to the human to allow some relevant information to be gained from 
mouse models (Paria et al., 2002).  
 
1.5 Clinical perspective: Disorders associated with impaired decidualisation 
Humans are a relatively sub-fertile species compared to other mammals with a 20% average 
monthly fertility rate (Evers, 2002; Gnoth et al., 2005). Assisted reproductive techniques 
(ART) have subsequently been used widely (Diedrich et al., 2007). However, despite the 
rapid improvement, the implantation rate is only 20-30% for in vitro fertilisation (IVF) (Scott 
et al, 2013; Schoolcraft and Katz-Jaffe, 2013; Shapiro et al, 2011). Successful implantation 
requires a receptive endometrium and a viable embryo. Failure of decidualisation results in 
infertility (Gellersen and Brosens, 2014), whereas, impairment of decidualisation alters 
embryo-maternal interactions. This can cause recurrent pregnancy loss, preeclampsia, and 
diminished embryo selection (Salker et al., 2010; Macklon and Brosens, 2014). In order to 
improve pregnancy rates and prevent miscarriage, researchers have been focused on gaining 
a clearer understanding of the mechanisms involved during the dynamic process of ESC 
decidualisation and implantation.  
 
1.5.1 Endometriosis 
Endometriosis is a female reproductive disorder that results from abnormal extra-uterine 
growth of endometrial tissue mainly the outer surface of the ovaries, or Fallopian tubes. The 
cause of endometriosis is still unknown and as yet there is no cure for this disorder. It is 
associated with serious pelvic pain, heavy menstrual periods and 35-50% of infertile women 
are diagnosed with endometriosis (Macer and Taylor, 2012). Eutopic endometrium was 
found to be the underlying cause of infertility and has been shown to exhibit an impaired 
decidual response. Microarray studies have identified various genes involved in 
decidualisation and implantation that are aberrantly expressed in the endometrium of women 
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with endometriosis (Kao et al., 2003). In addition, the expression of decidualisation markers 
is also altered in endometriosis (Aghajanova et al., 2009; Aghajanova et al., 2010; Su et al., 
2015). Lower expression of dPRL and IGFBP-1 mRNA and IGFBP-1 secretion were 
observed in primary hESC isolated from women with endometriosis compared to cells from 
healthy women (Aghajanova et al., 2011). FOXO1 mRNA expression was reported to be 
significantly decreased in endometriosis compared to the healthy endometrium in the 
secretory phase (Shazand et al., 2004; Burney et al., 2007) which may be due to defective 
notch signalling (Su et al., 2015). 
HOXA10 expression was also found to be reduced in mid-secretory phase hESC from 
women with endometriosis compared to healthy women (Matsuzaki et al., 2009; Taylor et 
al., 1999). Taken together, these findings suggest that women with endometriosis show 
changes in the decidual response including the expression of PRL, IGFBP-1, FOXO1 and 
HOXA10 which may in part explain the increased infertility associated with this disorder. 
 
1.5.2 Recurrent miscarriage 
Recurrent miscarriage is a prevalent cause of reproductive failure. Although many 
anatomical, endocrine, immunological, and genetic perturbations have been implicated as 
causes of recurrent miscarriage, none are definitive (Saravelos et al., 2014). Several studies 
have reported that women with recurrent miscarriages show impaired decidualisation 
(Teklenburg et al., 2010; Salker et al., 2010). One study found that hESC from women with 
recurrent miscarriage failed to transition between a pro-inflammatory and anti-inflammatory 
decidual response (Salker et al., 2012). A large body of research has investigated 
endometrial defects including the interaction of fetal-maternal endometrial interface and 
how these lead to the recurrent miscarriage. Decidual cells act as biosensors of embryo 
viability by recognising, selecting and eliminating defective embryos (Teklenburg et al., 
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2010). Consistent with this hESC from recurrent miscarriage patients are also reported not 
to be able to distinguish between high or low-quality embryos (Weimar et al., 2012).  
 
1.5.3 Preeclampsia 
Preeclampsia is a severe pregnancy complication which affects ~8% of pregnancies 
worldwide (Winn et al., 2011; Fisher, 2015). This disorder is mainly characterised by 
hypertension, proteinuria and other signs of maternal vascular damage (Roberts and Cooper, 
2001). Currently, there is no cure for preeclampsia other than delivery of the placenta and 
consequently, the fetus which increases the rate of preterm births (Goldenberg et al., 2008; 
Duley, 2009). Despite decades of research, a full understanding of preeclampsia 
pathogenesis remains elusive due to the difficulties in the identification of predictive 
biomarkers for the development of targeted therapies. The pathogenesis of preeclampsia has 
been investigated in many studies which have shown that placenta plays a central role 
(Khong et al., 1986, Zhou et al., 1997). The endometrial contribution to the aetiology of 
preeclampsia has received little attention. Global transcriptional profiling of chorionic villus 
samples has demonstrated that defective decidualisation in pregnancies may lead to 
preeclampsia (Rabaglino et al., 2015). Furthermore, Garrido-Gomez et al. (2017) showed 
the failure of in vitro decidualisation in primary hESC isolated from women with previous 
preeclamptic pregnancies with 129 genes differentially expressed and the conditioned 
medium (CM) from decidual cells failing to promote trophoblast invasion. This study 
concluded that PRL and IGFBP-1 could be potential biomarkers for preeclampsia (Garrido-
Gomez et al., 2017). 
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1.5.4 Intrauterine Growth Restriction 
Intrauterine growth restriction (IUGR) is a common pregnancy complication that increases 
the risk for perinatal morbidity and mortality (Pallotto and Kilbride, 2006), diabetes and 
cardiovascular disease in later life (Gluckman et al., 2008). Placental insufficiency resulting 
in decreased fetal oxygen and nutrient availability is believed to be the most common cause 
of IUGR (Krishna and Bhalerao, 2011). Abnormal increase in utero-placental blood flow, as 
a result of inadequate trophoblast invasion into the maternal decidua, has been suggested to 
cause placental insufficiency leading to IUGR (Gagnon, 2003). However, the molecular 
mechanisms underlying the development of IUGR remain poorly understood. There are no 
clinically useful biomarkers for the early detection of IUGR, and currently no specific 
treatment is available for IUGR once diagnosed (Poljak et al., 2017). Insulin-like growth 
factor (IGF)-binding protein 1 (IGFBP-1) is the predominant IGFBP that determines IGF-1 
bioavailability during pregnancy (Hills et al., 1996). The decidua is also believed to be the 
primary source of IGFBP-1 in the maternal circulation during pregnancy, thereby regulating 
the bioavailability of maternal IGF-1, a positive regulator of placental function and growth 
(Sferruzzi-Perri et al., 2007). Human IUGR is associated with increased IGFBP-1 levels and 
IGFBP-1 hyperphosphorylation in umbilical cord plasma (Shehab et al., 2014). The decidua 
synthesizes and secretes IGFBP-1 locally in the maternal-fetal interface regulating the 
actions of IGF-1, which is known to promote trophoblast invasion and placental function 
(Lacey et al., 2002). A very recent study in hESC following decidualisation in vitro 
demonstrated that hypoxia and leucine deprivation markedly increased IGFBP-1 
phosphorylation and decreased IGF-1 bioavailability (Shehab et al., 2017). These findings 
are consistent with increased of IGFBP-1 phosphorylation in decidualised stromal 
mesenchymal cells in human IUGR (Singal et al., 2018), which possibility constitutes a link 
between decreased decidual oxygen and nutrient availability and reduced fetal growth due 
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to diminished IGF-1 bioavailability, leading to inhibition of trophoblast invasion and 
placental function. Therefore, maternal IGFBP-1 phosphorylation may constitute a sensitive 
early pregnancy biomarker for IUGR (Gupta et al., 2019).  
 
1.6 Decidualisation cues 
1.6.1 Endocrine cues 
Progesterone plays an essential role in gland development, ovulation, decidualisation, 
implantation, menstruation and maintenance of pregnancy (Brosens et al., 2009). Prior to 
ovulation, ESC are predominantly under the influence of oestrogen and mount the decidual 
response following the rise of progesterone levels. It is reported the morphological signs of 
decidualisation are not seen until nine days following ovulation, indicating that other factors 
are important to initiate this process (Gellersen and Brosens, 2003). Consistent with these 
findings, studies with primary hESC show that induction of decidual markers takes 7-10 
days of stimulation with progesterone analogues and can be accelerated by other factors for 
example, relaxin (Tseng et al., 1992; Telgmann et al., 1997). This indicates that 
progesterone, although is critical for the development and maintenance of the decidualised 
ESC, is not the primary initiating factor in ESC differentiation (Gellersen and Brosens, 
2014). 
 
1.6.2 Paracrine and autocrine signals 
A number of growth factors, cytokines, peptides and lipids are secreted following the onset 
of ESC decidualisation which further promote decidualisation. The heparin-binding 
epidermal growth factor (HB-EGF) is known to be up-regulated during the mid-secretory 
phase of the cycle and in hESC decidualisation in vitro (Lessey et al., 2002). It is reported 
that blockade of HB-EGF during decidualisation reduced decidual marker expression in 
hESC (Chobotova et al., 2005). Transforming growth factor-b1 (TGFβ1) inhibits the 
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expression of decidualisation markers such as dPRL, IGFBP-1 and tissue factor in isolated 
primary hESC (Kane et al., 2010). Activin A is a secretory, dimeric glycoprotein of the TGF 
family which is an early inducer of decidualisation through the up-regulation of MMPs and 
promotes angiogenesis, inflammation and trophoblast differentiation and adhesion (Jones et 
al., 2002 & 2006; Menkhorst et al., 2010; Rocha et al., 2012). 
Other paracrine factors involved in decidualisation are the interleukin family of cytokines, 
such as interleukin-11 (IL-11), which is a pro-inflammatory cytokine up-regulated during 
decidualisation (Dimitriadis et al., 2005).  IL-11 receptor knock-out mice are infertile due to 
a lack of sustained decidualisation resulting in implantation failure (van Mourik et al., 2009). 
Other interleukins include IL-1b which is important for complete decidualisation and 
embryo implantation (Strakova et al., 2005) and IL-6, which is mostly produced by 
endometrial epithelial and stromal cells during implantation and its expression reaches a 
peak during the secretory phase. Deficiency of IL-6 during decidualisation and placenta 
development causes recurrent miscarriage (van Mourik et al., 2009). Leukaemia inhibitor 
factor (LIF), a member of the IL-6 class of cytokines, is an important cytokine for 
endometrial epithelial cell function. Although it is unclear whether LIF is involved in hESC 
decidualisation, the LIF receptor is up-regulated in hESC and may be important in pregnancy 
(Shuya et al. 2011). 
 
1.6.3 Cyclic adenosine monophosphate signalling 
Activation of the cyclic adenosine monophosphate (cAMP) pathway is essential to initiate 
decidualisation (Gellersen & Brosens, 2003). Many pieces of evidence suggest that the 
decidual process is initiated by increased cAMP signalling and sustained activation of the 
protein kinase A (PKA) pathway (Gellersen & Brosens, 2003; Telgmann et al., 1997). 
Levels of cAMP increase following exposure of the endometrium to relaxin, prostaglandins, 
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corticotrophin releasing hormone (CRH) and pituitary gonadotropins following ovulation 
via activation of a-subunits ligands of G-protein coupled receptors (GPCRs) leading to the 
catalytic conversion of adenosine triphosphate (ATP) into cAMP by adenylate cyclase 
(Christian et al., 2002; Dimitriadis et al., 2005). Cyclic AMP predominantly activates the 
protein kinase A (PKA) by binding to its two regulatory subunits, causing a conformational 
change that leads to the release of two catalytic subunits to regulate several target proteins 
in cytoplasm and nucleus (Chen et al., 2008). Several studies show that elevated cAMP 
levels sensitise hESC to progesterone signalling. First, it is reported that higher levels of 
cAMP are detected in the endometrial tissues obtained from patients in the secretory phase 
than in the proliferative phase of the menstrual cycle (Tanaka et al., 1993). Second, basal 
and prostaglandin-stimulated adenylate cyclase activity is higher in the secretory phase than 
the proliferative phase (Tanaka et al., 1993). Finally, progesterone treatment of hESC in 
vitro increases intracellular cAMP levels (Brar et al., 1997). In addition, studies on the effect 
of cAMP or progesterone alone or in combination revealed that cAMP is a potent inducer of 
the decidual phenotype (Figure 1.5) (Tang et al., 1993; Gao et al., 1994; Brosens et al., 
1999; Reem et al., 1999).  
In the nucleus of hESC, the catalytic subunit of PKA activates a number of target proteins 
including the cAMP response element binding protein (CREB), cAMP response element 
modulating protein (CREM), signal transducer and activator of transcription 3 (STAT3), 
CCAAT-enhancer binding protein (C/EBPb) and FOXO1 (Christian et al., 2002; Gellersen 
and Brosens, 2003; Brosens and Gellersen, 2006; Gellersen et al., 2007). The maintenance 
of cAMP signalling during decidualisation is highlighted by the studies which demonstrate 
that inhibition of PKA prevents decidual gene expression in hESC (Brar et al., 1997; 
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Matsuoka et al., 2010). The siRNA-mediated knock-down of the exchange protein directly 
activated by cAMP (EPAC) also prevents decidualisation in hESC (Kusama et al., 2013).  
 
 
1.6.4 Progesterone signalling 
Progesterone acts primarily through activation of the progesterone receptor (PR). PR knock-
out in mice leads to diverse reproductive defects including changes in sexual behaviour and 
implantation (Rider, 2002; Lydon et al., 1995). There are two isoforms of PR, PR-A and PR-
B, as a result of alternative promoter usage and translation at two distinct start codons (Wen 
et al., 1994). Progesterone receptor expression is driven by oestrogen acting on the oestrogen 
receptor a (ERa) during the proliferation phase (Schultz et al., 2003). It is therefore essential 
when culturing hESC to have oestrogen present not only to promote growth but to ensure 
progesterone receptor expression is maintained. PR-A is known to be expressed in stromal 
cells throughout the menstrual cycle, whereas PR-B is expressed in the mid-proliferative 
phase (Mote et al., 1999). PR-A is the predominant PR in hESC (Brosens et al., 1999). On 
binding progesterone, PRs undergo a conformational change leading to phosphorylation, 
Figure 1.5: Initiation of decidual process is primarily dependent on cAMP. 
hESC treated with cAMP alone show marked induction of decidual marker PRL but fail to 
maintain the decidual phenotype. Treatment with medroxyprogesterone (MPA) alone induces 
PRL after 8 to 10 days of stimulation. The combination of cAMP and MPA has a synergistic 
effect on PRL production and maintenance of the decidual phenotype (adapted from Brosens et 
al., 1999). 
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dimerisation and binding to promoter and enhancer elements of specific target genes (Patel 
et al., 2015; Jones et al., 2006). PR is able to control the expression of various genes involved 
in decidualisation even if they lack a progesterone response element (PRE) by hijacking 
other transcription factors and binding to response elements indirectly (Maruyama and 
Yoshimura, 2008). 
 
1.6.5 cAMP and progesterone cross-talk 
The human endometrium is exposed to progesterone for 7-10 days before decidualisation is 
observed and only a few genes respond to short-term progesterone exposure; decidual 
protein induced by progesterone (Depp) and promelocytic leukaemia zinc finger protein 
(PLZF) (Watanabe et al., 2005). Depp is up-regulated within 30 min of progesterone 
treatment, however, its function still remains to be determined (Watanabe et al., 2005). PLZF 
is rapidly induced by progesterone and is indispensable for progesterone-dependent 
decidualisation (Kommagani et al., 2016).  
Treating stromal cells with both cAMP and progesterone in vitro enhances decidualisation 
(Samalecos et al., 2009). However, it has recently become apparent that progesterone does 
not trigger the decidual response but is required for maintenance of the decidual phenotype 
and cAMP, via activation of PKA pathway, is the initiating factor sensitising the stromal 
cells to progesterone signalling leading to the convergence of cAMP-PKA and progesterone 
pathways as shown in Figure 1.6. Firstly, cAMP signalling activates the expression of 
transcription factors such as STAT3, FOXO1, and C/EBPb (Christian et al., 2002; Mak et 
al., 2002) which have the ability to bind to the PR and facilitate PR modulation of gene 
transcription without the need for a PRE (Gellersen and Brosens, 2003). Second, 
progesterone-dependent hESC decidualisation occurs simultaneously with intracellular 
cAMP elevation and is blocked in the presence of PKA inhibitor (Brar et al., 1997). 
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Figure 1.6: Crosstalk between cAMP and progesterone signalling. The activation 
of G-protein coupled receptors (GPCRs) by ligands such as relaxin, prostaglandin and 
corticotrophin releasing hormone (CRH) increases cellular cAMP levels. Consequently, there is 
an accumulation of transcription factors within the nuclei of stromal cells which form a complex 
with the activated progesterone receptor PR-A, resulting in activation of a number of decidua-
specific genes such as prolactin (PRL). 
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1.6.6 Hormones, cytokines and growth factors that are associated with decidualisation 
No Abbreviation Protein Name Functions References 
(A) Hormones 
1 E2 Oestrogen Induces progesterone receptors Lydon et al., 
1995 
2 ER-α Oestrogen receptor-
a 
Mediates up-regulation of progesterone 
receptors, endometrial proliferation and 
differentiation 
Kurita et al., 
2001 
3 ER-β Oestrogen receptor-
b 
Up-regulates progesterone receptors; 
regulates vascular function  
Lecce at al., 
2001 
4 P4 Progesterone Inducing and maintaining complete 
decidualisation 
Kurita et al., 
2001 
5 PR-A Progesterone 
receptor A  
Predominant PR in decidualisation; 
represses transcriptional activity of PRB 




Auto-immune reaction to an 




7 FSH Follicle stimulating 
hormone 




8 LH Luteinizing 
Hormone 
Induces cAMP to initiate decidualisation Tang and 
Gurpide,1993 
    9 hCG Human chorionic 
gonadotropin 
Prevents degeneration of corpus luteum; 
variety functions in and outside of 
embryo-endometrium 
Licht et al., 
2001 
10 PTHLH Parathyroid 
hormone-like 
hormone 
Inhibits decidualisation and stimulates 





11 PGE2 Prostaglandin E2 Synergistic with E2/P4 to enhance 
differentiation and PRL expression 
Frank et al., 
1994 




(B)  Growth factors 
1 Activin A Activin A Trophoblast invasion, promotes 
decidualisation 
Jones et al., 
2002 
2 EGF Epidermal growth 
factor 
Mediates the actions of oestrogen and 
progesterone on the proliferation and 
differentiation in human endometrium 
Watson et al., 
1996 
3 VEGF Vascular 
endothelial growth 
factor 
Stimulates angiogenesis and 
vasculogenesis 
Sugino et al., 
2002 
4 TGFβ1 Transforming 
growth factor β1 
Pro-apoptotic effect via FasL/Fas system; 
inhibits decidualisation 
Chatzaki et al., 
2003 
5 Decorin Decorin Binds to TGFb to inhibit trophoblast 
invasion 
Xu et al., 2002 
6 BMP2 Bone 
morphogenetic 
protein 2 
Induces Wnt4 and mediates progesterone 
to induce decidualisation 
Li et al., 2007 





Activin A mediator; modulates 
menstruation, proliferation, implantation 
and decidualisation 
Mangioni et al., 
2005 
 (C)  Cytokines 
1 IL-1β Interleukin-1b Pro-inflammatory cytokine stimulates IL-
8 and IL-8; inhibits cAMP-mediated 
decidualisation  
Yoshino et al., 
2003b 
2 IL-8 Interleukin-8 Stimulates trophoblast secretion of 
progesterone to maintain embryo-
endometrium interaction and successful 
pregnancy 
Tsui et al., 2004 




4 IL-15 Interleukin-15 Modulates uNK and decidualisation Ashkar et al., 
2003; Godbole 
and Modi, 2010 
5 LIF Leukaemia 
inhibitory factor 
Enhances decidualisation and up-
regulates IL-6 and IL-15, essential for 
implantation and decidualisation  
Shuya et al., 
2011 
6 MMP2/3/9 Matrix 
Metallopeptidase 
2/3/9 
Connective tissue controlling, 




7 TIMP3 Tissue inhibitor 
metallopeptidase 3 
Inhibits MMP9 and regulates trophoblast 
invasion 
Vassilev et al., 
2005 
8 CBR-1 Cannabinoid 
receptor 1 
Inhibits human decidualisation and 
encourages apoptosis by a cAMP-
dependent mechanism 
Kessler et al., 
2005 
9 SRC-1 steroid receptor 
coactivator-1 




(D)  Signalling 
1 Akt AKT1 kinase Intracellular mediator of cAMP/PKA 
pathway 
Yoshino et al., 
2003 
2 Wnt4/5 Wingless-type 
MMTV integration 
Progesterone mediator of cAMP by up-
regulating SOD2 anti-apoptosis 
Matsuoka et 
al., 2010 
3 PKA Protein kinase A  Phosphorylates prolactin promoter and 
induces prolactin during decidualisation 
Tierney et al., 
2003 
4 Notch1 Notch1 Dual function in the window of 
implantation: Initially mediates a hCG 
survival signal for endometrium from the 
blastocyst and subsequently down-
regulated for decidualisation  






Table 1.1: Hormones, cytokines, growth factors and signalling intermediates that regulate 
ESC decidualisation via progestereone and cAMP signalling. 
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1.7 Decidualisation markers 
1.7.1 Decidual Prolactin  
Decidual prolactin (PRL) is detected around day 22 of the menstrual cycle (Maslar et al., 
1986) and reaches a peak during the secretory phase of the menstrual cycle and is an 
established marker for decidualisation (Tseng et al., 1992). Secretion of PRL during in vitro 
ESC decidualisation is induced by progesterone, cAMP and combination of these, with a 
prominent role of the PKA signalling pathway in activating transcription of PRL (Telgmann 
and Gellersen, 1998; Tang et al., 1993; Brosens et al., 1999) (Figure 1.5). MPA treatment 
increases PRL mRNA and protein expression in secretory phase of the endometrium (Reis 
et al., 1999). Whereas, the anti-progestin RU 486 reduces mRNA expression of PRL and 
PRL receptor in ESC in vitro (Tseng and Mazella, 1999) showing that PRL expression is 
regulated by progesterone. The expression of PRL receptor has been detected in stromal 
cells in the mid- to late-secretory endometrium (Jones et al., 1998) consistent with its role 
in decidualisation. Mice deficient in PRL or its receptor are infertile due to a failure in 
embryo implantation (Horseman et al., 1997; Bole-Feysot et al., 1998). PRL is essential for 
trophoblast growth and invasion, angiogenesis, cytotoxic activity of uNK cells, as well as 
regulation of water transport to the maternal compartment (Corbacho et al., 2002; Stefanoska 
et al., 2013). Consistent with these findings, PRL deficiencies during the window of 
implantation can cause unexplained infertility in women (Garzia et al., 2004).  
 
1.7.2 Insulin-like growth factor binding protein-1  
Insulin-like growth factor binding protein-1 (IGFBP-1) (a.k.a placental protein 12) is 
induced in secretory phase endometrium and decidua and its expression is used to assess the 
extent of decidualisation in vitro (Bell et al., 1991; Giudice et al., 1991; Bryant-Greenwood 
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et al., 1993). Studies using IGFBP-1 promoter-reporter constructs in primary hESC have 
identified PR-A as the dominant transactivator of the IGFBP-1 promoter (Gao et al., 2000). 
Dysregulation of IGFBP-1 is associated with pregnancy complications like intrauterine 
growth restriction (IUGR), pre-eclampsia and polycystic ovarian syndrome (PCOS) 
(Crossey et al., 2002). High levels of IGFBP-1 in early pregnancy appear to be beneficial 
but promote obstetrical disorders in late pregnancy (Giudice, 2002; Fazleabas et al., 2004). 
IGFBP-1 triggers trophoblast invasion interacting with the invading extravillous 
trophoblasts (EVT) and regulating the insulin-like growth factor (IGFs) activity during 
decidualisation (Gleeson et al., 2001; Giudice et al., 1998). Oestrogen stimulates IGF-1 and 
facilitates endometrial growth and is expressed during proliferative and early secretory 
phases. Whereas, IGF-II is expressed by EVT during the secretory phase and early 
pregnancy (Zhou et al., 1994). IGF-1 and IGF-II knockout mice show impaired placenta 
growth and develop IUGR (Crossey et al., 2002). Furthermore, the addition of recombinant 
IGF-1 leads to failure of primary hESC decidualisation in vitro (Matsumoto et al., 2008).  
 
1.7.3 Homeobox A10 (HOXA10) 
Homeobox (HOX) transcription factors play a crucial role in embryonic development and 
reproductive tract in the developing human and mouse embryo (Taylor et al., 1997). 
HOXA10 is also an important decidualisation associated transcription factor in both human 
(Taylor et al., 1998) and mouse (Lim et al., 1999) endometrium. HOXA10 expression is 
increased in the primary hESC treated with oestrogen and progesterone during the secretory 
phase (Taylor et al., 1998). HOXA10 has been reported to regulate the expression of several 
genes involved in the differentiation process such as IGFBP-1 (Kim et al., 2003), integrin-
b3 (Daftary et al., 2002) and MMP26 (Jiang et al., 2014) to promote embryo adhesion during 
the window of implantation. HoxA10 knock-out mice are sub-fertile due to endometrial 
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dysfunction (Satokata et al., 1995) and HOXA10 expression is decreased in the secretory 
ESC of women with unexplained infertility (Wu et al., 2005; Matsuzaki et al., 2009).  
 
1.7.4 CCAAT- enhancer binding protein b  
During the early phase of decidualisation, increased levels of CCAAT- enhancer binding 
protein b (C/EBPb) are detected in ESC. C/EBPs are members of basic leucine-zipper (bZIP) 
superfamily of transcription factors (Lekstrom and Xanthopoulos, 1998). C/EBPb has been 
detected in the nuclei of decidual cells during mid-secretory phase of the menstrual cycle 
(Plante et al., 2009). There is also evidence indicating that C/EBPb is implicated in IL-11 
and cell cycle regulation during decidualisation (Wang et al., 2012). C/EBPb deficiency 
impairs ESC decidual transformation leading to infertility in mice (Mantena et al., 2006). 
Loss of C/EBPb also decreases the expression of bone morphogenetic protein 2 (BMP2), 
which plays an important role in mouse and human ESC decidualisation (Wang et al., 2012). 
 
1.7.5 Forkhead box O (FOXO) transcription factors 
The FOXO subfamily of forkhead transcription factors were first identified in Drosophila 
melanogaster (Weigel et al., 1989). In mammals, there are four members: FOXO1, 
FOXO3A, FOXO4 and FOXO6. FOXOs show similar DNA binding specificity and bind 
with high affinity to the forkhead recognition element (FHRE) DNA consensus sequence 
(5’-TTGTTTAC-3’) due to the high conservation within the DNA-binding domain 
(Furuyama et al., 2000). FOXOs bind DNA via a 100 amino acid forkhead DNA-binding 
domain which has a winged-helix domain (Kaestner et al., 2000) to either activate or repress 
gene transcription. They increase the accessibility of genomic regions within chromatin to 
promote transcription factor recruitment and binding to a region of DNA (Lalmansingh et 
al., 2012). FOXOs are important in the regulation of several diverse processes including the 
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cell cycle, apoptosis, responses to oxidative stress, DNA damage and repair and tumour 
suppression (Zhang et al., 2011). The transcriptional activity of FOXO1, 3A and 4 is 
regulated by multiple post-translational modifications including phosphorylation, 
acetylation, ubiquitination and methylation (Calnan and Brunet, 2008). In the absence of 
growth factor signalling, FOXOs are predominantly located in the nucleus (Brownawell et 
al., 2001).  Phosphorylation of FOXOs by serine/threonine protein kinase B (AKT) on three 
conserved residues: threonine 24; serine 256; and serine 319, inhibits FOXO transcriptional 
activity by blocking DNA-binding and relocalising FOXOs to the nucleus. The presence of 
three highly conserved phosphorylation sites was predicted based on a consensus motif for 
Akt phosphorylation (Arg-X-Arg-X-X-(Serine/Threonine)) (Alessi et al., 1996). 
Phosphorylation of serine-256 is critical for nuclear exclusion of FOXOs (Zhang et al., 
2002) and its phosphorylation can limit gene transactivation by FOXOs independent of 
threonine-24 and serine-319 phosphorylation (Zhang et al., 2002). FOXO phosphorylation 
induces 14-3-3 proteins to bind to the first two FOXO1 phosphorylated sites and 
subsequently block the DNA binding (Boura et al., 2007; Brunet et al., 1999). In addition, 
14-3-3 protein binding to FOXOs causes a shift from the nucleus to the cytoplasm (Figure 
1.7) (Obsilova et al., 2005). Multiple kinases have been identified to regulate FOXO 
transcriptional activity in both a positive and negative manner including serum-and 
glucocorticoid-inducible kinase (SGK), IkB kinase (IKK), c-jun N-terminal kinase (JNK) 
and mammalian sterile 20-kinase-1 (MST1) (Calnan and Brunet, 2008). JNK is activated by 
oxidative stress in mammalian cells and subsequently phosphorylates FOXOs on multiple 
alternative residues leading to nuclear accumulation (Esser et al., 2004; Kawamori et al., 
2006). Similarly, MST1 is activated by cellular stress and reduces 14-3-3 binding to FOXO 
leading to nuclear translocation (Yuan et al., 2009). 





FOXO1 is critical for the induction of decidualisation (Grinius et al., 2006; Kajihara et al., 
2013) regulating various key genes such as dPRL (Lynch et al., 2009; Christian et al., 2002) 
and IGFBP-1 (Kim et al., 2003). Immunohistochemical studies show that FOXO1 
expression increases in human endometrial tissues during the secretory phase with only 
cytoplasmic epithelial staining during the early secretory phase and both cytoplasmic and 
nuclear epithelial and stromal cell staining during the late secretory phase (Christian et al., 
2002). It is known that cAMP and progesterone signalling positively regulate FOXO1 
Figure 1.7: Translocation of FOXO transcription factors regulates their 
transcriptional activity. In the presence of growth factor/survival signals activated Akt, 
which translocates to the nucleus and phosphorylates FOXO releasing it to bind to the 14-3-3 
chaperone proteins transporting it out of the nucleus. In the absence of growth factor/survival 
signals, FOXO is dephosphorylated, 14-3-3 is released and it re-enters nucleus (modified from 
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expression upon in vitro decidualisation of hESC. Activation of FOXO1 protects the 
decidual cells from oxidative stress (Brosens and Gellersen, 2006; Buzzio et al., 2006; 
Takano et al., 2007). In response to progesterone withdrawal, FOXO1 translocates to the 
nucleus of decidual ESC (Labied et al., 2006). Various genes involved in hESC 
decidualisation are regulated by FOXO1, overexpression of FOXO1 increased the 
expression of PRL, IGFBP-1 and TIMP3, while FOXO1 deletion significantly reduced their 
expression (Buzzio et al., 2006; Grinius et al., 2006). In summary, increased levels of 
progesterone in ESC during secretory phase of menstrual cycle activate the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt pathway which causes 
localisation to FOXO1 in the cytoplasm. However, progesterone stimulation also increases 
the levels of intracellular cAMP in hESC which activates the PKA pathway and inactivates 




FOXO3A acts to protect the cells from oxidative stress, apoptosis and plays an essential role 
in follicular development and oocyte growth (Wang et al., 2014; Christian et al., 2011). 
FOXO3A was found to be down-regulated during hESC decidualisation and silencing of 
FOXO3A reduces apoptosis in hESC (Kajihara et al., 2006). A very recent study reported 
that FoxO3a expression increased in the decidualisation of mouse primary stromal cells, and 
siRNA-mediated FoxO3a knock-down reduced the apoptosis (Long et al., 2018).  









Figure 1.8: Model of the regulation of FOXO1 transcriptional activity in a 
progesterone-dependent manner in ESC through the PI3K/Akt and PKA 
pathways.  The rise of progesterone levels in hESC during secretory phase of menstrual cycle 
activates the PI3K/Akt pathway which stimulates localisation of FOXO1 in the cytoplasm to 
prevent its transcriptional activity (right). However, progesterone stimulation also increases the 
levels of intracellular cAMP in hESC which activates the PKA pathway, up-regulates FOXO1 
expression and inactivates PI3K/Akt pathway causing FOXO1 to enter the nucleus to increase 
target gene transcription (left). 
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1.7.6 Transcription factors associated with hESC decidualisation 
No Abbreviation Protein Name Functions References 
1 FOXO1 Forkhead box O1  Induces dPRL during 
decidualisation, protects against 
reactive oxygen species apoptosis 
Labied et al., 
2006 
2 C/EBPβ CCAAT/enhancer-
binding protein β  
Cooperates with FKHR in the 
regulation of decidual specific- 
genes expression e.g. dPRL 
Christian et al., 
2002 
3 PLZF Promelocytic leukemia 
zinc finger protein 
Progesterone-induced 




4 HOXA10 Homeobox A10  Essential for uterine receptivity 
during the window of 
implantation 
Gui et al., 1999 
5 FOXM1 Forkhead Box M1 Downstream of HOXA10 in 
decidualisation 
Gao et al., 2015 
6 STAT3 signal transducer and 
activator of 
transcription 3 
Downstream of FOXM1 in 
decidualisation 
Jiang et al., 2015 
7 TWIST1 TWIST homolog 1 Associated with FOXO1 and 
ETS1 
Schroeder et al., 
2011 
8 ETS1 v-ets erythroblastosis 
virus E26 
Enhances decidual markers e.g. 
PRL, IGFBP-1 
Kessler et al., 
2005 
9 HAND2 Heart and neural crest 
derivatives expressed 
transcript 2  
Regulated by progesterone, 
important in decidualisation 
Huyen and Bany, 
2011 
10 CREB cAMP response 
element binding 
protein  
Central transcription factor 
downstream of cAMP signalling 
Yoshie et al., 
2015 
11 p300/CBP p300/CREB-binding 
protein 
Forms complex with progesterone 
receptor in the secretory phase 
Shiozawa et al., 
2003 
12 KLF-9 Kruppel-like factor 9 Progesterone receptor-interacting 
protein, loss of KLF-9 leads to 
subfertility 
Pabona et al., 
2012 
13 LEFTY LEFTY Inhibits induction of 
decidualisation 
Tabibzadeh, 
2011; Li et al. 





1.8 Angiogenesis in the endometrium 
1.8.1 Angiogenesis  
The vascular system forms through two independent processes: vasculogenesis and 
angiogenesis. Vasculogenesis is the de novo formation of blood vessels from endothelial 
progenitors which is important for embryo development and in adults (Kolte et al., 2016). 
Table 1.2: Transcription factors associated with decidualisation of hESC. 
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Angiogenesis is the process by which new blood vessels are formed from pre-existing 
vessels. It is essential in various physiological processes, for example, embryo development, 
reproductive function, wound healing and pathological conditions such as tumorigenesis 
(Ribatti, 2005). Angiogenesis is a complex and coordinated process requiring sequential 
activation of receptors by numerous families of ligands in endothelial and mural cells 
(Ferrara, 2009; Carmeliet and Jain, 2011).  
 
1.8.2 Angiogenesis and vascular remodelling in the endometrium 
Angiogenesis occurs in normal tissues during wound healing and in the ovary and 
endometrium during female reproductive life (Fraser and Wulff, 2003). Angiogenesis is 
important in the development and differentiation of human endometrium in preparation for 
implantation and pregnancy (Gordon et al., 1995). As discussed earlier, there is dynamic 
remodelling of the vasculature in the endometrium during the menstrual cycle. A complex 
process of proliferation, differentiation, regeneration of vascular, stromal and glandular cells 
occurs each month during female reproductive life. The endometrium is supplied by the 
spiral arterioles arising from arteries in the myometrium supplying the basal and functional 
layer (Farrer-Brown et al., 1970). Upon decidualisation, the endometrial spiral arteries 
become increasingly tortuous (Kaiserman-Abramof and Padykula, 1989; Rogers and 
Gargett, 1998), and undergo dynamic remodelling/transformation if pregnancy occurs to 
ensure adequate nutrient supply for the growing fetus (Plasier, 2011; Smith, 2001). Many 
pro-angiogenic factors such as VEGF (-A), VEGF-C, placenta growth factor (PIGF) and 
angiopoietins have been identified in the endometrium (Li et al., 2001; Smith, 2001).  
 
1.8.3 Angiogenesis and VEGF 
VEGF and its receptors are essential for blood vessel development. Mice lacking a single 
allele of Vegf die in utero between day 11 and 12 due to inadequate vascular development 
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(Ferrara et al., 1996; Carmeliet et al., 1996). Whereas, the over-expression of VEGF causes 
severe abnormalities in heart development and embryonic lethality at day 12.5 to day 14 
(Miquerol et al., 2000). This indicates that the level of VEGF present is critical and that it 
needs to be tightly regulated for normal development. VEGF and PIGF are known to regulate 
early placental vascular development and are important factors in implantation success 
(Andraweera et al., 2012). In addition, studies in transgenic mice have shown that VEGF is 
a prime regulator of angiogenesis during decidualisation (Douglas et al., 2009).  
It is interesting that the loss of PIGF and VEGF-B does not cause embryonic lethality. Mice 
deficient in PIGF are viable and fertile, and only show some impairment of wound healing 
(Carmeliet et al., 2001). Inactivation of Vegf-b reduces heart size and impairs the coronary 
vasculature (Bellomo et al., 2000). VEGF-C plays an essential role in vascular development 
and deletion of VEGF-C causes embryonic lethality due to a failure of lymphatic 
development (Karkkainen et al., 2004). 
 
1.9 Vascular endothelial growth factor-A (VEGF) 
1.9.1 VEGF structure 
VEGF was identified in 1983 as a vascular permeability factor (VPF), secreted by a guinea 
pig tumour cell line (Senger et al., 1983). In 1989, an endothelial-specific mitogen was 
isolated from the conditioned medium of bovine pituitary follicular cells by Ferrara and 
Hanzel and named VEGF (Ferrara and Hanzel, 1989). Subsequently, Connolly et al. (1991) 
independently isolated and sequenced the VPF from U937 cells. The cloning and sequencing 
of VEGF (Leung et al., 1989) and VPF (Keck et al., 1989) cDNAs was reported in 1989, 
which concluded that VEGF and VPF were the same protein. VEGF is also known as VEGF-
A following the discovery of its homologues: PIGF, VEGF-B, VEGF-C, VEGF-D. 
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VEGF is a highly conserved, heparin binding small disulfide-linked ~46 kDa homodimeric 
glycoprotein (Ferrara and Henzel, 1989). There are several VEGF isoforms that differ in 
their degree of extracellular matrix binding capacity affecting their distribution and 
bioavailability (Park et al., 1993) (Figure 1.9). The human VEGF gene is located on 
chromosome 6p21.3 (Vincenti et al., 1996), which composed of eight exons and separated 
by seven introns (Houck et al., 1991). The main human VEGF isoforms are VEGF121, 
VEGF145, VEGF165, VEGF189, and VEGF206 formed by alternative mRNA splicing (Figure 
1.9) (Cross et al., 2003; Ferrara, 2009). VEGF121 and VEGF165 are the most abundant 
isoforms (Neufeld et al., 1999). VEGF121 is a freely diffusible protein with poor extracellular 
matrix (ECM) binding capacity as it lacks exons 6 and 7 which confer heparin-binding 
properties (Park et al., 1993). VEGF165 is the predominant biologically active isoform which 










Figure 1.9: Exon structure of the VEGF gene.  The VEGF gene consists of eight exons. 
Exon 6 and 7 encode heparin binding domains responsible for determining whether VEGF is 
membrane bound or soluble. VEGF206 and VEGF189 contain all eight exons and are predominantly 
membrane bound. VEGF165, the most abundant isoform, and lacks exon 6 and VEGF145 lacks exon 
7. Whereas, VEGF121 diffuses freely lacking exons 6 and 7. Domains 1 to 5 are conserved between 
all VEGF isoforms and are the VEGFR-1 and VEGFR-2 binding domains (modified from Fearnley 
et al., 2013). 
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VEGF206 are found tightly bound to ECM, because they contain all eight exons (Ferrara, 
2009). VEGF145 is detected in placental tissue and is the major VEGF produced by cell lines 
derived from carcinomas of the female reproductive tract (Poltorak et al., 1997). 
 
1.9.2 VEGF gene regulation 
VEGF expression is regulated by many factors including hormones, growth factors and 
primarily oxygen tension (Figure 1.10). VEGF mRNA expression is up-regulated in low 
oxygen tensions in a variety of pathological conditions (Semenze, 2003; Dor et al., 2001). 
Hypoxia inducible factor-1a (HIF-1a) is a key regulator of VEGF gene expression in 
response to hypoxia and binds to the hypoxia-responsive element (HRE) in the VEGF gene 
promoter region increasing its expression and mRNA stabilisation (Wenger et al., 2005; 
Kietzmann et al., 2016). Growth factors including platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), transforming growth factor b (TGFb) are reported to regulate 
VEGF expression (Frank et al., 1995; Pertovaara et al., 1994). Ovarian hormones such as 
oestrogen and progesterone have also been reported to induce VEGF in endometrium both 















Figure 1.10: Schematic representation of the VEGF promoter region.  The arrow 
indicates the transcriptional start site. PRE: progesterone response element; ERE: oestrogen 
response element; HIF-1a/b: hypoxia inducible factor-1 a/b; STAT3: signal transducer and 
activator of transcription 3 (adapted from Pagès and Pouysségur, 2004). 
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1.9.3 VEGF receptors 
VEGF binds to two closely related receptor tyrosine kinases (RTK); VEGFR-1 and VEGFR-
2 primarily via the second and third immunoglobulin-like domains of VEGFR-1 and 
VEGFR-2 (Fuh et al., 1998). These receptors contain seven immunoglobulin-like domains 
in the extracellular domain, a single transmembrane region and other receptor tyrosine 
kinase sequences. Flt-1 and VEGFR-2 are necessary for embryonic vascular development in 
mice (Fong et al., 1999; Shalaby et al., 1995). A third member of this RTK family, VEGFR-
3 (Flt-4), is not a receptor for VEGF, but instead binds specifically to VEGF-C and VEGF-
D (Figure 1.11). In addition, neuropilin-1 & 2 (NRP1 & 2) have also been identified as co-
receptors for VEGF (Soker et al., 1998).  
 
1.9.3.1 Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) 
VEGFR-2 is a 230 kDa protein is also known as kinase insert domain receptor (KDR) in 
human, and fetal liver kinase-1 (Flk-1) in mouse (Ferrara, 2009). VEGFR-2 is expressed 
mostly in vascular endothelial cells from early fetal development (Cortés et al., 1999). VEGF 
activates VEGFR-2 inducing dimerisation and phosphorylation at various tyrosine residues 
resulting in a chemotactic, mitogenic and pro-survival signal (Ferrara, 2009). This stimulates 
phosphorylation of various downstream mediators including PI3K, phospholipases Cγ, ras 
GTPase activating protein, Src tyrosine kinases, protein kinase C and MAPK-ERK pathway 
(Ferrara, 2009). The role of VEGFR-2 in angiogenesis and haematopoiesis was 
demonstrated through the study of Flk-1 null mice led to the death in utero due to the lack 
of vasculogenesis and failure in blood vessel development (Shalaby et al., 1995). Therefore, 
VEGFR-2 is a key mediator of the angiogenic and permeability-enhancing effect of VEGF. 
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1.9.3.2 Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1) 
Flt-1 (a.k.a the fms-like tyrosine kinase-1/ VEGFR-1) is a 180 kDa protein that was the first 
VEGF receptor identified (Ferrara, 2004). However, the full functional activity of this 
receptor remains unclear. Studies indicate that the function and signalling properties of Flt-
1 vary depending on the cell type and developmental stage at which it is acting (Ferrara, 
2004). Flt-1 binds to the VEGF, PIGF and VEGF-B (Figure 1.11) (Park et al., 1994; 
Olofsson et al., 1998). Flt-1 is also produced in a soluble form, sFlt-1 (sVEGFR-1), which 
is a potent physiological inhibitor of VEGF activity (Figure 1.11) (Kendall and Thomas, 
1993). 
There are many studies that report Flt-1 acts as a VEGF ligand-trap or “decoy receptor” 
which negatively regulates the access of VEGF to VEGFR-2 (Park et al., 1994; Fong et al., 
1995). Flt-1 knockout mice die at embryonic day (E) 8.5 to E9.5 due to the increased 
proliferation of endothelial progenitor cells resulting in a disorganised vasculature (Fong et 
al., 1999). However, transgenic mice which have the tyrosine kinase domains of Flt-1 
deleted develop a normal vasculature and are viable (Hiratsuka et al., 1998) suggesting that 
Flt-1/sFlt-1 acts mainly as a decoy receptor modulating embryonic development by 
sequestering VEGF and preventing over-activation of VEGFR-2. 
Our understanding of the role of the Flt-1 receptor has deepened with findings indicating the 
involvement of PIGF signalling in angiogenesis (Carmeliet et al., 2001; Autiero et al., 2003). 
Carmeliet et al. (2001) showed that PIGF binds to Flt-1 to promote angiogenesis by 
displacing VEGF and consequently enhancing VEGFR-2 activation. Autiero et al. (2003) 
demonstrated that PIGF can also initiate intermolecular signalling through binding to Flt-1 
leading to transphosphorylation of VEGFR-2.  The direct inhibition of Flt-1 signalling was 
found to inhibit endothelial cell migration (Gille et al., 2000) and it is also reported to 
produce weak mitogenic signals (Maru et al., 1998). Our laboratory has shown that Flt-1 can 
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negatively regulate VEGFR-2 signalling via heterodimerisation (Cudmore et al., 2011). In 
addition, Flt-1 is also present in other cell types including retinal pericytes (Takagi et al., 





Neuropilins 1 & 2 (NRP1 & 2) were originally discovered as semaphorins II receptors which 
are involved in neuronal growth and axonal guidance (Kolodkin et al., 1997). NRP1 was 
shown to bind VEGF acting as a co-receptor to enhance VEGFR-2 signalling in response to 
Figure 1.11: Schematic illustration of the VEGF family members and their 
specific interactions with VEGF receptors. VEGF receptors (VEGFR-1, VEGFR-2 and 
VEGFR-3) contain seven immunoglobulin-like domains in the extracellular region, a single 
transmembrane domain and split intracellular tyrosine kinase domains. Arrows indicate which 
ligands are capable of binding to each receptor. VEGF can bind to two cell surface receptors 
VEGFR-1/Flt-1 and VEGFR-2/KDR. VEGF binds to Flt-1 with higher affinity than VEGFR-
2/KDR. Alternatively, spliced soluble forms of Flt-1, sFlt-1 act as inhibitors of VEGF, VEGF-
B and PIGF activity. Neuropilin co-receptors (NRP1 & 2) bind specific VEGF ligand splice 
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VEGF (Soker et al., 1998; Gelfand et al., 2014). NRP1 knock-out mice die in utero with 
seriously disorganised vasculature (Kawasaki et al., 1999; Takashima et al., 2002). NRP1 
may positively regulate the level of Flt-1 within the cell as NRP-1 knock-down leads to 
reduced Flt-1 expression (Quante et al., 2009). 
 
1.9.4 Flt and sFlt-1 structure and function 
The Flt-1 gene expresses one long mRNA form of approximately 8 kb which encodes the 
full-length receptor and shorter truncated mRNAs encoding most of the extracellular domain 
of between 2.5 to 3.0 kb. The sFlt-1 isoforms contain the N-terminal six immunoglobulin-
like (Ig-like) domains and lack a transmembrane domain and so are freely soluble (Shibuya 
et al., 1999). As sFlt-1 contains the same extracellular domain as Flt-1, sFlt-1 competes with 
Flt-1 to bind VEGF and PIGF, subsequently reducing free VEGF and PIGF levels and 
blocking their interaction with and signalling from membrane bound VEGF receptors 
(Figure 1.12). 
The role of sFlt-1 is further complicated by the existence of multiple mRNA splice variants 
(Figure 1.13). The two most abundant splice variants, sFlt-1-i13 (a.k.a sFlt1_v1) and sFlt-
1-e15a (a.k.a sFlt1_v2), are differentially expressed in human tissues (Thomas et al., 2007; 
Heyderian et al., 2009; Rajakumar et al., 2009; Whitehead et al., 2011; Jebbink et al., 2011). 
sFlt-1-i13 was the first sFlt-1 identified (Kendal and Thomas, 1993) and comprises of the 
first 13 exons of Flt-1 with an extension of exon 13 into the intronic sequence (Figure 1.13) 
(Heydarin et al., 2009). It shares 657 amino acids of full-length Flt-1, encoding a unique 31 
amino acid C-terminus producing an 85-95 kDa protein (Figure 1.13) and is expressed in 
most tissues including brain, heart, and kidney (Thomas et al., 2007).  
In comparison, sFlt-1-e15a is specific to primates and mainly expressed in the placenta 
(Whitehead et al., 2011; Jebbink et al., 2011). sFlt-1-e15a encodes the first 14 exons of Flt-
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1 followed by a 480 nucleotide stretch of an intronic sequence which forms an alternative 
exon (15a) (Figure 1.13) (Sela et al., 2008; Thomas et al., 2007; Gu et al., 2008). More than 
80% of all Flt-1 transcripts are spliced to become sFlt-1-e15a in the human placenta which 
indicates that sFlt-1-e15a may be the major isoform involved in preeclampsia (Jebbink et 
al., 2011). Whereas sFlt-1-i14 is generated by skipped mRNA splicing and extension of exon 
14, and sFlt-1-e15b contains the alternative exon 15b derived from another intronic 
sequence. sFlt-1-i14 and sFlt-1-e15b are expressed at low levels compared to sFlt-1-i13 and 
sFlt-1-e15a and so were not investigated in this study. 
 
Figure 1.12: sFlt-1 blocks VEGF signalling.  Soluble Flt-1 sequesters free VEGF and 
prevents it from binding to full length VEGFRs. sFlt-1 also forms dominant-negative complexes 
with VEGFRs so that no signal can be initiated (adapted and modified from Ahmed and 
Cudmore, 2009). 
 




Figure 1.13: The Flt-1 and sFlt-1 gene exon arrangement and protein structure.  
The full-length Flt-1 receptor is encoded by an mRNA transcript of 30 exons which composed of 
seven extracellular Ig-like domains containing the ligand-binding regions, a transmembrane domain 
and intracellular tyrosine kinase domains. sFlt-i13 contains the first six lg-Like domains, 657 amino 
acids (aa) of Flt-1 and it is generated by skipped splicing and extension of exon 13, while, sFlt-1-
e15a diverges from Flt-1 after 706 aa and alternatively spliced exon derived from intronic sequences 
(exon 15a). sFlt-1-i14 is generated by skipped splicing and extension of exon 14 and sFlt-1-e15b 
encodes the alternative spliced exon of 15b derived from an intronic sequence (adapted from Palmer 
et al., 2016). 
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The oxygen-sensing Jumonji domain containing protein 6 (JMJD6) directly affects the 
splicing pattern of Flt-1 to produce sFlt-1 in endothelial cells (Palmer et al., 2016; Boeckel 
et al., 2011). JMJD6 was able to hydroxylate U2 small nuclear ribonucleoprotein auxiliary 
factor 65-kDa subunit (U2AF65), a component of the splicing machinery under normal 
conditions to produce the full-length Flt-1 receptor transcripts (Boeckel et al., 2011). 
However, under hypoxic conditions JMJD6 activity decreases which reduces its ability to 
hydroxylate U2AF65, leading the splicing machinery to produce shorter alternatively spliced 
sFlt-1 transcripts (Boeckel et al., 2011). 
sFlt-1 is suspected to act as a biochemical barrier between the fetal and maternal circulation 
in the placenta by stopping excess angiogenesis and abnormal vascular permeability. 
Patients with preeclampsia have abnormally high plasma levels of sFlt-1 (Maynard et al., 
2003). The placental trophoblasts are the major cell type producing large amounts of sFlt-1 
in preeclampsia (Maynard et al., 2003). The suppression of VEGF activity by sFlt-1 in the 
maternal circulation causes hypertension and proteinuria in patients. Over-expression of 
sFlt-1 in pregnant mice induces hypertension and proteinuria, showing that sFlt-1 is, at least 
in part, the cause of the maternal preeclamptic syndrome (Maynard et al., 2003; Roberts and 
Rajakumar, 2009). 
 
1.10 VEGFs in the endometrium 
VEGF is expressed in both endometrial epithelial and stromal cells (Perrot-Applanat et al., 
2000). Immunohistochemical studies in human endometrial epithelial and stromal cells have 
demonstrated that the expression of VEGF is highest during the mid-secretory phase of cycle 
(Sugino et al., 2002). In addition, the expression of VEGF in stromal cells was also detected 
in decidua in early pregnancy, but not in epithelial cells in the late secretory phase and early 
pregnancy (Sugino et al., 2002). In the human endometrium, Flt-1 and VEGFR-2 are 
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detected mainly in vascular endothelial cells (Meduri et al., 2000). Flt-1 is reported to be 
present only in stromal and endothelial cells in early pregnancy but not during the normal 
menstrual cycle (Sugino et al., 2002). However, VEGFR-2 was readily detected in epithelial 
and endothelial cells throughout the menstrual cycle, in stromal cells during the secretory 
phase and in early pregnancy (Sugino et al., 2002). In addition, oestrogen and progesterone 
treatment in primary hESC in vitro increased VEGFR-2 mRNA expression (Sugino et al., 
2002). 
VEGF transcription was reported to be regulated by oestrogen via oestrogen receptor (ER) 
in human endometrial epithelial and stromal cells (Mueller et al., 2000). ERα knock-out in 
mice was reported to lead to a failure of angiogenesis (Johns et al., 1996). Furthermore, 
VEGF is the most prominent pro-angiogenic factor in endometriosis and is found at higher 
levels in the peritoneal fluid and lesions of endometriosis patients compared to healthy 
controls (McLaren et al., 1996). This has led to an interest in the development of anti-VEGF 
therapies for endometriosis (Hull et al., 2003, Rein et al., 2010). 
 
1.11 Rationale and Aims 
hESC decidualisation is a highly regulated event and is crucial for the maintenance of a 
successful pregnancy. It encompasses various morphological changes underpinned by 
extensive biochemical changes, and the signalling pathways involved in this cell 
differentiation are complex. Research into the process of decidualisation may lead to greater 
understanding of endometriosis, female infertility, recurrent miscarriage as well as 
pregnancy complications like preeclampsia and intrauterine growth restriction (IUGR). 
VEGF family members are essential for maintaining the cycling endometrium under normal 
hormonal regulation and for a successful pregnancy. VEGF is up-regulated in hESC by 
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cAMP and levels of VEGF and sFlt-1 in the endometrium are linked to fertility and 
successful pregnancy.  
We propose that VEGF activity is under the direct control of the PKA/FOXO1 pathway in 
hESC undergoing decidualisation and may modify the functional activity of these cells in 
addition to promoting vascular remodelling and trophoblast migration. Therefore, the aim of 
this thesis is to identify the pathways regulating VEGF activity during the decidualisation of 
ESC and how this may impact on vascular remodelling/angiogenesis. 
The specific objectives are: 
• To establish and characterise the in vitro decidualisation of primary hESC and St-
T1b cell line and determine changes in pro-angiogenic activity. 
• To examine the relative levels of VEGF, Flt-1 and sFlt-1 expression and secretion 
during hESC decidualisation. 
• To determine whether FOXO1 directly regulates VEGF and Flt-1 gene expression 
during hESC decidualisation.  
• To assess the relative activity of decidual hESC-derived VEGF on endothelial cell 
and hESC function. 
 
  





























Chapter 2: Materials and Methods 
 
 47 
2.1 Cell culture 
2.1.1 Isolation of Primary Cells 
2.1.1.1 Human Endometrial Stromal Cells (hESC) Isolation 
The endometrial tissues were collected in accordance with the University of Birmingham 
approved ethics protocol numbered 10-014. Endometrial cell isolation was based on a 
modification of previous methods (Zhang et al., 1995; Chen and Roan, 2015). The 
endometrial tissues from pipelle biopsies was collected in Dulbecco’s phosphate buffered 
saline (PBS) containing Penicillin/Streptomycin (Pen/Strep) (100 U/ml Penicillin and 100 
µg/ml of Streptomycin (Gibco)) and processed immediately or stored at 4oC. The tissue was 
transferred to a Petri dish and minced into 1 mm3 pieces between scalpel blades. The pieces 
were transferred to a 15 ml tube and were centrifuged at 300 x g for 2 min to pellet the tissue 
cells. The supernatant was discarded, and pellet resuspended in 10 ml of 1 x digestion media 
(2 x concentration: 6.4 mg/ml Collagenase Type 1 (Worthington Biochemical Corporation) 
and 125 U/ml hyaluronidase (Sigma) in Dulbecco’s modified eagle’s medium and Ham’s F-
12 (DMEM/F12) supplemented with Pen/Strep (100 U/ml Penicillin and 100 µg/ml of 
Streptomycin (Gibco)). The tissues were incubated on a rotator for 2 h at 37oC. The digest 
was then passed through a 100 µm cell strainer placed on top of an opened 50 ml tube. The 
flow-through was centrifuged at 300 x g for 5 min to remove the digestion media and the 
pellet resuspended in growth medium comprising DMEM/F-12 (Gibco), 10% (v/v) of Foetal 
Bovine Serum (FBS) (Sigma), 1 nM 17-β-Oestradiol (E2), 1 µg/ml insulin (Gibco), 2 mM 
L-glutamine (Sigma) and Pen/Strep (100 U/ml Penicillin and 100 µg/ml of Streptomycin 
(Gibco)). The cells were then plated in a T-25 flask and incubated overnight. On the next 
day, the cells were washed with PBS and fresh medium added.  
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2.1.1.2 Mouse Endometrial Epithelial and Stromal Cells Isolation 
The endometrial cell isolation was based on the modification of previously published 
methods (Grant et al., 2003; Inada et al., 2006). The uteri from three mice were opened 
lengthwise and cut into ~ 0.5 cm2 pieces. The tissue was pooled together and incubated in 5 
ml of 0.25% of trypsin-EDTA (Gibco) for 2 h in 4oC followed by 30 min at room 
temperature. The DMEM/F12 medium with 10% (v/v) FBS (Sigma) was added and the 
mixture vortexed three times to release the sheets of epithelial cells. The digested uteri were 
then passed through a 100 µm nylon mesh and the supernatant collected was centrifuged for 
10 min at 500 x g. The pellet was re-suspended in the complete growth medium (DMEM/F12 
supplemented with 10% FBS, 1 nM E2, 1 µg/ml insulin (Gibco), 2 mM L-glutamine (Sigma) 
and Pen/Strep (100 U/ml Penicillin and 100 µg/ml of Streptomycin (Gibco)). The cells were 
seeded on a 6-well plate.  
The remaining digested uterine material transferred to the universal tube containing 
DMEM/F12 medium with collagenase (1 mg/ml) and incubated at 37oC for 40 min to isolate 
the stromal cells. The digest was dispensed onto a 40 µm nylon mesh and gently washed 
through with fresh medium. The supernatant collected was centrifuged for 10 min at 500 x 
g and the pellet was re-suspended in complete growth medium. The cells were seeded on 6-
well plate. The cells were observed every day and the medium changed after 48 h. 
 
2.1.1.3 Mouse Embryonic Fibroblast preparation 
Floxed FoxO mice were kindly provided by Prof Domineco Acilli, Columbia University, 
New York USA and described previously (Paik et al., 2007). Timed pregnant mice were 
used to prepare mouse embryonic fibroblasts (MEFs) (Lengner et al., 2004). E14 embryos 
were removed from the uterus, dissected out from yolk sac and transferred into a sterile dish 
containing PBS. The head, tail and internal organs of each foetus were removed carefully 
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and washed with sterile PBS to remove as much blood as possible. The foetuses were then 
minced between scalpel blades and transferred to 1 ml of 0.25% trypsin/EDTA followed by 
10 min incubation at 37oC. The trypsin was neutralised with fresh growth medium (below) 
and the digest was filtered through 70 µm mesh. The cells were pelleted at 1,700 x g for 5 
min and plated on 10 cm2 culture dishes. The cells were incubated at 37oC, 6% CO2 with 
humidified atmosphere. The medium was changed the next day and cells grown to 
confluence and then cryopreserved. MEFs were cultured in DMEM supplemented with 10% 
(v/v) FBS (Sigma), 2 mM L-glutamine, Pen/Strep (100 U/ml Penicillin and 100 µg/ml of 
Streptomycin (Gibco)), 1 mM sodium pyruvate (Sigma, S8636), 1% of MEM non-essential 
amino acid 100 x (Sigma, M7145). 
 
2.1.2 Cell Culture 
2.1.2.1 St-T1b hESC Line 
St-T1b, a telomerase-immortalised hESC line (Samalecos et al., 2009) was provided by Dr. 
Birgit Gellersen (Endokrinologikum, Hamburg, Germany). St-T1b cells were cultured in 
growth medium comprising DMEM/F-12 (Gibco), 10% (v/v) FBS (Sigma), 1 nM E2, 1 
µg/ml insulin (Gibco), 2 mM L-glutamine (Sigma) and Pen/Strep (100 U/ml Penicillin and 
100 µg/ml of Streptomycin (Gibco)). The cells were used between passage 22 and passage 
35 in all the experiments. 
 
2.1.2.2 Human embryonic kidney cells (HEK-293) 
HEK-293, human embryonic kidney cells (Graham et al., 1977) and the SV40 large T 
antigen transformed HEK-293T cell line (DuBridge et al., 1987) were provided by Dr. Philip 
Kitchen (University of Birmingham, United Kingdom) and cultured in DMEM with high 
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glucose (Sigma) supplemented with 10% (v/v) FBS, 2 mM L-glutamine and Pen/Strep (100 
U/ml Penicillin and 100 µg/ml of Streptomycin (Gibco)).  
 
2.1.2.3 Human Umbilical Vein Endothelial cells (HUVEC) 
Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from PromoCell and 
cultured on 0.2 % gelatin-coated plates in Endothelial Cell Growth Medium 2 (EGM-2, 
PromoCell), which is a low serum cell culture medium for endothelial cells from large blood 
vessels, free from bovine hypothalamic extract. HUVEC were used between passage 2 and 
passage 6 in experiments. 
 
2.1.2.4 Human microvascular endothelial cell line (HMEC-1) 
The human microvascular endothelial cell line, HMEC-1 (Ades et al., 1992) were cultured 
in MCDB 131 medium (Gibco) supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 
Pen/Strep (100 U/ml Penicillin and 100 µg/ml of Streptomycin (Gibco)). 
 
2.1.3 Maintenance of Cells 
All the cell lines were grown in T-75 flasks and passaged once confluent. Culture medium 
was removed, and cells washed gently with PBS (Ca2+-/Mg2+-free) before incubation with 
0.25% Trypsin-EDTA (1X) (Gibco) at 37oC for 1-2 min. Cells were re-suspended in an 
appropriate volume of culture medium to inactivate the trypsin. Cell number was calculated 
using haemocytometer and the cells plated at the desired density. All the cells were incubated 
under standard culture condition at 37oC with 6% CO2 and humidified atmosphere. 
 
2.1.4 Cell Viability 
50 µl of cell suspension was placed in a 1.5 ml Eppendorf tube. An equal part of 0.4% trypan 
blue dye (GibcoTM) was added to the cell suspension to obtain a 1:2 dilution. The mixture 
was mixed by pipetting up and down. The haemocytometer counter was filled with the cell 
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suspension (10 µl) by placing the tip of the pipette at the notch. The viable cells (clear) and 
non-viable cells (blue) were counted. The percentage of viable cells was calculated by 
dividing the number of viable cells by the number of total cells and multiplying by 100 using 
the formula below.  
𝐶𝑒𝑙𝑙	𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦	(%) =
𝑣𝑖𝑎𝑏𝑙𝑒	𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙	𝑐𝑒𝑙𝑙𝑠 × 100 
 





10% (v/v) FBS 
2 mM L-Glutamine  
100 U/ml penicillin 
100 μg/ml streptomycin  
1 μg/ml Insulin 




2% (v/v) Charcoal-stripped FBS 
2 mM L-Glutamine  
100 U/ml penicillin 
100 μg/ml streptomycin  
1 µM Medroxyprogesterone (MPA) 
0.5 mM 8-Br-cAMP 
HEK293/293T  DMEM (high glucose) with: 
10% (v/v) FBS 
2 mM L-glutamine 
100 U/ml penicillin 
100 μg/ml streptomycin  
HMEC-1 MCDB 131 with: 
10% (v/v) FBS 
2 mM L-glutamine 
100 U/ml penicillin 
100 μg/ml streptomycin  
MEFs DMEM (high glucose) with: 
10% (v/v) FBS 
2 mM L-glutamine 
100 U/ml penicillin 
100 μg/ml streptomycin  
1 mM sodium pyruvate 
1% MEM non-essential amino acid 100 x 
 Table 2.1: Lists of cell culture medium. 
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2.1.6 Cryopreservation of Cells 
Freezing of cells was routinely performed to maintain cell stocks for later research. The cells 
were detached by exposure to trypsin as described in section 2.1.3 and then transferred to a 
15 ml centrifuge tube and pelleted at a low speed (200 x g) for 5 min. The supernatant was 
then discarded, and cell pellets were re-suspended in freezing medium, consisting of 10% 
(v/v) dimethyl sulphoxide (DMSO) (Sigma) in their respective growth medium. The cells 
were aliquoted in cryovials (1 ml) and placed in a “Mr Frosty” (BDH) at room temperature 
and transferred to a -80oC freezer. The cells were then transferred to liquid nitrogen storage 
within 3 days for long term storage.  
 
2.1.7 Thawing cells 
Frozen cells were thawed at 37oC. Immediately, the contents were removed into 9 ml of pre-
warmed complete medium in a 15 ml Falcon tube. The cells were re-suspended, and the tube 
was centrifuged at 200 x g for 5 min. The supernatant was discarded, and the cell pellet was 
re-suspended in 5 ml complete medium. The suspended cells were transferred into a 75 cm2 
flask and complete medium was added to a final volume of 15 ml. Cells were incubated at 
37oC in humidified conditions supplemented with 6% CO2. The medium was changed the 
next day and the cell condition and viability was observed. 
 
2.1.8 Mycoplasma Test 
To ensure the absence of mycoplasma, the cells were tested using the EZ-PCR Mycoplasma 
Test Kit (Biological Industries) according to the manufacturer’s instructions. Briefly, cell 
culture supernatants (1 ml) were centrifuged at 16,000 x g for 10 min to sediment 
mycoplasma. The supernatant was discarded, and the pellet re-suspended in 50 µl of buffer 
and heated at 95oC for 3 min. PCR was performed with the following conditions: 
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denaturation 94oC, 30 secs; amplification 94oC, 30 secs; annealing 60oC, 2 min; 72oC for 1 
min, with 35 cycles. The PCR product was loaded on a 2% agarose gel electrophoresis. 
 
2.2 In Vitro Decidualisation of hESC 
In vitro decidualisation of primary hESC and St-T1b cells was induced as described 
previously (Samalecos et al., 2009). The hESC were plated onto 6-well plates at 3 x 105 
cells/well, or 10 cm Ø Petri dishes at 1 x 106 cells/dish and allowed to grow until confluent. 
The growth medium was aspirated, and cells were washed once with PBS. The cells were 
then treated with decidualisation medium (MM1) comprising DMEM/F-12, 2% charcoal-
stripped FBS (Biosera, South America), 0.5 mM 8-Br-cAMP (Enzo Life Sciences), 1 µM 
medroxyprogesterone acetate (MPA) (Sigma) and Pen/Strep (100 U/ml Penicillin and 100 
µg/ml of Streptomycin (Gibco)). Non-decidualised control cells were maintained in a 
proliferative state by culturing in E2-containing medium (E2 medium) (DMEM/F-12, 10% 
(v/v) of charcoal-stripped FBS, 1 nm E2, 1 µg/ml insulin and Pen/Strep (100 U/ml Penicillin 
and 100 µg/ml of Streptomycin (Gibco)). The cells were re-stimulated with fresh medium 
24 h prior to harvesting (Figure 2.1). Conditioned medium (CM) was collected from the 
cells after various time periods. CM was centrifuged at 1,000 x g to remove cells and the 
supernatant frozen at -20oC. 








2.3 Total RNA Extraction 
Total RNA was extracted using Total RNA plus Extraction Kit (Norgen, Biotek Corporation, 
Canada) according to the manufacturer’s instructions. Cells grown on 6-well plates were 
washed with PBS twice and incubated with 120 µl Lysis Buffer per well for 5 min at room 
temperature. The lysate from three wells was combined and stored at -20oC. Samples were 
passed through the gDNA column by centrifugation at 13,000 x g for 1 min to remove 
genomic DNA. The flow-through then mixed with 210 µl molecular-grade ethanol and 
transferred to RNeasy columns followed by centrifugation at 13,000 x g for 1 min. The flow 
through was discarded, and the columns were washed with 400 µl of wash buffer three times. 
RNA was eluted with 50 µl of elution buffer and centrifuged at 2,000 x g for 2 min followed 
by 14,000 x g for 1 min at 4oC. The RNA concentration was measured by a 
spectrophotometer and the purity assessed by 260:280nm absorbance ratio greater than 1.8. 
The purified RNA was either used immediately for cDNA synthesis or stored at -80oC. 
 
Figure 2.1: Stimulation of hESC for decidualisation.  The incubation of primary hESC 
and St-T1b cells is outlined. Cultures were treated with E2 or MM1 medium for 1, 3 or 6 days. 
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2.4 cDNA Synthesis 
A stock solution of cDNA reaction mix was prepared using the Tetro cDNA synthesis kit 
(Bioline, UK) according to the manufacturer’s guidelines. RNA concentrations were 
normalised so that all cDNA reactions contained the same amount of RNA (1 µg). The 
priming premix (1 µg of total RNA, 1 µl Oligo (dT)18 primer, 1 µl of 10 mM dNTP were 
made up in diethyl pyrocarbamate (DEPC)-treated water to a total volume of 12 µl) and 
incubated at 65oC for 5 min to denature any secondary structures of RNA formed in samples 
followed by 2 min on ice. The reaction premix (for one reaction: 4 µl 5x RT buffer, 1 µl 
Ribosafe RNase inhibitor, 1 µl of Tetro Reverse Transcriptase and 2 µl of DEPC-treated 
water) were prepared. The mixture was incubated at 42oC for 30 min and followed by 55oC 
for 30 min. The samples were then stored at -20oC or used immediately for polymerase chain 
reaction (PCR). 
 
2.5 Reverse Transcription PCR 
A reaction master mix was made using the MangoTaq PCR kit (Bioline) and prepared as 
following per sample : 4 µl 5x MangoTaqTM Reaction Buffer, 2 µl of MgCl2 (50 mM), 0.3 
µl of dNTP mix (100 mM), 0.3 µl of primer mix (50 µM), 0.3 µl of Mango Taq polymerase 
(1000 units) and PCR grade water was added to a total volume to 19 µl/reaction. The master 
mix (19 µl) was aliquoted into 0.2 ml PCR tubes followed by adding 1 µl of cDNA. The 
samples were mixed, centrifuged and placed into the PCR instrument (SensiQuest 
Labcycler). PCR amplification conditions were as follows: Denaturation at 95oC for 10 min 
followed by 35-40 cycles of denature 95oC, 30 sec; annealing (refer to Table 2.2), 30 sec; 
extension 72oC, 1 min and final extension step at 72oC for 10 min. The PCR products were 
separated on 1 to 2% (w/v) agarose gels.  
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2.5.1 Agarose Gel Electrophoresis 
Agarose gels were prepared by mixing molecular grade agarose (Bioline) into 100 ml of 1x 
TAE electrophoresis buffer (Table 2.3) and heating using a microwave to dissolve the 
agarose. The gel was then allowed to cool to 50oC before adding 5 µl of 10 mg/ml Midori 
Green Advance DNA Stain (Nippon Genetics Europe GmbH). Immediately, the gel was 
poured into a casting tank and left to solidify for 10 min. The gel was placed in a 
electrophoresis tank and filled with 1 x TAE buffer. Samples and DNA Hyperladder IV or 
V marker (Bioline) were loaded and the gel was run to 100 V for approximately 30 min. Gel 
images were captured using a SyngeneII gel doc system. 
Buffer Recipe 
50 X TAE For 1 L: 
242.2 g Tris base  
57.1 ml glacial acetic acid 
100 ml 0.5 M Ethylenediaminetetraacetic Acid (EDTA), pH 8.0 
Bring the volume up to 1L with ddH2O 
0.5 M EDTA, pH 8.0 For 500 ml: 
93.05  Na2•EDTA•2H2O (disodium dyhydrate) 
9 g solid NaOH  
Adjust the pH to 8 
Bring the volume up to 500 ml with ddH2O 
 
Table 2.2: Oligonucleotide primers and amplification conditions for RT-PCR. 
Table 2.3: Buffers for agarose gel electrophoresis 
Chapter 2: Materials and Methods 
 
 57 
2.6 Real-Time Quantitative PCR  
The cDNA was diluted with polymerase chain reaction grade water (PCR.H2O) in a 1:3 ratio. 
The master mix for one reaction: 7.5 µl of 2x SensiMixTM SYBRâ No-ROX (Bioline), 0.1 
µl primer (50 pmol/µl), 1 µl of diluted cDNA and PCR.H2O added to a final volume of 15 
µl was prepared. Primers were designed or verified using Primer Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Correct amplicon size was confirmed by 
running product on an agarose gel and the standard curves were run with genomic DNA 
(gDNA) to ensure suitable amplification efficiency. Samples were amplified under the 
following conditions: denaturation 95oC 10 min followed by 40-45 cycles of denature 95oC, 
10 secs; annealing temperature (see Table 2.4 and Table 2.5), 15 secs; extension 72oC, 20 
secs on a Rotor-Gene Q (Qiagen). Reactions were run in duplicate and repeated twice. CT 
values were extracted to Microsoft Excel format and target gene values normalised to the 
control b-actin values using the comparative DDCt method (DDCt = DCt	sample − DCt b-
actin) (Pfaffl, 2004). Fold change was then calculated using the equation 2@DDAB	. 
 






β-actin  5’-TCACCCACACTGTGCCCATCTACGA-3’ 
5’-CAGCGGAACCGCTCATTGCCAATGG-3’ 












61oC  211 bp Yang et al., 
2012 
SOD-2 5’-TCAGCGGTAGCACCAGCACT-3’ 
5’- ATCTGCGCGTTGATGTGAGG -3’ 
65oC  163 bp Araujo et al., 
2011 
VEGF 5’- CCTTGCCTTGCTGCTCTACC-3’ 
5’- ACACTCCAGGCCCTCGTCATTG-3’ 
58oC  250 bp In house 
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sFlt-i13 5’- ACAATCAGAGGTGAGCACTGCAA-3’ 
5’- TCCGAGCCTGAAAGTTAGCAA-3’ 
56oC  180 bp Whitehead et 
al., 2011 










200 bp In house 
C/EBPβ 5’- AACTCTCTGCTTCTCCCTCTG-3’ 
5’- TGCGTCAGTCCCGTGTAC-3’ 




60oC  236 bp Kommagani 
et al., 2016 
FOXM1 5’-GACATCAGCTTTCCTGGCCT-3’ 
5’-CAGTGGCTAGGGTGTGACTG-3’ 
60oC  248 bp Jiang et al., 
2015 
PLZF 5’- TAGGGTGCACACAGGTGAGA-3’ 
5’- GTGCAGATGGTGCACTGGTA-3’ 
60oC  129 bp Kommagani 
et al., 2016 
c-Myc 5’-TCGGATTCTCTGCTCTCCTCG-3′ 
5’-CTGCGTAGTTGTGCTGATGTGTG -3′ 
60oC  274 bp McConnell 
et al., 2015 
STAT3 5ˈ- GAGAAGGACATCAGCGGTAAG -3ˈ  
5ˈ- AGTGGAGACACCAGGATATTG -3ˈ 
60oC  137 bp Turton et al., 
2015 
Akt-1 5’-AGGCTCCCCTCAACAACTTC-3’  
5’-CTCCTCCTCCTCCTGCTTCT-3’ 






















58oC 62 bp In house 
FoxO1 5’-TTCAATTCGCCACAATCTGTCC-3’ 
5’-GGGTGATTTTCCGCTCTTGC-3’ 
58oC 118 bp Tanaka et al., 
2009 
Vegf 5’-GAGTACCCCGACGAGATAGAGT-3’  
5’-GGTGAGGTTTGATCCGCATGA-3’ 
58oC  148 bp In house 
FoxO3a 5’- TGAACTCCTTGCGTCAGTCACC-3’ 
5’- CGGTGCTAGCCTGAACATCAA-3’ 
58oC  177 bp Tanaka et al., 
2009 
Table 2.4: Human real-time qPCR primers. 
Table 2.5: Mouse real-time qPCR primers. 
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2.7 Western Blot 
2.7.1 Protein Extract and Protein Assay 
Confluent cells plated on 6-well dishes were washed with PBS and harvested using PierceTM 
Radioimmunoprecipitation Assay Buffer (RIPA) lysis buffer (Fisher Scientific) with 20 
µl/ml 50 X protease inhibitor (cOmplete mini EDTA free, Roche Diagnostics GmbH). The 
cells were incubated on ice for 2 min, scraped off the dish and transferred to a cold Eppendorf 
tube and stored at -20oC for later analysis or centrifuged at 13,000 x g for 30 min at 4oC prior 
to Western Blotting. Protein concentrations were measured using the Bradford protein assay 
according to the manufacturer’s instructions (Bio-rad). 20 µg of protein was aliquoted and 
an equal volume of 2 x Laemmeli loading buffer (Bio-rad) was added. The samples were 
boiled for 5 min at 95oC, centrifuged at 12,000 x g for 1 min and loaded onto 10% sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
 
2.7.2 SDS-PAGE 
The mini gel plates (1.0 mm) (Geneflow) were cleaned with distilled water and assembled. 
A 10% (w/v) resolving gel (2.5 ml of 1.5 M Tris pH 8.8, 3.3 ml of 30% acrylamide, 4 ml of 
dH2O, 100 µl 10% SDS, 90 µl 10% ammonium persulphate (APS) and 10 µl N.N.N’N’ 
tetramethylethylenediamine-1,2-diamine (TEMED)) was poured and isopropanol was added 
immediately over the top to prevent oxidation. Once the gels were set, the isopropanol was 
poured off and a 5% stacking gel (3 ml dH2O, 700 µl 30% acrylamide, 1.25 ml 0.5 M Tris 
pH 6.8, 50 µL 10% SDS, 50 µl of freshly prepared 10% APS and 10 µl TEMED) was added. 
Combs were inserted and the gels left to set. Gels were placed into electrophoresis tanks 
containing 1 x running buffer (0.1 M Tris pH 8.0, 0.1 M glycine, 0.1% (w/v) SDS) and the 
combs removed carefully. The pre-stained protein markers (GeneFlow) and samples (20 µg 
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Polyvinylidene fluoride (PVDF) membrane (Immobilon, Merck Millipore) was activated 
with 100 % methanol for 30 secs, then transferred to dH2O for 5 min and placed in the 
transfer buffer (25 mM Tris-HC1, 150 mM glycine and 10% methanol). The SDS-PAGE gel 
was removed from the glass plates and transferred onto a Scotch pad and pre-soaked filter 
paper in a transfer cassette before the membrane was placed on top with another layer of 
filter paper and Scotch pad before closing the cassette. The cassette and a cool block were 
then placed in a tank filled with transfer buffer and left to transfer at 100 V for 1 h. 
After transfer, the membrane was removed from the tank and stained with 0.1% Ponceau S 
solution to visualise the protein. The membrane was then de-stained with PBS in a tray on 
the shaker at room temperature and the membrane was blocked with 20% (w/v) dried 
skimmed milk powder (Marvel) in PBS whilst shaking for 1 h at room temperature, or 
overnight at 4oC. After blocking, the membrane was washed three times in PBS with 0.1% 
Tween-20 (PBS-T) for 5 min each on a shaker at room temperature. The membrane was then 
incubated with the appropriate concentration of primary antibody (see Table 2.6) in 5% 
bovine serum albumin (BSA) (Millipore) in PBS-T on a roller stirrer at 4oC overnight (Table 
2.6). The membrane was washed three times with PBS-T, for 5 min each, on the shaker and 
then incubated with agitation at room temperature with the appropriate secondary antibody 
diluted in 5% (w/v) skimmed milk powder (Marvel) in PBS for an hour followed by three 
washes with PBS-T. EZ-ECL (Biological Industries) (1 ml/membrane) was added to the 
membranes, which were then wrapped in Saran Wrap and exposed to Amersham 
HyperfilmTM ECL (GE Healthcare) and developed. 
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Antibody  Species 
raised in 
Dilution factor Code No/Clove 
Primary Antibody (monoclonal) 
a/b- Tubulin Antibody  Rabbit 1:1000 #2148, CST 
FOXO1  Rabbit 1:1000 C29H4, CST 
FOXO1  Mouse 1:1000 D7C1H, CST 
Anti-Phospho-FOXO1 (Ser256)  Rabbit 1:1000 #9461, CST 
Flt-1  Mouse 1:500 V4262, Sigma 
Akt Antibody  Rabbit 1:1000 #9272, CST 
Phospho-Akt (Ser473) Antibody  Rabbit 1:1000 #9271, CST 
P44/42 MAPK (Erk1/2) Antibody  Rabbit 1:1000 #9102, CST 
Phospho-p44/42 MAPK (Erk1/2)(Thr202/Tyr204)  Rabbit 1:1000 #9101, CST 
FOXO3A  Rabbit 1:1000 D19A7, CST 
Neuropilin-1 Rabbit 1:1000 D62C6, CST 
Secondary Antibody 
Anti-rabbit IgG, HRP-linked Antibody  Rabbit 1:3000 # 7074, CST 





2.7.4 Stripping and re-probing membranes 
After the signal development, the membrane was washed twice in PBS and placed in 20 ml 
of stripping buffer (see Table 2.7) for 15 min twice at room temperature. The membrane 
was then washed twice in PBS-T for 10 min each and re-blocked for further use. 
Buffer Recipe 
1.5 M Tris, pH8.8 
(Resolving gel) 
90.8 g Tris Base 
500 ml ddH2O 
2g SDS 
0.5 M Tris, pH6.8 
(Stacking gel) 
6.06 g Tris Base 
100 ml ddH2O 
0.4 g SDS 
2X Sample Loading Buffer 1M Tris-HCI, pH 8 
10 % SDS 
1M DTT 
20% Glycerol 
1% Bromophenol Blue 
ddH2O 
10 X Running Buffer 30.3 g Tris Base 
144 g Glycine 
10 g SDS 
1L ddH2O 
Table 2.6: Details of primary and secondary antibodies used for Western Blotting including 
dilution factors, incubation conditions and suppliers. 
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10 X Transfer Buffer 30.3 g Tris Base 
144 g Glycine 
1L ddH2O 
1 X Transfer Buffer 100 ml 10 X Transfer Buffer 
200 ml Methanol 
700 ml ddH2O 
Stripping Buffer, pH 2.2 7.5 g Glycine 
0.5 g SDS 
5 ml Tween-20 




2.8 Cell Staining 
2.8.1 FITC Phalloidin Staining 
Cells were plated onto 8-well glass microculture slides (Nunc) at 2 x 104 cells/well in 300 
µl of growth medium and incubated at 37oC, 6% CO2 in a humidified atmosphere. Primary 
hESC and St-T1b cell were used. The cells were stimulated with MM1 medium for 5 days 
then re-stimulated for 24 h and then fixed with 4% formaldehyde (Pierce) in PBS for 20 min 
in room temperature. Cells were washed twice with PBS for 5 min each, permeabilised with 
0.1% Triton X-100 for 15 min and then washed twice with PBS. The cells were then stained 
with a 1:500 dilution Phalloidin-iFluor 488 Reagent CytoPainter (ab176753, Abcam) with 
PBS in a volume of 200 µl for 1 h at room temperature with gentle rocking. Cells were 
washed with PBS and counterstained with Hoescht (33342) at 1:500 dilution in PBS (200 
µl/well) for 45 min with gentle rocking and washed twice in PBS. The cells were visualised 
under a confocal microscope LSM 780 at 10 X magnification. All the incubations were 
performed in the dark due to the light sensitivity of fluorescent dye. 
 
2.8.2 Immunofluorescence Staining  
Cells were plated onto 8-well glass microculture slides (Nunc) at a density of 2 x 104 
cells/well in 300 µl growth medium and incubated at 37oC, 6% CO2 and a humidified 
Table 2.7: Buffers for SDS-PAGE and Western blotting. 
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atmosphere. Primary hESC and St-T1b cell were stimulated with MM1 medium for 3 days 
and re-stimulated for 24 h prior to staining. Cells were rinsed with PBS and fixed with 4% 
formaldehyde in PBS for 20 min in a fume hood at room temperature. The cells were rinsed 
with PBS, incubated with methanol for 10 min and then washed twice with PBS. The cells 
were then blocked with 5% goat serum (Sigma, D9663) in PBS for 20 min, followed by 
overnight incubation at 4oC with 1:50 dilution of primary antibody (Anti-FOXO1(C29H4); 
Anti-FOXO3A (D19A7); Flt-11 and C/EBPb (H-7)) in 1% BSA and 0.3% Triton X-100 in 
PBS. The cells were then washed twice with PBS and incubated with 1:1000 dilution of 
Alexa FluorTM 594 F(ab’)2 fragment of goat anti-rabbit IgG (H+L) or Alexa FluorTM 488 
F(ab’)2 fragment of goat anti-mouse IgG (H+L) secondary antibody (Invitrogen, Thermo 
Fisher Scientific) in 1.5% blocking serum in PBS for another 1 h in dark. The cells were 
washed again with 1 X PBS, mounted with Vectashield mounting medium H-1500 (Vector 
Laboratories) and visualised under LSM 780 confocal microscope. 
 
2.8.3 Indirect Flow Cytometry (FACS) 
Cells were plated on the 10 cm Ø dishes, grown to confluence and stimulated with E2 or 
MM1 medium for up to 6 days. Cells were re-stimulated with fresh medium 24 h and the 
total cell number determined. Cells (1 x 106 cells/ml) were re-suspended in ice-cold PBS 
and fixed with 4% formaldehyde for 20 min then washed three times with PBS and incubated 
with 1:100 dilution of anti-Flt-1 monoclonal antibody (Sigma) or relevant IgG control 
antibody in 3% BSA in PBS for 1 h on ice with agitation. The cells were centrifuged at 500 
x g for 5 min and re-suspended in ice-cold PBS three times. The cells were then incubated 
with diluted Alexa Fluor-488 labelled secondary antibodies in 3% BSA in PBS and 
incubated for 1 h on ice with agitation. The PI stain was added to label DNA. The cells were 
analysed in a 5 ml sterile non-pyrogenic FACS tubes with FACSCalibur Flow Cytometer 
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(Becton-Dickinson). The Flowing software 2 (free online software - 
http://flowingsoftware.btk.fi) was used to analyse the data for all experiments. 
 
2.9 Enzyme-Linked Immunosorbent Assay (ELISA) 
The conditioned media (1 ml/well) collected from stimulated cells were assayed for VEGF 
and sFlt-1 levels using the commercial human VEGF and Flt-1 DuoSet ELISA kits 
(DY293B & DY321B, R&D Systems) following the manufacturer’s guidelines. ImmunoTM 
96-well plates (Nunc) were coated with 100 µl capture antibody overnight at room 
temperature. The plates were aspirated and washed three times with 400 µl wash buffer (PBS 
with 0.05% Tween-20) and blocked with 300 µl of Reagent Diluent (0.22 µm filtered 1% 
(w/v) BSA in PBS) 1 h at room temperature. The wells were washed three times with wash 
buffer. 100 µl of protein standards or culture samples was added to the wells in duplicate 
and incubated for 2 h followed by three washes with wash buffer. 100 µl/well of detection 
antibody was added and incubated for 2 h at room temperature. The plates were washed 
three times again and 100 µl/well of Streptavidin-HRP was added and incubated for 20 min 
in the dark. The Substrate solution (100 µl/well) following three washes for 20 min in the 
dark. Stop solution (2N H2SO4) (50 µl/well) was added and the optical density read 
immediately at 450 nm with background correction at 540 nm using BioTek Synergy HT 
Microplate reader. Sample concentrations were calculated with Microsoft Excel from the 
standard curve. 
 
2.10 Proteome Profilling 
2.10.1 Human Angiogenesis Array 
hESC were plated at density of 2.5 x 106 cells on 10 cm Ø dishes overnight. The cells were 
then stimulated with E2 and MM1 medium for 5 days. The cells were detached by exposure 
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to trypsin and re-plated onto 6-well plates with a seeding density of 8 x 105 cells/well in 1 
ml DMEM/F12 containing 2% FBS or MM1 medium overnight and re-stimulated with fresh 
medium for 24 h. Cell supernatants were collected and aliquots stored at -20oC. Human 
Angiogenesis Proteome Profiller Array kits (R&D Systems) were used according to the 
manufacturer’s instructions. Briefly, 1 ml of CM was used per membrane. Each membrane, 
which carries capture antibodies to 55 angiogenesis-related factors spotted in duplicate, was 
treated with a cocktail of biotinylated detection antibodies and binding detected using 
streptavidin-HRP and chemiluminescence reagent. The signal density from each spot on the 
film was quantified using ImageJ software after exposure to film. Integrated densities for 
each spot were corrected using the negative control spots and normalised to the positive 
controls.  
 
2.10.2 Human Phospho-Kinase Array 
The St-T1b cells were plated in 10 cm Ø dishes at a cell density of 2.5 x 106 cells. After 24 
h, the medium was changed to DMEM/F12 with 2% FBS overnight. The cells were treated 
with 2% charcoal-stripped FBS medium or MM1 medium for 6 h and re-treated with their 
respective fresh medium 1 h prior to harvesting. The cells were rinsed with PBS, scraped 
into 1 ml of PBS and centrifuged at 200 x g for 5 min. The supernatants were discarded, and 
the cell pellet was solubilised at ~ 1 x 107 cells/ml of lysis buffer (Buffer 6) and incubated 
at 4oC for 30 min on a shaker. The lysate was centrifuged at 14,000 x g for 5 min and the 
supernatant transferred into a clean tube. The protein concentration in the lysates was 
quantified using the Bradford assay as described in section 2.7.1. Aliquots were stored at -
20oC before analysis using Human Phospho-Kinase profiler array kits (ARY003B, R&D 
Systems) according to the manufacturer’s instructions. The phospho-kinase array detects 43 
kinase phosphorylation sites and 2 related total proteins, each spotted in duplicate. A total 
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of 400 µg of cell lysate per membrane was mixed with a cocktail of biotinylated detection 
antibodies and the signal was detected with streptavidin-HRP and chemiluminescence 
reagent. Signal densities on the film were quantified using ImageJ software. Integrated 
densities of each spot were corrected using the negative control spots and normalised to the 
positive controls.  
 
2.11 Plasmids  
2.11.1 Recovery of plasmids stored on the filter paper 
Plasmids that had been archived on filter paper were extracted by cutting out the region 
carefully where the DNA had been spotted and placing it in 30 µl of QIAGEN elution buffer 
in an Eppendorf tube. The tube was warmed at 37oC for 15 min and centrifuged at 1,000 x 
g for 1 min to elute the plasmid. 
 
2.11.2 Transformation of plasmids into E.Coli 
TOP10 competent cells (Alpha-select gold efficiency, Bioline) were thawed on ice and 
plasmids (3 µl) was added gently and incubated on ice for 30 min. The cells were heat 
shocked for 45 secs at 42oC and placed on ice for 2 min before adding 500 µl of Luria Broth 
(LB) (Sigma). The cells were incubated at 37oC for 1 h in a shaking incubator. Between 20 
µl and 100 µl of bacterial culture was spread onto LB agar plates containing the appropriate 
antibiotics (100 µg/ml ampicillin or 50 µg/ml kanamycin (Table 2.8) and incubated at 37oC 
overnight.  
 
2.11.3 Plasmid Mini preparation 
A single bacterial colony was selected and inoculated into 5 ml LB medium containing the 
appropriate antibiotic and left to grow overnight at 37oC in a shaking incubator. 1 ml of 
culture was transferred to an Eppendorf tube and centrifuged at 12,000 x g for 1 min 
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according to QIAprep Miniprep protocol (Qiagen). The supernatant was discarded, and the 
pellet re-suspended in 250 µl of Buffer P1 and transferred to a centrifuge tube. Buffer P2 
(250 µl) was added and mixed thoroughly by inverting the tube a few times. Buffer N3 was 
immediately added and mixed by inverting a few times. The mixture was centrifuged at 
13,000 x g for 10 min and the supernatant transferred to a QIAprep 2.0 spin column followed 
by a quick spin at 13,000 x g. The column was washed with 0.5 ml Buffer PB, centrifuged 
for 1 min and then 0.75 ml Buffer PE, centrifuged for 1 min followed by an additional 1 min 
centrifugation after discarding the flow through. The column was placed in a clean 1.5 ml 
Eppendorf tube and 50 µl Buffer EB added, allowed to stand for 1 min and centrifuged for 
1 min to elute the DNA.  
 
2.11.4 Restriction digests to confirm the correct plasmid 
Plasmids isolated from bacteria clones were examined by restriction digestion to ensure the 
correct insert was present. All restriction digests were performed in a final volume of 20 µl. 
Restriction enzyme master mix was prepared by adding 2 µl Restriction enzyme buffer 
(NEB), 0.2 µl 100 x BSA, 1 µl of restriction enzyme (Table 2.8) and 5 µg of digesting 
fragment size determined on 1% agarose gels. 
 
2.11.5 Plasmid Maxi Preparation 
After verification, 500 µl of the overnight bacterial cultures was added to 200 ml of LB 
Broth with antibiotic and grown up overnight in a shaker at 500 rpm at 37oC. The plasmids 
were extracted using an Endotoxin-free Maxi DNA kit (QIAGEN). Briefly, the bacterial 
culture was harvested by centrifuging at 6,000 x g for 15 min at 4oC and the pellet re-
suspended in 5 ml of Buffer P1 followed by 5 ml of Buffer P2. The lysate was then mixed 
by inverting the tube until viscous and then incubated at room temperature for 3 min. 
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Immediately, the pre-chilled Buffer P3 (10 mL) was added, mixed and transferred to a 
QIAfilter cartridge. The lysate was incubated at room temperature for 10 min and then 
filtered into a 50 ml tube. The Buffer ER (5 ml) was added, mixed and incubated on ice for 
30 min. While a QIAGEN-tip 500 was equilibrated with 25 ml of buffer QBT. The lysate 
was then passed through the QIAGEN-tip 500 under gravity. The QIAGEN-tip was then 
washed twice with 30 ml of Buffer QC and the DNA was eluted in 10 ml of Buffer QN. The 
DNA was precipitated by adding an equal volume of isopropanol and centrifuging at 15,000 
x g for 30 min at 4oC. The DNA pellet was washed with 70% ethanol and centrifuged at 
15,000 x g, 10 min then allowed to air-dry and dissolved in 100 µl of endotoxin-free Tris-
EDTA (TE) buffer. The DNA concentration and purity was determined using a 
spectrophotometer by measuring 260:280nm absorbance. 
 
2.11.6 Cryopreservation of bacterial stocks 
Bacterial glycerol stocks were established for long-term storage. 500 µl of overnight 
bacterial culture was added to 500 µl of autoclaved 50% glycerol in PBS in a cryovial and 






FHRE-luc Ampicillin BamHI and Bgl II Michael Greenberg (plasmid 
#1789) 
pcDNA3.1-EGFP Ampicillin Bgl II and Xbal Doug Golenbock (Addgene 
plasmid # 13031 
 
pVEGF-Luc Ampicillin  Dr Padma-Sheela Jayaraman, 
University of Birmingham, 
UK 
pFlt-1-Luc Ampicillin  Dr Peter Hewett, University of 
Birmingham, UK 
pFOXO1(-AAA) Ampicillin  William Sellers (Addgene # 
9022) 
 
pFOXO3(-AAA) Ampicillin  William Sellers (Addgene # 
10709) 
pBABE-GFP Ampicillin BamHI and Xbal William Hahn (Addgene # 
10668) 
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pBABE-puroL HA FKHR AAA Ampicillin BamHI and Xhol William Sellers (Addgene # 
9025)   
pBABE-puroL FKHR AAA delta DB Ampicillin BamHI and Xhol William Sellers (Addgene # 
10697)   
pLenti-FOXO1 AAA Ampicillin BamHI and SalI Prof. Khandror, Boston 
University, USA 
pLenti-FOXO1 Wild Type Ampicillin BamHI and SalI Prof. Khandror, Boston 
University, USA 
pUMVC Kanamycin NotI and SalI Bob Weinberg (Addgene # 
8449)   
pWPT-GFP Ampicillin Bgl II Dr Samir Sissaoui, University 
of Worcester, Cambridge, 
USA 
pMD2.G Ampicillin Bgl II Didier Trono (Addgen plasmid 
# 12259)   
psPAX2 Ampicillin Xbal and SalI Didier Trono (Addgen plasmid 
# 12260)   
 
 
2.12 Viral Production and Infection 
2.12.1 Lentivirus and pBABE retrovirus production 
HEK293T cells were plated at density 1 x 106 cells/well in a 6-well plate for 24 h. After 24 
h, a ratio of 2:2:1 of the plasmid carrying the gene of interest, psPAX2 (packaging plasmid) 
and pMD2.G (envelope plasmid) was used to make up the lentivirus with various 
transfection reagents such as PEI, CaPO4, TransIT-2020 and TransIT-LT1. The transfected 
cells were topped up with fresh medium after 24 h of transfection. After 48 h of transfection, 
the supernatant was collected and aliquoted into sterile 1.5 ml tubes and centrifuged for 10 
min at 1,500 x g. The supernatant was then transferred to a new tube and stored at -80oC, 
used immediately for infection. 
Similar procedures were employed to produce retroviral vectors using pBABE. A ratio of 
4:3:1 of pBABE carrying the gene of interest (GOI) plasmid, pUMVC (packaging plasmid) 
(Stewart et al., 2003) and pMD2.G (envelope plasmid).  
 
Table 2.8: Lists of plasmids used in this study. 
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2.12.2 Viral Transduction 
The HEK293 cells were plated onto 6-well plates at a density of 1 x 106 cells/well and St-
T1b cells with 1 x 105 cells/well at least 24 h before infection. The growth medium was 
aspirated and replaced with fresh medium. The appropriate amount of virus was added to 
the well with 8 µg/ml of polybrene and incubated for 48-72 h. The medium was collected 
after every 24 h of infection. The GFP expression level was visualised under a fluorescence 
microscope. After 48-72 h of infection, the RNA, or protein lysates was harvested for later 
analysis. 
To select cells expressing the gene of interest (GOI) following viral infection, puromycin 
was used for negative selection. The lowest concentration of puromycin required to kill cells 
was established by treating the cells with different concentration of puromycin and incubated 
for 10-12 days. The medium containing puromycin was changed every 2-3 days. 
 
2.12.3 Puromycin Kill Curve 
A 10 mg/ml puromycin (Gibco, Life Technologies) stock solution was used. The cells were 
plated at 1 x 106 cells/well into a 6-well tissue culture plate. Once the cells were 60-80% 
confluent they were incubated in a range of 0 to 1.0 µg/ml of puromycin and incubated for 
5 days. After 5 days, the lowest concentration of puromycin in which 100% of cells died was 
the optimal concentration to use for transduced cell selection. 
 
2.13 Transient Transfection 
Transient plasmid transfections were carried out in St-T1b cells. The transfection efficiency 
was optimised using various reagents: Lipofectamine® 2000 (Invitrogen), JetPRIME 
(Polyplus Transfection), K2 (Biontex), HappyFect, polyethyleneimine (PEI), TransIT-X2 
(Mirus, Gene Flow), TransIT-2020 (Mirus, Gene Flow), Viromer Red (Lipocalyx) (see 
Appendix A). The cells were plated onto 12-well plates with appropriate cell density 
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according to TransIT-2020 manufacturer’s guidelines and incubated overnight. 
Transfections were performed with 1 µg of pcDNA3-EGFP gift from Doug Golenbock 
(AddGene) and the DNA complexes added dropwise to each well following manufacturer’s 
guideline. The plates were incubated for 24 h at 37oC and transfection medium replaced with 
fresh growth medium. 
 
2.13.1 Dual-luciferase reporter assay  
Dual-Luciferase Reporter Assays (Promega) were performed with various reporter vectors 
(see Table 2.7) and pRL-CMV Renilla control plasmid. TransIT-2020 transfection reagent 
was used. The cells were co-transfected with 1 µg of firefly luciferase test plasmid and ~50 
ng pRL-CMV Renilla control plasmid into cells overnight followed by 24 h stimulation with 
E2 or MM1 medium. The firefly reporter activity was determined using the Dual-Luciferase 
assay (Promega) in transfected cells following manufacturer’s guidelines, and the results 
normalised to Renilla luciferase reading measured using a Berthold Sirius Single Tube 
Luminometer. 
 
2.13.2 siRNA-mediated knock-down of genes expression in hESC  
hESC were plated at a density of 2.2 x 105 cells per well in 6-well plates and transfected 
with 50 nM of siRNAs targeting FOXO1 (siFOXO1), FOXO3A (siFOXO3A), Akt-1 (siAkt-
1), Flt-1 (siFlt-1), VEGF (siVEGF) or control (siControl) in Viromer Blue (4 µl/well) 
following the manufacturer’s guidelines. siRNA sequences are shown in Table 2.9. After 24 
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Potente et al., 2005 
AKT-1 5'-GGAGGGUUGGCUGCACAAAtt-3' 
5'-UUUGUGCAGCCAACCCUCCtt-3’ 
Jiang et al., 2005 
FOXO3A 5′- GAGCUCUUGGUGGAUCAUCtt-3′  
5’- GAUGAUCCACCAAGAGCUCtt-3’ 





VEGF  5’-GGAGUACCCUGAUGAGAUtt-3’ 
 5’-AUCUCAUCAGGGUACUCCtt-3’ 
 




2.13.3 FoxO Knock-out MEFs 
To generate the FoxO knock-out in MEFs, the cells were infected with an adenovirus 
expressing Cre recombinase (Ad-Cre), a kind gift of Dr Chris Kantos, Durham University, 
USA. Briefly, Ad-Cre viral supernatant was added onto 90% confluent HEK-293 cells (T-
75 flask). The supernatant was harvested after the cells had rounded up resembling bunches 
of grapes and the medium changed to bright yellowish colour. The viral supernatant was 
stored at -80oC. 
The MEFs were passaged and split onto T-75 flasks to be ~ 90% confluent on the next day. 
The cells were treated with Ad-Cre virus in 8 ml of serum-free MEFs medium and incubated 
overnight. The plate was rocked gently every 10-15 min for the first hour. 
 
2.14 Adenoviral-mediated transduction of hESC  
hESC cells (2.5 x 105 cells/well) were plated on 6-well plates and incubated overnight. The 
cells were then transduced with a multiplicity of infection (MOI) of 50 infection units (ifu)/ 
cell of recombinant adenovirus expressing HA-tagged murine FoxO1 (Ad-FoxO1) or empty 
Table 2.9: siRNA duplex used in this study. 
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control virus (Ad-CMV) for 24 h and incubated in E2 medium for another 24 h prior to 
harvesting. The Ad-FoxO1 was kindly provided by Prof. Domenico Acilli (Columbia 
University, New York, USA). Cell supernatants, RNA and protein lysate were harvested. 
 
2.15 Immunoprecipitation (IP) of Flt-1 from cell supernatants 
St-T1b cells were plated on 150 cm Ø tissue culture dishes and grown to confluence and 
stimulated with E2 or MM1 medium for 6 days. The cells were re-stimulated with fresh 
medium 24 h prior to harvesting. The supernatants were collected in clean Eppendorf tubes 
and centrifuged at 1,000 x g for 5 min to remove the cells and debris. Anti-Flt-1 antibody (3 
µg, Flt-11 mouse mAb, Sigma) was added and incubated at room temperature for 2 h on a 
rotary stirrer. The protein A/G magnetic beads (50 µl) were washed with 1 ml of reduced 
serum medium three times and the beads re-suspended with 100 µl of serum-reduced 
medium. The beads were then added into the antibody mixture and incubated overnight at 
4oC on a rotary stirrer. Magnetic separation was used to wash the pellet with 300 µl of Wash 
Buffer three times. The supernatants were collected in clean Eppendorf tubes and stored at -
20oC Antibody-protein complexes were eluted with 100 µl of 4 X SDS Lysis Buffer (Table 
2.10) at 95oC for 10 min and analysed by SDS-PAGE and Western blotting. 
Buffer Recipe 
Wash Buffer 10 mM Tris, pH 7.4 
1 mM EDTA 
1 mM EGTA, pH8.0 
150 mM NaCI 
1% Triton-X-100 
0.2 mM sodium orthovanadate 
+ Protease Inhibitor (1X) 
4 X SDS Lysis Buffer 60 mM Tris-HCI, pH6.8 
2% SDS 
20% Glycerol 
100 mM DTT 
0.001% Bromphenol blue 
 
Table 2.10: Buffers for Immunoprecipitation (IP) 
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2.16 Chromatin Immunoprecipitation-quantitative PCR (ChIP-qPCR) 
For ChIP, ~ 1 x 107 cells were used per condition. The cells were fixed on the plates by 
adding methanol-free formaldehyde (PierceTM (28906), Thermo Scientific) directly to the 
culture medium to a final concentration of 1% and incubated for 10 min at room temperature 
in a fume hood with agitation. The formaldehyde was then quenched by adding 2 M glycine 
(Sigma) to a final concentration of 0.4 M. The cells were scraped into ice-cold PBS and 
pelleted by centrifugation at 300 x g, 4oC for 5 min and washed twice with ice-cold PBS. 
The cells were then resuspended in ice-cold Buffer A (Table 2.11) and incubated for 10 min 
at 4oC with end-over-end mixing on a rotary stirrer. The nuclei were pelleted by 
centrifugation and resuspended with ice-cold Buffer B (Table 2.11) and incubated for 
another 10 min at 4oC with rotation then pelleted and snap frozen on dry ice and stored at -
80oC or processed further. The nuclei were re-suspended in ice-cold ChIP buffer (300 µl/ 1 
x 107 cells) and transferred to clean low-binding tube (Axygen).  
The chromatin was sonicated by using a Bioruptor (Diagenode, USA) set at high=240W; 30 
secs ON; 30 secs OFF. The degree of sonication was optimised using a series of cycles (0, 
15, 20, 25, 30, 35 and 40 cycle) for each cell type to ensure that the majority of fragments 
were around 200 – 500 bp. The sonicated material was then centrifuged for 10 min at 16,000 
x g at 4oC and the supernatants transferred to fresh tubes. Chromatin was diluted with 3x 
ChIP-dilution buffer (1:3 ratio) and 50 µL was kept as “input” control sample. 
Protein A/G Magnetic Beads (Pierce; Thermo Scientific), 10 µl per IP were washed twice 
with phosphate buffer (pH 8.0) and resuspended in 100 mM phosphate buffer (10 µl per 
sample). 10 µg of primary antibody (FOXO1A – ab39670 rabbit polyclonal, Abcam; FoxO1 
(C29H4) rabbit monoclonal; FKHR (H-128) sc-11350 Rabbit polyclonal; Anti-FOXO3A – 
ab12162 rabbit polyclonal, Abcam; Anti-Pol II – ab26721 rabbit polyclonal, Abcam) and 
BSA (0.5% (w/v) final concentration) was added to the Protein A/G Dynabeads. A non-
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specific rabbit IgG sc-2027 (Santa Cruz Biotechnology, Inc) was used as the negative control 
antibody. The antibody-Dynabeads mixture was incubated for 2 h at 4oC with rotation then 
washed with 100 mM phosphate buffer with 0.5% BSA and re-suspended in 10 µl of 100 
mM phosphate buffer. The diluted chromatin (400 µl) was added into the antibody-
Dynabead mixture and incubated for another 3 h at 4oC with rotation. The beads were 
washed with 1 ml of wash buffer 1, twice with wash buffer 2, once with LiCl buffer and 
finally twice with TE/NaCl. Each was for 10 minutes at 4oC. The beads were then transferred 
to a new tube and incubated with 50 µl of elution buffer twice for 15 min at room temperature 
with shaking. The chromatin cross-links were reversed by adding 1 µl of RNase A (10 
mg/ml) and incubated for 30 min incubation at room temperature. The chromatin was then 
incubated overnight at 55oC in a water bath with 4 µl of 5 M NaCl, 2 µl of 0.5 M EDTA and 
1 µl of proteinase K (50 mg/mL). 
The DNA was isolated by adding AxyPrep MagTM PCR clean-up beads (Axygen, 
Biosciences) [(Volume AMPure) =1.8 x reaction volume]. The DNA was mixed thoroughly 
by pipetting up and down and incubated at room temperature for 10 min. The beads were 
washed with 200 µl of 80% ethanol twice and air dried for 10 to 20 min. The DNA was 
eluted with 50 µl of 0.1 x TE buffer and the supernatant transferred carefully to new tubes. 
Real-time qPCR was run to determine the level of binding to sites in target genes. Table 
2.12 shows the lists of primers sequences and conditions used for amplification. 
The percentage of Input which represents the amount of DNA pulled down using the 
antibody of interest in the ChIP reaction relative to the amount of starting material (Input 
DNA) was calculated. The average Ct values for each antibody used were averaged and the 
delta Ct (the difference in Ct values between the input and the antibody of interest) was 
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calculated. Finally, the percentage of input was calculated based on the delta Ct using the 
formula below. 





















2.16.1 Identification of putative FOXO transcription factor binding sites and ChIP 
primer design  
The VEGF and Flt-1 reference sequences were obtained from University of California Santa 
Cruz (UCSC) genome browser (http://genome.ucsc.edu/) and then analysed using rVista 
(http://rvista.dcode.org/) (Loots and Ovcharenko, 2004) and Genomatix MatInspector 
Figure 2.2: Illustration of the key steps in ChIP-qPCR (Collas and Dahl, 2008). 
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(http://www.genomatix.de/) (Cartharius et al., 2005) for the presence of FHRE consensus 
sequences. Primers were then designed using Primer3 (http://primer3.wi.mit.edu/) 
(Koressaar and Remm, 2007) and Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) to amplify 80-200bp containing the sites of interest.  
Buffer Recipe 
Buffer A 10 mM HEPES, pH 8.0 
10 mM EDTA 
0.5 mM EGTA 
0.25 % Triton X-100 
(+ protease inhibitor cocktail (PIC) 1X) 
optional: 10 mM Na-butyrate 
Buffer B 10 mM HEPES, pH 8.0 
200 mM NaCl 
1mM EDTA 
0.5 mM EGTA 
0.01 % Triton X-100 
(+ PIC 1X) 
optional: 10 mM Na-butyrate 
ChIP Buffer 25 mM Tris-HCl, pH 8.0 
150 mM NaCl 
 2 mM EDTA 
1 % Triton X-100 
0.25 % SDS 
(+ PIC (1:1000), 0.1 mM PMSF) 
optional: 10 mM Na-butyrate 
3 X ChIP Dilution Buffer 25 mM Tris-HCl, pH 8.0 
150 mM NaCl 
2 mM EDTA 
1 % Triton X-100 
7.5 % Glycerol 
(+ PIC (1:1000), 0.1 mM PMSF) 
optional: 10 mM Na-butyrate 
Phosphate Buffer, pH 8.0 2 ml 1M Na2HPO4 
6 ml 1M NaH2PO4 
Wash Buffer 1 20 mM Tris-HCl (pH 8.0) 
150 mM NaCl 
2 mM EDTA 
1 % Triton X-100 
0.1 % SDS 
Wash Buffer 2 20 mM Tris-HCl (pH 8.0) 
500 mM NaCl 
 2 mM EDTA 
1 % Triton X-100 
0.1 % SDS 
LiCI Buffer 10 mM Tris-HCl (pH 8.0) 
250 mM LiCl 
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1 mM EDTA 
0.5 % NP-40 
0.5 % Na-deoxycholate 
TE/NaCI Buffer 10 mM Tris-HCl (pH 8.0) 
50 mM NaCl 
1 mM EDTA 
Elution Buffer 100 mM NaHCO3 








IGFBP-1 5’-CTGGACCTGGGCTGTCTTT-3’  
5’-ACACAGCGCGCACCTTAT-3’ 
58oC  287 bp Tamura et al., 
2012 
HBP1 5’-TGTCCCAGACACCAAAACAA -3’ 
5’-CGGGGAAGAGCTGGACTAC-3’ 
























58oC  174 bp Active Motif 
VEGF-FOXM1 5’-TCCGGGTTTTATCCCTCTTC-3’ 
5’-TCTGCTGGTTTCCAAAATCC-3’ 








58oC 172 bp In House 
VEGF-ChIP-4 5’-GGAGTGACTGGTGATGGCTA-3’ 
5’-TCAGCCCCTAAAAGAGCCAA-3’ 
60oC 123 bp In House 
VEGF-ChIP-5 5’-GGAGGTGGGCCATACTTTCT-3’ 
5’-GGTACCCAGCAAGGTGTGTT-3’ 
58oC 172 bp In House 
Flt-1-ChIP-1 5’-CCAAGTTGCAGGAGCAGTTT-3’ 
5’-GCCCAAGTCATTTCCTCAGT-3’ 
60oC 103 bp In House 
Flt-1-ChIP-2 5’-GAGCCATCACAGTCCCTTGT-3’  
5’-GAGCAGCCCAGTCTTGTCTC-3’  
60oC 97 bp In House 
Table 2.11: Buffers used for ChIP. 





60oC 120 bp In House 
Flt-1-ChIP 4 5’-CGACATGCTGGAAAGACAGA-3’ 
5’-GCTATCTGGCTGCCCTTGT-3’ 




2.17 In Vitro Angiogenesis Assays 
2.17.1 Scratch-wound Migration Assay 
Cells (2 x 105) were seeded into 12-well plates and allowed to grow in their respective 
growth medium until they reached confluence. The cells were starved with serum-free 
medium for 4 h. Cell monolayers were then scratched with a sterile 200 µl pipette tip and 
the dislodged cells were washed away with PBS. Cells were then incubated in DMEM/F12 
containing 2% FBS with, or without, growth factors (50 ng/ml VEGF-165, 50 ng/ml PIGF-
2 or 100 ng/ml EGF) or with various CM. Eight images of cells per condition were captured 
on 0 and 24 h with an EVOS inverted phases microscope at 10 X objective as shown in 
Figure 2.3. The wound closure was quantified by ImageJ with Trainable Weka 
Segmentation and Voxel Counter plugins (Arganda-Carreras et al., 2017). The area of cell 
migration was calculated by the difference between time 24 h and 0 h.  
 
2.17.2 Tube Formation Assay 
Growth factor-reduced, phenol red-free Matrigel (Corningâ Matrigelâ Matrix USA) was 
stored at -80oC and thawed on ice. A 12-well plate was rinsed with PBS and 70 µl of Matrigel 
was immediately pipetted into each well and left to set at room temperature. HUVEC were 
harvested and 180,000 cells were mixed with 1 ml of medium pipetted into each well. The 
tube formation was visualised using an IncuCyte ZOOMÒ system control (Essen 
BioScience) under 4 X objective and the images were taken every 6 h. The tube networks 
were quantified using Angiogenesis Analyser, ImageJ (plugin software) (Gilles, 2012). 
Table 2.12: ChIP primer sequences and conditions for PCR amplification. 




2.17.3 Spheroid Sprouting Assay 
hESC spheroids (5,000 cells/spheroid) or mixed cell spheroids (HUVEC and St-T1b cell 
with a ratio 1:1) were seeded on 96-well round bottom non-TC-treated plates in DMEM/F12 
medium supplemented with 2% FBS and 0.25% methylcellulose (Polymer). The cells were 
incubated overnight at 37oC to allow aggregation and formation of the spheroid. 
Growth factor-reduced Matrigel (200 µl) was added to each well of a pre-cooled 24-well 
plate and incubated at 37oC and 5% CO2 for 45 min to set. Spheroids were harvested by 
rinsing with PBS and 12 spheroids were rapidly transferred to a well and covered 200 µl of 
Matrigel. The gel was mixed very carefully with a pipette tip without breaking the bottom 
layer of Matrigel to achieve an even distribution of the spheroids in the gel and incubated 




















Well 1 Well 2 Image segmentation   
Area migrated  
 (24 h - 0 h) 
 
0 h 24 h 
Figure 2.3: Illustration of the Wound healing assay plate layout. Confluent cell 
monolayers were scratched with a 200 µl tip and images were taken at 0 and 24 h according to 
the areas labelled. 
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spheroids sprouting observed under phase contrast with 10 X objective up to 24 h. Images 
of 10 spheroids per condition were taken and the mean length of the sprouts was measured 






2.18 Statistical Analysis 
The statistical significance of the data was determined using GraphPad Prism; two-tailed t-
tests (Nonparametric Tests), one-way and two-way ANOVA with multiple comparisons 
using the Dunnett test. All data are expressed as means and standard error (+/- SEM). 
Overall, p< 0.05 was considered to be statistically significant.     
DMEM/F12 + 1% 







Figure 2.4: Formation and embedding of spheroids in Matrigel for sprouting assays. 
The spheroids were formed in a round bottom non-tissue culture plate and embedded in growth factor-
reduced Matrigel on 24-well plate and conditioned medium (CM) or control medium added.  
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Unlike most adult tissues, uterine endometrium undergoes cyclic growth and tissue 
remodelling throughout the reproductive years to prepare for blastocyst implantation. During 
the mid-secretary phase of the cycle, the endometrial stromal cells (ESC) differentiate into 
decidual cells (decidualisation) regulated by ovarian steroids such as oestrogen, 
progesterone and various cytokines, beginning a few days after ovulation, at the onset of the 
window of implantation (Gellersen and Brosens, 2014). Impaired decidualisation can cause 
miscarriage independently of the quality of the blastocysts, or even lead to preeclampsia and 
IUGR later in pregnancy (Zhang et al., 2013; Large et al., 2014).  
In humans, the decidualisation process is maternally controlled and is initiated independently 
of a signal from an implanting blastocyst, by progesterone and increased intracellular cAMP 
levels. In vivo, rising progesterone levels in the secretory phase of the menstrual cycle 
stimulate stromal cells, increasing intracellular cAMP and activating downstream PKA 
signalling leading to the expression of decidual genes (Telgmann et al., 1997) such as PRL 
and IGFBP1 accompanied with morphological changes (Samalecos et al., 2009). Both 
oestrogen and progesterone have been widely used to induce in vitro decidualisation for up 
to 14 days (Dimitriadis et al., 2002; Sakai et al., 2003). However, in vitro decidualisation 
can also be induced by the addition of progesterone analogues such as MPA, which has a 
much longer half-life in aqueous solution than progesterone and/or cAMP (Tawadros et al., 
2007; Samalecos et al., 2009).  
To date, accumulating data have shown that numbers of genes including cytokines, growth 
factors, and transcription factors are involved in decidualisation (Zhang et al., 2013; Tamura 
et al., 2014a). FOXO1 is an important regulator of various integral cell functions including 
apoptosis and metabolism (Samalecos et al., 2009; Gellersen and Bronsens, 2003). The 
activity of FOXO1 is regulated by the PI3K via Akt-mediated phosphorylation of FOXO1 
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leading to its nuclear translocation (Tang et al., 1999). Decidualised ESC support the 
remodelling and development of the endometrial vasculature and play a critical role in 
embryonic growth and survival in response to female sex hormones such as oestrogen and 
progesterone which act indirectly via many regulators (Girling and Rogers, 2005; Smith, 
2001). Decidualised ESC play a role in protecting the embryo from oxidative stress (Okada 
et al., 2017). Decidualised ESC are known to be more resistant to oxidative cell death 
compared to the undifferentiated ESC through increased expression of copper, zinc (SOD1) 
and manganese superoxide dismutases (SOD2) in early pregnancy (Kajihara et al., 2006).  
Despite advances in assisted reproductive technology (ART), many couples experience 
infertility due to the failed or defective implantation of the fertilised embryo into the uterus 
leading to pregnancy loss (Venners et al., 2004; Brosens et al., 2011). Therefore, knowledge 
of the mechanism of decidualisation is important to help in improving the success rate of 
ART and to lay a foundation for the development of the new treatments in reproductive 
clinical practice. In addition, impairment of ESC decidualisation may be a factor in 
preeclampsia, IUGR, recurrent miscarriage and other pregnancy disorders. In order to 
investigate the molecular mechanisms regulating human decidualisation, cultured hESC are 
critical tools due to the ethical issues associated with in vivo human studies. In this chapter, 
primary hESC and the established St-T1b hESC line (Samalecos et al., 2009) were used to 
establish conditions for in vitro decidualisation, characterise changes that occur during this 
process and to investigate the secretion of angiogenesis associated factors. 




3.2.1 Characterisation of hESC 
In order to induce decidualisation, primary hESC and St-T1b cells were stimulated with 
MPA and 8-Br-cAMP at various time points over 7 days. The cell lysates and supernatants 
were collected depending on the type of experiment as shown in Figure 3.1. The Trypan 
Blue dye exclusion was used to determine the cell viability in a cell suspension. The 
expression of angiogenic factors and various decidual marker genes was examined. 
Differentiation of the cells was confirmed by observing cell morphology (Figure 3.2) and 









3.2.1.1 Morphological Changes of hESC with decidualisation 
Primary hESC and St-T1b cells were incubated with E2 or MM1 medium and harvested at 
a range of time point up to 7 days and the cell viability was greater than 90%. In order to 
determine whether the cells had undergone decidualisation, the morphology of the cells was 
monitored under bright field illumination on the phase contrast microscope every 24 h. The 
Figure 3.1: Protocol for stimulation of hESC decidualisation in vitro.   Primary hESC 
and St-T1b cells were incubated as outlined in the scheme. Cultures were treated with E2 or MM1 
medium for 1, 3 or 6 days. Supernatants were collected at each time point, RNA or protein lysates 
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cell morphology started to change from an elongated, fibroblast-like appearance to a more 
rounded epithelial cell appearance after 24 h (Figure 3.2A). 
In order to determine the changes in the actin cytoskeleton arrangement of the cells, the cells 
were incubated with E2 or MM1 medium, for 6 days followed by Phalloidin staining. The 
localisation of F-actin filaments in decidualised hESC showed the expected cytoskeletal 
reorganisation and the changes of shape that were consistent with the transformation from 

































3.2.1.2 Biochemical Changes of hESC with decidualisation 
Decidualisation of ESC with cell viability >95% was confirmed by checking the expression 
of decidual-specific markers PRL and IGFBP1 (Samalecos et al., 2009) with GAPDH as 
control by RT-PCR. The expression of PRL and IGFBP-1 were increased with 
decidualisation. Interestingly, both PRL and IGFBP-1 expression decreased from day 3 to 
day 6 of stimulation in primary hESC (Figure 3.3A). St-T1b cells also behaved as primary 
Figure 3.2: Changes in hESC actin cytoskeleton following in vitro 
decidualisation. (A) Primary hESC and St-T1b cells were seeded on 6-well plates and 
stimulated with E2 or MM1 medium over 6 days. Images were taken using EVOS phase contrast 
microscope at 10 X objective magnification. (B) Primary hESC and St-T1b were decidualised on 
culture slides for 5 days and stained with rhodamine phalloidin (green) and Hoescht 33342 (blue). 
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hESC where PRL and IGFBP-1 were increased with decidualisation and the expression was 
observed as early as 24 h after stimulation (Figure 3.3B).   
 
 
3.2.2 Regulators of decidualisation  
3.2.2.1 Expression and activity of FOXO1 transcription factor in hESC during in vitro 
decidualisation 
The FOXO1 transcription factor is a key regulator of ESC decidualisation (Gellersen and 
Brosens, 2003). Changes in FOXO1 mRNA expression were examined by real-time qPCR 
as well as protein levels by Western blotting. The expression of FOXO1 mRNA and protein 
was examined in primary hESC. FOXO1 mRNA and protein were increased dramatically 
during decidualisation in primary hESC (Figure 3.4A&B). The FOXO1 mRNA and protein 
Figure 3.3: Induction of PRL and IGFBP-1 in hESC. (A) Primary hESC and (B) St-
T1b cells were cultured in 6-well plates and stimulated with E2 (-) and MM1 medium (+) for 3 
days (3d) and 6 days (6d). Induction of transcripts for decidualisation markers PRL and IGFBP-1 
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expression were also examined in St-T1b cells. The results obtained from St-T1b cells 
validated the increased of FOXO1. There was a large increase in FOXO1 mRNA levels from 
day 3 which was maintained to day 6 of decidualisation in St-T1b cells (Figure 3.5A). The 
expression of FOXO1 mRNA was detected as early as 2 h (Figure 3.5B). The FOXO1 
protein levels mirrored the expression of mRNA. There was no increase in FOXO1 
expression in control cells incubated in E2 medium (Figure 3.5B).  
As FOXO1 activity is also subject to post-translational regulation, a FHRE promoter firefly 
luciferase reporter construct (FHRE-Luc) was used to investigate FOXO1 activity in St-T1b 
cells during decidualisation. St-T1b cells were co-transfected with FHRE-Luc plasmid and 
the pRL-CMV Renilla luciferase control plasmid for 24 h, followed by 24 h stimulation with 
E2 or MM1 medium containing 2% charcoal-stripped FBS and 0.5 mM 8-Br-cAMP. 
Luciferase activity was determined by dual luciferase reporter assay and the data was 
normalised to Renilla luciferase control readings. A 4-fold increase of FHRE promoter 
activity was detected in the cells stimulated with 8-Br-cAMP compared to control and the 
increase in activity was independent on the concentration of cAMP (Figure 3.6). 











    -      +        -        +  MPA+ 8-Br-cAMP 
 
Figure 3.4: FOXO1 expression in primary hESC during in vitro decidualisation.  
(A) Real-time qPCR analysis of FOXO1 mRNA normalised to β-actin in primary hESC treated 
with E2 or MM1 medium for 3 and 6 days. (B) Representative Western blot showing of FOXO1 
in whole-cell lysates with tubulin as a control. Results are the mean (+/- SEM) of 3 experiments 
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Figure 3.5: FOXO1 expression in St-T1b cells during in vitro decidualisation. 
Real-time qPCR analysis of FOXO1 mRNA normalised to β-actin in St-T1b cells treated with 
E2 or MM1 medium (A) for 3 and 6 days, and (B) short-term stimulation. (C) Representative 
Western blot showing of FOXO1 in whole-cell lysates with tubulin as a control. Results are the 
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3.2.2.2 Characterisation in changes of key decidualisation-related genes in primary 
hESC and St-T1b  
Other key decidualisation-related genes including C/EBPβ, SOD2, HOXA10, FOXM1, IRF-
4 and PLZF expression were investigated in primary hESC and St-T1b cells under our in 
vitro decidualisation conditions. C/EBPb plays an important role in regulating decidual 
marker gene expression in association with FOXO1 transcription factors (Tamura et al., 
2014b). C/EBPb mRNA dramatically increased by ~ 6-fold during decidualisation in both 
primary hESC (Figure 3.7A) and St-T1b cells (Figure 3.7B).  
Superoxide dismutase-2 (SOD2) and Interferon regulatory factor 4 (IRF-4) which is reported 
to be a direct target of FOXO1 (Ujavri et al., 2017; Vazquez et al., 2015), was found to 
significantly increase in the decidualised St-T1b cells (Figure 3.8A&D). In addition, the 
increasing of HOXA10, PLZF, and FOXM1 also detected in St-T1b cells (Figure 3.8B-D).  
Figure 3.6: FOXO1 activity in St-T1b cells during in vitro decidualisation.  St-T1b 
cells were plated on 12-well plates overnight and co-transfected with a FOXO1 luciferase reporter 
(FHRE) and pRL-CMV Renilla luciferase control plasmid. FHRE activity was normalised to pRL-
CMV Renilla activity to control for differences in transfection efficiency. Results are the mean (+/- 







































Figure 3.7: Up-regulation of C/EBPb during decidualisation in hESC. Real-time 
qPCR analysis of C/EBPβ mRNA expression normalised to β-actin in (A) primary hESC and (B) 
St-T1b cells treated with E2 or MM1 medium after 3 and 6 days. Results are the mean (+/- SEM) 
of 3 experiments and analysed using an unpaired, non-parametric t-test; *p<0.05; **p<0.01; 

























































































































Figure 3.8: Up-regulation of various decidual factor during decidualisation in 
St-T1b cells.  Real-time qPCR analysis of (A) SOD2, (B) HOXA10; (C) FOXM1; (D) IRF-4 and 
(E) PLZF expression normalised to β-actin in St-T1b cells treated with E2 or MM1 medium after 
3 and 6 days. Results are the mean (+/- SEM) of 3 experiments and analysed using an unpaired, 
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3.2.3 Secretion of angiogenic factors by hESC during decidualisation 
Decidualised hESC are known to play a critical role in angiogenesis in the endometrium 
(Okada et al., 2017). Therefore, human proteome profiler angiogenesis arrays were used to 
determine the profile of angiogenic factors secreted by hESC during decidualisation. 
Primary hESC and St-T1b cells were incubated with E2 or MM1 medium for 5 days and 
then re-plated with DMEM/F12 medium containing 2% FBS or MM1 medium overnight, 
the cells were re-stimulated with E2 or MM1 medium 24 h prior to harvesting and the 
supernatants analysed using the angiogenesis array. The results were analysed by measuring 
the mean spot density normalised to spots reference using ImageJ as described in Section 
2.11.1.  
As shown in Table 3.1, we found that in primary hESC angiopoeitin-1, amphiregulin, EG-
VEGF, HB-EGF, MCP-1, MMP-8, MMP-9, PRL, TIMP-4 and VEGF were changed during 
decidualisation compared to proliferative cells while in St-T1b cells, the factors like 
endoglin, GM-CSF, HB-EGF, HGF, IGFBP-1, MCP-1, MMP-9, PDGF-AA, PF4, PRL, 
TIMP-4, and VEGF were changed during decidualisation. However, only angiopoeitin-1, 
MCP-1, MMP-8, MMP-9, PRL, and VEGF were significantly increased with 
decidualisation in primary hESC (Figure 3.9B). The secretion of GM-CSF, HB-EGF, and 
PDGF-AA were significantly decreased with decidualisation, while, HGF, IGFBP-1, MCP-
1, PRL and VEGF secretion were significantly increased in St-T1b cells (Figure 3.9D). 
There were only three identical factors, PRL, VEGF, and MCP-1 that were significantly up-
regulated in both primary hESC and St-T1b cells. Surprisingly, IGFBP-1 which is a 
commonly used decidual marker was significantly increased in St-T1b cells during 
decidualisation, which is consistent with the previous as shown in Figure 3.3. However, low 
IGFBP-1 mRNA detected at day 6 in primary hESC did not show the changes of IGFBP-1 
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secretion. There are many angiogenic factors that were highly expressed in hESC (Table 




Primary hESC St-T1b 
Proliferative Decidualised Proliferative Decidualised 
Angiopoietin-1 0.66 0.89 0.79 0.88 
Amphiregulin 0.32 0.49 0.12 0.17 
EG-VEGF 0.27 0.39 0.29 0.30 
Endoglin 0.83 0.91 0.42 0.30 
GM-CSF 0.60 0.68 0.64 0.18 
HB-EGF 0.27 0.40 0.84 0.19 
HGF 0.47 0.59 0.29 0.91 
IGFBP-1 0.85 1.00 0.45 1.00 
MCP-1 0.16 0.47 0.17 1.00 
MMP-8 0.39 0.79 0.29 0.33 
MMP-9 0.34 0.86 0.53 0.35 
PDGF-AA 0.26 0.31 0.97 0.44 
Platelet Factor 4 (PF4) 0.19 0.31 0.16 0.37 
Prolactin 0.45 0.97 0.14 0.73 
TIMP-4 0.30 0.37 0.46 0.96 













Table 3.1: Lists of angiogenesis involved proteins differentially expressed during decidualisation 
in primary hESC and St-T1b cells. 
  
 
Table 3.2: List of angiogenic factors that expressed in primary hESC and St-T1b cells 
without showing any differences in decidualisation.Table 3.1: Lists of angiogenic factors 
modified by the decidualisation effect in primary hESC and St-T1b cells. 
 
 
Table 3.2: List of angiogenic factors that expressed in primary hESC and St-T1b cells 
without showing any differences in decidualisation. 
  
 
Table 3.2: List of angiogenic factors that expressed in primary hESC and St-T1b cells 
without showing any differences in decidualisation.Table 3.1: Lists of angiogenic factors 
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Table 3.2: List of angiogenic factors that expressed in primary hESC and St-T1b cells 
without showing any differences in decidualisation.Table 3.1: Lists of angiogenic factors 
modified by the decidualisation effect in primary hESC and St-T1b cells. 
  





Primary hESC St-T1b 
Proliferative Decidualised Proliferative Decidualised 
Activin 0.89 0.99 0.99 0.99 
ADAMTS-1 0.14 0.18 0.29 0.23 
Angiogenin 0.90 0.99 1.00 0.98 
Angiopoietin-2 0.79 1.00 0.49 0.47 
Angiostatin/Plasminogen 0.14 0.17 0.20 0.16 
Artemin 0.27 0.28 0.17 0.13 
Coagulation Factor III 0.89 0.92 0.87 0.77 
CXCL16 0.31 0.35 0.28 0.38 
DPPIV 0.85 0.91 0.22 0.32 
EGF 0.09 0.13 0.17 0.17 
Endostatin/Collagen XV 0.88 0.90 0.63 0.56 
Endothelin-1 0.66 0.65 0.65 0.42 
FGF acidic 0.26 0.26 0.22 0.27 
FGF basic 0.35 0.41 0.14 0.17 
FGF-4 0.22 0.23 0.10 0.27 
FGF-7 0.22 0.33 0.10 0.28 
GDNF 0.21 0.26 0.19 0.21 
IGFBP-2 0.87 0.97 0.48 0.32 
IGFBP-3 0.83 0.99 1.00 1.00 
IL-1b 0.12 0.15 0.21 0.18 
IL-8 0.89 1.00 0.72 0.92 
TGF-b1 0.53 0.50 0.22 0.19 
Leptin 0.17 0.19 0.11 0.24 
MIP-1a 0.38 0.40 0.25 0.23 
NRG1-b1 0.15 0.24 0.29 0.42 
Pentaxin 3 (PTX3) 0.54 0.72 0.98 1.00 
PD-ECGF 0.29 0.37 0.27 0.26 
PDGF-AB/BB 0.10 0.11 0.18 0.13 
Persephin 0.30 0.34 0.34 0.39 
PIGF 0.20 0.25 0.17 0.26 
Serpin B5 0.35 0.56 0.25 0.23 
Serpin E1 0.99 1 0.97 0.98 
Serpin F1 0.96 0.98 0.99 0.98 
TIMP-1 0.98 1.00 1.00 1.00 
Thrombospondin-1 1.00 1.00 0.99 1.00 
Thrombospondin-2 0.57 0.58 0.36 0.34 
µPA 1.00 1.00 0.99 0.96 
Vasohibin 0.45 0.46 0.11 0.11 







Table 3.2: List of angiogenesis involved proteins expressed in primary hESC and St-T1b cells 
without showing any differences in decidualisation. 
  
 
Table 3.2: List of angiogenic factors that expressed in primary hESC and St-T1b cells 
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3.3.1 Up-regulation of decidual markers, PRL and IGFBP-1 
In the present study, St-T1b cell line was confirmed as having similar characteristics as 
primary hESC following the induction of decidualisation by MPA and cAMP (Samalecos et 
al., 2009). Primary hESC and St-T1b cells stimulated with 8-Br-cAMP and MPA showed a 
dramatic increase of both common decidual markers, PRL and IGFBP-1 mRNA transcripts 
supporting the previous findings (Samalecos et al., 2009). Surprisingly, unlike the mRNA 
expression, IGFBP-1 protein was highly secreted in both proliferative and decidualised 
primary hESC and these results are consistent with the earlier findings in T-HESC cells 
during decidualisation (Gellersen et al., 2013).  
 
3.3.2 Up-regulation of transcription factors during hESC decidualisation 
FOXO1 has been identified as a key transcriptional regulator of decidualisation (Gellersen 
and Brosens, 2003; Samalecos et al., 2009; Christian et al., 2011). The activation of protein 
kinase A (PKA) results in the up-regulation and nuclear localisation of FOXO1 and is 
accompanied by the induction of C/EBPβ expression (Christian et al., 2011). C/EBPβ is 
another transcription factor that regulates the expression of a number of decidualisation 
related genes. As shown in Figure 3.4 & 3.5, FOXO1 and C/EBPβ were up-regulated from 
Figure 3.9: Summary of primary hESC and St-T1b cell analysis using the 
angiogenesis proteome profiler arrays. The (A) primary hESC and (C) St-T1b cells were 
treated with (i) E2 and (ii) MM1 medium for 5 days in 10 cm culture dishes and re-plated on 6-
well plate with cell density 8.0 x 105 cells/well for another 48 h. The cells were re-stimulated with 
fresh medium after 24 h and the supernatants were analysed using Human Proteome Profiler 
Angiogenesis Arrays. The density was measured by densitometry using ImageJ and the results 
were normalised to positive reference control spots following subtraction of the negative control 
spots. All the significant changes of angiogenic factors in both (B) Primary hESC, and (D) St-T1b 
cells were shown in the graph. The results are the mean (+/- SEM) of 4 experimental repeats and 
analysed using student t-test; *p<0.05; **p<0.01; ***p<0.001.   
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day 3 to day 6 during the decidualisation in both primary hESC and St-T1b cells, while no 
changes were observed in proliferative cells. Studies show that dPRL and IGFBP-1 are 
induced by cAMP through the recruitment of C/EBPβ during decidualisation of ESC 
(Christian et al., 2002; Tamura et al., 2014b). Furthermore, Manganese superoxide 
dismutase (Mn-SOD/SOD2), an anti-oxidant enzyme is expressed in hESC at basal levels 
without decidualisation stimulus, and its expression increases with decidualisation, 
contributing to cell survival by scavenging superoxide radicals produced by decidualisation 
stimulus in primary hESC (Kajihara et al., 2006). Previous studies also demonstrated the 
increase of SOD2 in primary hESC decidualisation (Brar et al., 2001; Garrido-Gomez et al., 
2011). In this study, SOD2 mRNA was detected and its expression was dramatically 
increased during decidualisation in St-T1b cells (Figure 3.6) which supports the previous 
studies in primary hESC (Brar et al., 2001; Kajihara et al., 2006; Garrido-Gomez et al., 
2011). IRF4 was reported to be regulated by FOXO1 in hESC (Vasquez et al., 2015) which 
is consistent with my results showing an increase of IRF4 in hESC during decidualisation. 
HOXA10 is one of the known homeobox gene family that is essential in development. 
HOXA10 is up-regulated in the response to steroid hormones including oestrogen and 
progesterone and its expression rises dramatically during the mid-secretory phase of the 
menstrual cycle (Taylor et al., 1997). The HOXA10 deficient mice are infertile due to the 
impairment of endometrial decidualisation (Benson et al., 1996), and HOXA10 expression 
was found at high levels in the late secretory phase of implantation (Cakmak and Taylor, 
2011). In addition, the injection of antisense oligonucleotides to HOXA10 into the mouse 
uterus leads to a reduction of implantation rates (Bagot et al., 2000). However, the exact role 
of HOXA10 in uterine stromal cell differentiation remains unclear. HOXA10 has been found 
to cooperate with FOXO1 in the regulation of IGFBP-1 expression during decidualisation 
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(Kim et al., 2003). However, it has also been reported that HOXA10 acts as an inhibitor to 
IGFBP-1 expression during decidualisation, where knock-down of HOXA10 was found to 
increase IGFBP-1 expression (Kim et al., 2007). Moreover, HOXA10 has been reported to 
play a role in proliferation by regulating 494 genes during decidualisation in primary hESC 
(Lu et al., 2008). As shown in the present study, the expression of HOXA10 mRNA was up-
regulated with decidualisation in St-T1b cells (Figure 3.8), which is consistent with the 
previous findings in primary hESC.  
FOXM1 plays an important role in cell cycle progression and differentiation (Laoukili et al., 
2007). It is expressed in hESC and its inhibition is found to prevent decidualisation (Jiang 
et al., 2015). In agreement with these findings in hESC, the conditional deletion of FOXM1 
in the mouse led to the implantation failure with decidualisation defects (Gao et al., 2015). 
In our study, FOXM1 mRNA levels increased during decidualisation in St-T1b cells 
consistent with previous studies in primary hESC (Gao et al., 2015; Jiang et al., 2015).  
PLZF has been reported recently as a direct target of the progesterone receptor and it is up-
regulated during decidualisation of St-T1b cells (Samalecos et al., 2009) and primary hESC 
(Kommagani et al., 2016; Szwarc et al., 2018). In this study, PLZF expression was 
significantly up-regulated with decidualisation in St-T1b cells as the previous findings in 
primary hESC (Kommagani et al., 2016; Scwarc et al., 2018). No PLZF was detected in the 
cells treated with just cAMP alone. 
 
3.3.3 Changes of angiogenic factors during hESC decidualisation 
Adequate angiogenesis is reported to be the most critical factor during decidualisation to 
ensure successful implantation and placentation (Tory et al., 2007). Our protein array results 
show that in vitro decidualisation not only up-regulates major angiogenic factors and 
regulators such as angiopoietin-1, VEGF, MMP-8, MMP-9, but also other cytokines and 
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chemokines such as MCP-1. Monocyte chemoattractant protein-1 (MCP-1) is important for 
angiogenesis, tissue remodelling, embryo implantation, early pregnancy and trophoblast 
invasiveness (Houser, 2012; Bourdiec et al., 2016). Angiopoietin-1, MMP-8, and MMP-9 
secretion increased during decidualisation of primary hESC, but not in St-T1b cells. While, 
MCP-1 was increased with decidualisation in both primary hESC and St-T1b cells. Many 
studies have reported the up-regulation of MCP-1 expression in primary decidual ESC 
(Lockwood et al., 2006; He et al., 2007) and St-T1b cells (Schwenke et al., 2013) supporting 
the findings in this study. 
In this study, VEGF secretion was increased during decidualisation in both primary hESC 
and St-T1b cells. The up-regulation of VEGF expression has been reported in primary hESC 
under decidualisation conditions supporting my findings (Sugino et al., 2002; Schwenke et 
al., 2013). However, very little is known about the significance of the contribution of VEGF 
produced by decidual cells during decidualisation in hESC. Further studies are needed to 
investigate the contribution of VEGF in decidualisation which will be discussed in the later 
chapter in this thesis. 
Angiopoietins are another key factor in promoting angiogenesis and vessel remodelling in 
the endometrium. The balance between angiopoietin-1 and angiopoietin-2 expression is 
important for angiogenesis in the endometrium (Tsuzuki et al., 2013). Angiopoitein-1 
expression was suppressed by hypoxia and oestrogen which increase angiopoietin-
2/angiopoietin-1 ratio appears to favour the remodelling of endometrial blood vessel in 
primates (Albrecht and Pepe, 2010). Whereas, angiopoietin-2 expression was suppressed by 
MPA for maturation and maintenance of newly formed vessels in endometrium (Tsuzuki et 
al., 2013). In this study, high expression of angiopoietin, angiopoietin-1 and angiopoietin-2 
were detected in both primary hESC and St-T1b cells. The expression of angiopoietin-1 was 
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found to increase in primary hESC during decidualisation which may be influenced by the 
oestrogen and MPA.  
Furthermore, a large amount of MMPs are secreted in normal early pregnancy, while 
simultaneously producing TIMPs to inhibit MMPs to maintain the dynamic balance of 
MMPs/TIMPs (Singh et al., 2017). A significant increase of MMP-9 expression was found 
in the endometrium of women with spontaneous abortion (Skrzypczak et al., 2007; Jiang 
and Qi, 2015). In addition, the earlier study reported the increase of MMP-8 and MMP-9 
during decidualisation in T-HESC cells (Gellersen et al., 2013). It is known that MMPs are 
important in decidual development, but the information is very limited due to the actions of 
individual MMPs and also the interaction of MMPs and TIMPs. Therefore, it is difficult to 
explain the differential expression of MMPs between primary hESC and St-T1b cells in this 
study. Further study is needed to investigate the expression levels of MMPs and TIMPs 
during decidualisation. 
Heparin-binding epidermal growth factor (HB-EGF) plays a critical role in the human 
female reproductive system during the menstruation cycle, implantation, ESC 
decidualisation (Lim and Dey, 2009; Simone et al., 2012) as well as blastocyst adhesion and 
development (Leach et al., 2004). HB-EGF mRNA is expressed predominantly in the 
stromal compartment of the endometrium (Leach et al., 2004) and promotes decidualisation 
via increased levels of decidual markers, dPRL and IGFBP-1 in vivo (Chobotova et al., 
2005) and in vitro (Lessey et al., 2002). However, one study recently reported that there was 
a higher expression level of HB-EGF in endometrium in women with missed abortion 
(Ozbilgin et al., 2015). In the present study, the proteome profiler angiogenesis arrays 
showed a reduction of HB-EGF during decidualisation in St-T1b cells which support the 
earlier finding that no HB-EGF secretion was detected in decidualised St-T1b cells 
Chapter 3: Characterisation of hESC Decidualisation 
 
 104 
(Schwenke et al., 2013) with limited information on the expression in proliferative St-T1b 
cells. Surprisingly, HB-EGF expression was insignificantly increased in primary hESC 
which supporting the earlier study that HB-EGF expression was increased in in vitro 
decidualisation (Lessey et al., 2002).   
Previous studies reported PDGF-AA is a novel trophoblast-derived chemoattractant for ESC 
(Gellersen et al., 2013). However, only a few studies have looked at the expression of PDGF-
AA during hESC decidualisation. Our studies show that levels of PDGF-AA secreted by St-
T1b cells decreased during decidualisation, while, PDGF-AA is not expressed in primary 
hESC which is consistent with the previous studies in the T-hESC line (Gellersen et al., 
2013). PDGF-BB was not detected in St-T1b cells or primary hESC in the angiogenesis 
profiler array (Table 3.2). In the present study in angiogenesis array, there are changes in 
expression between primary hESC and St-T1b cells during decidualisation. This difference 
could due to the limitation in measuring the density of each spot. For example, IGFBP-1, 2 
and 3 secretions highly expressed in both proliferative and decidualised primary hESC which 
may lead to the difficulties in determining the changes. In addition, there are also factors that 
have a low expression which is under the detection limit. 
3.3.4 Conclusion 
In conclusion, changes in the St-T1b cells were characterised by morphology, mRNA and 
protein expression during decidualisation confirming and extending the previous findings 
(Samalecos et al., 2009), and with primary hESC showing that the St-T1b cell is a good 
model to use in the present study. Various angiogenic factors were found to express in the 
hESC decidualisation. MCP-1 and VEGF were the factors that were expressed in both 
primary hESC and St-T1b and will be focused in the next chapter. The next results chapter 
will focus more on the FOXO transcription factor, VEGF expression and its regulation 
during hESC decidualisation. 
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The FOXO transcription factor family consists of four members, namely FOXO1, FOXO3A, 
FOXO4 and FOXO6, in mammals (Zhang et al., 2011). FOXO1 is one of the earliest 
transcription factors induced upon decidualisation of stromal cells (Gellersen and Brosens, 
2003; Brar et al., 2001; Christian et al., 2002), a process that can be mimicked in vitro by 
cAMP and progesterone treatment (Labied et al., 2006). FOXO1 is important in the 
regulation of various integral cell functions including metabolism (Tzivion et al., 2011), 
while, FOXO3A is known to regulate inflammation and like FOXO1, FOXO3A also acts to 
protect the cells from oxidative stress and they both can promote apoptosis (Wang et al., 
2014). The deletion of FOXO3A in female mice leads to infertility due to the impairment of 
oocyte growth follicular development (Christian et al., 2011). FOXO1 has been shown to 
up-regulate various key genes in hESC decidualisation, for example, IGFBP-1, PRL, IRF-4, 
TIMP3 and decorin (Vasquez et al., 2015; Kim et al., 2005; Buzzio et al., 2006). It is known 
to co-operate with other transcription factors such as C/EBPb and IRF-4 to promote decidual 
gene expression including PRL and IGFBP-1 expression (Christian et al., 2002; Vasquez et 
al., 2015).  
The transcriptional activity of FOXO transcription factors is dependent on their localisation 
in the nucleus, which is controlled mainly by post-translational modifications such as 
phosphorylation, acetylation and ubiquitination (Brunet et al., 1999; Zhang et al., 2011) (see 
Figure 1.7).  Activation of the PI3K pathway leads to phosphorylation of Akt which in turn 
phosphorylates downstream target genes including FOXO transcription factors (Brunet et 
al., 1999; Tang et al., 1999; Barthel et al., 2005). The Akt-dependent phosphorylation of 
nuclear FOXO at threonine 24; serine 256; and serine 319 then generates binding sites for 
the 14-3-3 chaperone protein which causes FOXO to be exported from the nucleus and 
localised in the cytoplasm to inhibit its transcriptional activity (Brunet et al., 1999; Brosens 
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and Gellersen, 2006). There are three Akt isoforms: Akt-1, Akt-2, and Akt-3. Deficiency of 
Akt-1 in mice leads to increased neonatal mortality and reduced body mass (Cho et al., 
2001), mice deficient for Akt-2 exhibited glucose metabolism syndrome (Garofalo et al., 
2003), whereas Akt-3 deficient mice show reduced brain size (Easton et al., 2005). Studies 
have shown that progesterone activates the PI3K /Akt pathway causing localisation of 
FOXO1 in the cytoplasm (Ujvari et al., 2017).  
Little is known about the expression and function of FOXO3A in hESC decidualisation. 
FOXO3A was reported to be down-regulated in decidualised stromal cells but oxidative 
stress increased FOXO3A expression during decidualisation (Kajihara et al., 2006). Due to 
the up-regulation of FOXO1 in hESC during decidualisation and their similar, but not 
completely overlapping function in many processes, FOXO1 and FOXO3A expression and 




4.2.1 FOXO1 activity in hESC during decidualisation 
FOXO1 transcription factor activity increases in hESC following 8-Br-cAMP treatment 
(Section 3.3.3.1). To investigate FOXO activity following cAMP or/and MPA stimulation 
in hESC, St-T1b cells were plated on 12-well plates overnight and co-transfected with 1 µg 
of FHRE Luciferase-reporter (FHRE-Luc) (Brunet et al., 1999) and pRL-CMV plasmid for 
24 h followed by various treatments (0.5 mM or 0.25 mM 8-Br-cAMP, and 10 µM MPA) 
for a further 24 h.  
To demonstrate that the FHRE-Luc reporter was working, St-T1b cells were co-transfected 
with FHRE-Luc reporter construct which contains FOXO3A genes with constitutively active 
FOXO1 (caFOXO1) or FOXO3A (caFOXO3A) mutant plasmids (Ramaswamy et al., 2002), 
or the pcDNA3.1 parent plasmid as a control. The FHRE-firefly luciferase reading was 
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normalised to the pRL-CMV Renilla activity to determine the relative FHRE reporter 
activity. FHRE-Luc reporter activity increased with co-transfection of both caFOXO1 and 
caFOXO3A plasmids by 4- to 5-fold (Figure 4.1A) confirming successful co-transfection 
and the activity of the FHRE reporter and its response to both FOXO1 and FOXO3A.  
The FHRE firefly luciferase activity was determined after 24 h by dual-luciferase assay. 
Figure 4.1B shows a large increase in FOXO activity following 8-Br-cAMP treatment. 
while MPA (5 µM) alone did not affect FOXO activity compared to control. Furthermore, 
FOXO activity in the cells treated with both 8-Br-cAMP and MPA did not show greater 
FOXO activity than those treated with 8-Br-cAMP alone (Figure 4.1C). 
 








Figure 4.1: Relative FOXO activity determined using Forkhead responsive 
luciferase reporter.  St-T1b cells were co-transfected with forkhead responsive element (FHRE) 
luciferase-reporter construct (FHRE-luc) and (A) constitutively active mutant FOXO1 (caFOXO1) 
or FOXO3A (caFOXO3A) mutant plasmids or pcDNA3.1 as control for 24 h or stimulated with 
DMEM/F12 supplemented with 2% FBS and combinations of (B and C) 8-Br-cAMP and 10 µM 
MPA for 24 h. The firefly luciferase readings were normalised to Renilla activity. Results are the 
mean (+/- SEM) of 3 experiments and analysed using one-way ANOVA; *p<0.05; **p<0.01; 













































































































Figure 4.2: FOXO3A transcription factor expression in primary hESC 
decidualisation. Primary hESC were grown to confluence and incubated in E2 or MM1 medium 
over 6 days. (A) Real-time qPCR analysis of FOXO3A mRNA expression normalised to b-actin. 
(B) Representative Western blot showing FOXO3A expression in whole-cell lysates with tubulin 
as a loading control. (C) Graph of densitometry analysis of relative FOXO3A protein levels 
normalised to tubulin control. Results are the mean (+/- SEM) of 3 experiments and analysed using 
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4.2.2 Expression of FOXO3A transcription factor in hESC decidualisation 
FOXO3A was previously reported to be down-regulated in decidualised stromal cells 
following the up-regulation of FOXO1 (Kajihara et al., 2006). To confirm this, primary 
hESC and St-T1b cells were plated and stimulated with E2 or MM1 medium over 6 days. 
FOXO3A mRNA and protein expression level were measured using real-time qPCR and 
Western blotting. Surprisingly, FOXO3A mRNA increased with decidualisation in the 
primary hESC (Figure 4.2A) and St-T1b cells (Figure 4.3A) over 6 days. In addition, 
shorter-term stimulation over 24 h also showed significant up-regulation of FOXO3A 
mRNA expression in St-T1b cells (Figure 4.3B). However, examination of FOXO3A by 
Western blotting showed that FOXO3A protein levels were decreased with decidualisation 
compared to proliferative cells on day 3, but not at day 6 in primary hESC (Figure 4.2C). 
While, in St-T1b cells, the FOXO3A protein remained at similar levels following 
decidualisation and did not change compared to proliferative cells (Figure 4.3D).  











Figure 4.3: FOXO3A transcription factor expression in St-T1b decidualisation. 
ST-T1b cells were grown to confluence and incubated in E2 or MM1 medium over 6 days. Real-
time qPCR analysis of FOXO3A mRNA expression normalised to b-actin (A) over 6 days, and 
(B) over 24 h (2, 7, 24 h). (C) Representative Western blot showing FOXO3A expression in whole-
cell lysates with tubulin as a loading control. (C) Graph of densitometry analysis of relative 
FOXO3A protein levels normalised to tubulin control. Results are the mean (+/- SEM) of 3 
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4.2.3 FOXO1 regulates FOXO3A expression in hESC 
4.2.3.1 Deletion of FOXO1 suppresses FOXO3A expression in hESC 
The relationship between FOXO1 and FOXO3A was investigated to identify whether 
FOXO1 regulates FOXO3A or vice versa in hESC by using siRNA knock-down. The 
primary hESC and St-T1b cells were plated at a density of 2.2 x 105 cells/well on 6-well 
plates overnight and transfected with siRNAs targeting FOXO1 (siFOXO1), FOXO3A 
(siFOXO3A) (Potente et al., 2005) or a universal control (siControl) (Dharmacon) followed 
by stimulation with E2 or MM1 medium for 24 h. Knock-down of FOXO1, or FOXO3A 
(Figures 4.4 & 4.5) was confirmed by real-time qPCR and Western blotting (Figure 4.4A 
& Figure 4.5A). Both FOXO1 and FOXO3A mRNA and protein expression upon FOXO1 
or FOXO3A knock-down were analysed. FOXO1 knock-down was found to reduce 
FOXO3A mRNA and protein expression in both primary hESC (Figure 4.4) and St-T1b 
cells (Figure 4.5). Interestingly, FOXO3A knock-down significantly decreased the FOXO1 
mRNA (Figure 4.4C), but there were no changes in FOXO1 protein levels in primary hESC 
(Figure 4.4B). FOXO3A knock-down did not affect FOXO1 mRNA (Figure 4.5 D&E), or 
protein expression (Figure 4.5 B&C) in St-T1b cells. Collectively, these results show that 
FOXO1 promotes FOXO3A during decidualisation. 




Figure 4.4: Knock-down of FOXO1 suppresses FOXO3A expression in primary 
hESC. Primary hESC were transfected with siRNAs targeting FOXO1 (siFOXO1), FOXO3A 
(siFOXO3A) or control (siControl) overnight followed by stimulation with E2 or MM1 medium 
for 24 h. (A) Representative Western blots showing FOXO1 and FOXO3A expression in whole-
cell lysates and tubulin as a control. Graph of densitometry analysis of relative (B) FOXO1 and 
(C) FOXO3A protein levels normalised to tubulin control. Real-time qPCR analysis of (D) 
FOXO1 and (E) FOXO3A normalised to b-actin. Results are the mean (+/- SEM) with 3 
experiments and analysed using two-way ANOVA; *p<0.05; **p<0.01; ***p<0.001.   
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Figure 4.5: Knock-down of FOXO1 suppresses FOXO3A expression in St-T1b 
cells. St-T1b cells were transfected with siRNAs targeting FOXO1 (siFOXO1), FOXO3A 
(siFOXO3A) or control (siControl) overnight followed by E2 or MM1 medium for 24 h. (A) 
Representative Western blots showing FOXO1 and FOXO3A expression in whole-cell lysates 
with tubulin as a control. Graph of densitometry analysis of relative (B) FOXO1, and (C) 
FOXO3A protein levels normalised to the tubulin control. Real-time qPCR analysis of (D) 
FOXO1 and (E) FOXO3A mRNA expression normalised to b-actin. Results are the mean (+/- 
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4.2.3.2 Over-expression of FOXO1 up-regulates FOXO3A expression in hESC 
As the loss of FOXO1 suppressed FOXO3A expression in both primary hESC and St-T1b 
cells, the effect of FOXO1 over-expression on FOXO3A expression was investigated. St-
T1b cells were transduced with recombinant adenovirus expressing HA-tagged murine 
FoxO1 (Ad-FoxO1) or empty control virus (Ad-CMV) for 24 h and incubated in E2 medium 
for another 24 h prior harvesting. Successful viral transduction was confirmed by real-time 
qPCR and Western blotting for HA-tagged FoxO1 expression (Figure 4.6B) which showed 
a large increase of mouse FoxO1 mRNA (Figure 4.6A) in cells treated with Ad-FoxO1. 
Both FOXO3A mRNA (Figure 4.6C) and protein levels (Figure 4.6B) were significantly 
increased in FOXO1 over-expressing cells compared to the control confirming the regulation 
of FOXO3A expression by FOXO1 in hESC. 
 
4.2.3.3 Both FOXO1 and FOXO3A contribute to FOXO activity in hESC 
FOXO transcriptional activity was also measured during decidualisation. The FHRE-Luc 
were co-transfected with siRNAs targeting FOXO1 (siFOXO1), or FOXO3A (siFOXO3A) 
or control (siControl) to try to estimate the relative contribution of FOXO1 and FOXO3A to 
overall FOXO activity when hESC are stimulated to decidualise. FOXO activity was 
significantly suppressed by either FOXO1 or FOXO3A knock-down in decidualised cells,  









































Figure 4.6: Over-expression of FOXO1 promotes FOXO3A expression in hESC. 
St-T1b cells were transduced with recombinant adenovirus expressing HA-tagged murine FoxO1 
(Ad-FoxO1) or empty control virus (Ad-CMV) for 24 h and incubated in E2 medium for another 
24 h prior harvesting. Viral transduction was confirmed by detection of (A) mouse FoxO1 mRNA 
and HA-tagged FoxO1 expression. (B) Representative Western blots showing the HA-tagged 
FoxO1 over-expression and FOXO3A expression with tubulin as loading control. (C) Real-time 
qPCR showing FOXO3A mRNA up-regulation. Results are the mean (+/- SEM) of 3 experiments 












































4.2.4 Effect of FOXO1/O3A knock-down on decidualisation related genes in hESC 
FOXO1 regulates many genes involved in hESC decidualisation (Vasquez et al., 2015). To 
confirm this relationship, FOXO1 or FOXO3A was knocked-down in St-T1b cells followed 
by stimulation with E2 or MM1 medium for 24 h. The knock-down efficiency was > 80% 
for both FOXO1 and FOXO3A at mRNA and protein level as shown in Figure 4.5 D&E. 
The expression of C/EBPβ (Figure 4.8A) and STAT3 (Figure 4.8E) was significantly 
decreased in decidualised St-T1b cells following FOXO1 knock-down. SOD2, a gene 
regulated by FOXO1 was also significantly decreased in decidualised cells following 
FOXO1, or FOXO3A knock-down (Figure 4.8B). FOXM1 mRNA expression was up-
regulated in proliferative St-T1b cells following FOXO1 or FOXO3A knock-down, whilst 
it did not affect the cells treated for 24 h in MM1 medium (Figure 4.8C) suggesting that 
both FOXO1 and FOXO3A act as negative regulators of FOXM1 under proliferative 
Figure 4.7: Silencing of FOXO1, or FOXO3A decreases overall FOXO activity 
in hESC. St-T1b cells were plated on 12-well plates overnight and co-transfected with FHRE-
luc and siRNAs targeting FOXO1 (siFOXO1), FOXO3A (siFOXO3A) or control (siControl) 
overnight followed by incubation with E2 or MM1 medium for 24 h prior harvesting. The FHRE 
firefly luciferase activity was normalised to co-transfected pRL-CMV Renilla luciferase activity. 
Results are the mean (+/- SEM) of 3 experiments and analysed using two-way ANOVA; 
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conditions. HOXA10 mRNA expression was found to significantly increased in both 
proliferative and decidualised St-T1b cell following FOXO1, or FOXO3A knock-down 
(Figure 4.8D). 
 
4.2.5 Phosphorylation of FOXO1 by AKT kinase 
FOXO transcription factors are downstream targets of the PI3K/Akt pathway (Brunet et al., 
1999). To gain an insight into the activity of Akt and its effects on FOXOs in hESC 
decidualisation, the presence and activity of Akt was examined through Western blotting. 
Both Akt and active phosphorylated Akt serine 473 (pAktS473) were detected in hESC. No 
changes were found in the total Akt levels in St-T1b cells cultured in E2 or MM1 medium 
from day 1 to day 6, whereas, there was a significant decrease of pAktS473 in cells cultured 
under decidual conditions for up to 6 days (Figure 4.9). The phosphorylation of FOXO1 of 
serine 256 (pFOXO1S256) was also detected and decreased with decidualisation on day 6.  
The knock-down of Akt-1, the predominant Akt isoform in hESC (Jiang et al., 2005), led to 
an increase of FOXO1 protein and mRNA levels (Figure 4.10 A&E). As expected, total Akt 
activity was also reduced in St-T1b following the Akt-1 knock-down (Figure 4.9B). 

















Figure 4.8: The effect of FOXO1 and FOXO3A knock-down on decidual gene 
expression in hESC. St-T1b cells plated on 6-well plates (2.2 x 105 cells/well) overnight and 
transfected with siRNAs targeting FOXO1 (siFOXO1), FOXO3A (siFOXO3A) or control 
(siControl) for 24 h followed by a further 24 h incubation in E2 or MM1 medium. Real-time 
qPCR analysis of (A) C/EBPβ; (B) SOD2; (C) FOXM1; (D) HOXA10; and (E) STAT3 mRNA 
expression normalised to β-actin. Results are the mean (+/- SEM) of 3 experiments and analysed 







































































































































Figure 4.9: Akt activity decreases during hESC decidualisation. St-T1b cells were 
plated on 6-well plates (3.0 x 105 cells/well) overnight followed by 24 h stimulation with E2 or 
MM1 medium over 6 days and protein lysates were harvested in various time points. (A) 
Representative Western blots showing FOXO1, phospho-FOXO1 (pFOXO1S256), total Akt, 
phospho-Akt at serine 473 (pAktS473) and tubulin as loading control. Graph of densitometry 
analysis of relative (B) FOXO1, (C) pAktS473 / total Akt, (D) pFOXO1S256 /FOXO1 normalised to 
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Figure 4.10: Effect of Akt-1 knock-down on FOXO1 expression during 
decidualisation. St-T1b cells (2.2 x 105 cells/well) were plated on 6-well plates overnight and 
transfected with siRNAs targeting Akt-1 (siAkt-1), or control (siControl), for 24 h followed by 24 
h in E2 or MM1 medium. (A) Representative Western blots showing FOXO1, FOXO3A, total Akt, 
phospho-Akt (pAktS473) following Akt-1 knock-down with tubulin as a control. Graph of 
densitometric analysis of relative (B) FOXO1, (C) pAktS473 / total Akt, normalised to tubulin. Real-
time qPCR analysis of (D) Akt-1, (E) FOXO1, and (F) FOXO3A mRNA expression normalised to 
b-actin mRNA. Results are the mean (+/- SEM) of 3 independent experiments and analysed using 




        -             +              -            +             



























































































Chapter 4: The FOXO Activity in hESC Decidualisation 
 
 123 
4.2.6 Oxidative stress induces both FOXO1/O3A expression in hESC 
FOXO3A was shown to be induced only in proliferative hESC (Kajihara et al., 2006), the 
response to oxidative stress was examined in both proliferative and decidualised cells to 
further investigate the FOXO1 and FOXO3A expression in ESC. St-T1b cells were 
incubated with either E2 medium or MM1 medium for 24 h and then exposed to 200 µM 
H2O2 for a further 24 h. We found that exposure to H2O2 dramatically induced both FOXO1 
and FOXO3A expression in decidualised cells (Figure 4.11A&B). In addition, the FOXO 
activity also increased with H2O2 (200 µM) treatment in St-T1b cells transfected with FHRE 




















































































Figure 4.11: FOXO1 and FOXO3A expression are regulated by oxidative stress.  
St-T1b cells were pre-treated St-T1b cells with E2, or MM1, medium for 24 h and exposed to 200 
µM H2O2 for 24 h, and the cells were lysed for the mRNA expression of (A) FOXO1 and (B) 
FOXO3A determined by real-time qPCR normalised to b-actin. (C) St-T1b cells were plated in a 
12-well plate overnight and transfected with FHRE luciferase-reporter plasmids for 24 h followed 
by a further 24 h treatment with 200 µM H2O2. Firefly luciferase readings were normalised to Renilla 
activity. Results are the mean (+/- SEM) of 2 experiments and analysed using unpaired t-test; 
*p<0.05; ***p<0.001.   
 




FOXO1 has been identified as a key transcriptional regulator of decidualisation (Christian 
et al., 2011; Zhang et al., 2013) and its loss leads to the impaired decidualisation in isolated 
mouse ESC and hESC, and recurrent implantation failure (Zhang et al., 2014; Ujvari et al., 
2017). In agreement with previous studies, there was a large increase of FOXO1 expression 
in both primary hESC and St-T1b cells treated with 8-Br-cAMP (Section 3.3.3.1). In the 
present study showed that the treatment of cells with MPA alone did not induce FOXO1 
activity and the combination of MPA and cAMP was not found to enhance FOXO1 
expression consistent with Samalecos et al. (2009). These results are in contrast with the 
findings of Labied et al. (2006) which show greater FOXO expression with combined cAMP 
and MPA treatment in hESC. The activity of FOXO proteins is regulated by their subcellular 
localisation (Brunet et al., 1999).  
 
4.3.1 Dephosphorylation of FOXO1 by Akt in hESC decidualisation 
The activation of the PI3K pathway leads to phosphorylation of Akt which in turn 
phosphorylates downstream target genes including FOXO1/O3A eliminating them from the 
nucleus (Tang et al., 1999; Brosens and Gellersen, 2006). Studies have shown that 
progesterone activates the PI3K/Akt pathway leading to localisation of FOXO1 in the 
cytoplasm (see Figure 1.8). There are three Akt isoforms: Akt-1, Akt-2 and Akt-3. The 
double knock-out mice for Akt-1 and Akt-3 are embryonic lethal due to the failure of the 
placental vasculature (Yang et al., 2005). In hESC, the total Akt, pAktS473 and Akt-1 mRNA 
levels were all reported to be decreased during in vitro hESC decidualisation, whilst Akt-2 
and Akt-3 remain unchanged in decidualisation compared to control cells (Yoshino et al., 
2003, Fabi et al., 2017). In the present study, the pAktS473 levels dramatically decreased with 
decidualisation over 6 days without a change in total Akt protein expression. There is limited 
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information on the role of Akt isoforms in hESC decidualisation; one recent study 
demonstrated that Akt-1 and Akt-2 negatively regulate decidualisation (Fabi et al., 2017). 
Akt-1 is the predominant Akt isoform in hESC. Accordingly, knock-down of Akt-1 
significantly decreased Akt activity (pAktS473) and promotes FOXO1 activity and 
subsequently increased the FOXO1 expression. FOXO1 has been shown to drive its own 
expression in decidualisation (Vasquez et al., 2015). Collectively, these results are in line 
with the majority of literature indicating that progesterone is able to promote Akt activity 
which may reduce FOXO1 activity and expression, whilst cAMP increases PKA activity to 
up-regulate FOXO1 expression. Further investigation is needed to determine the effect of 
each Akt isoform on FOXO1 expression in hESC decidualisation. 
 
4.3.2 Up-regulation of FOXO3A in hESC decidualisation 
FOXO3A was reported to down-regulate in hESC decidualisation (Labied et al., 2006; 
Kajihara et al., 2006). Unlike FOXO1, FOXO3A is regulated by cAMP or MPA alone and 
suppressed in the combination of cAMP and MPA stimulation (Labied et al., 2006). In 
contrast to this, the FOXO3A mRNA levels did not change in the cells induced with cAMP 
alone or a combination of cAMP and MPA (Appendix I). Furthermore, FOXO3A mRNA 
levels actually increase whilst protein levels remain similar or reduced in primary hESC and 
St-T1b cells during decidualisation induced with cAMP and MPA. This is consistent with a 
very recent study where FoxO3A mRNA and protein were found to be present in 
decidualisation of mouse ESC both in vivo and in vitro and maintain decidualisation and 
apoptosis-related factors (Long et al., 2018). Furthermore, women with spontaneous 
abortion were found to have lower endometrial FOXO3A expression (Long et al., 2018) 
indicating an important role for decidual FOXO3A-driven apoptosis during early pregnancy.   
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4.3.3 FOXO1 regulates FOXO3A in hESC decidualisation 
Although FOXO1 and FOXO3A bind to similar FHRE DNA binding sequences, they 
regulate differently, but overlapping sets of genes. For example, in endothelial cells, PDGF 
and BMP4 are regulated by both FOXO1 and FOXO3A, whereas, the angiopoietin-2 
expression is regulated by FOXO1, but not FOXO3A (Potente et al., 2005). Here for the 
first time show that FOXO3A is regulated by FOXO1 in hESC. The knock-down of FOXO1 
in primary hESC and St-T1b cells inhibits FOXO3A mRNA, as well as protein expression 
indicating that FOXO1 can promote FOXO3A expression in hESC (Figure 4.2). In addition, 
FOXO3A expression was up-regulated in the FoxO1 over-expressing in St-T1b cells. 
Overall, FOXO3A did not affect FOXO1 protein expression in primary hESC and St-T1b 
cells (see Figure 4.3C). However, in other cell types, FOXO3A has been reported for 
example to negatively regulate autophagy by inhibiting FOXO1 expression in prostate, 
colon, and breast cancers (Zhu et al., 2014). In contrast, a study in human foreskin fibroblasts 
demonstrated that FOXO1 expression was stimulated by activated FOXO3A through direct 
binding to at least one FHRE consensus site in the FOXO1 promoter (Essaghir et al., 2009). 
In addition, FOXO1 has been reported to induce its expression in these cells (Essaghir et al., 
2009) in a similar manner to hESC under decidual conditions (Vasquez et al., 2015). Taken 
together, FOXO1 regulates FOXO3A positively, but FOXO3A does not regulate FOXO1. 
Further studies are required to determine the interplay between FOXO1 and FOXO3A in 
hESC decidualisation. 
 
4.3.4 Up-regulation of FOXO1 and FOXO3A in response to oxidative stress in hESC 
FOXO3A plays a critical role in oxidative stress responses and the regulation of apoptosis 
(Kajihara et al., 2006; Wang et al., 2014). It has been reported that oxidative stress increases 
FOXO3A expression in proliferative hESC, but not in decidualised cells and that FOXO1 
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levels decrease significantly in response to oxidative stress in both proliferative and 
decidualised primary hESC (Kajihara et al., 2006). It was proposed that the action of FOXO1 
was to up-regulate SOD2 and repress FOXO3A during decidualisation protect and promote 
the survival of decidual hESC under oxidative stress conditions (Kajihara et al., 2006). In 
contrast, the present study results show that FOXO1 and FOXO3A expression increases in 
decidualised cells after exposure to oxidative stress induced by hydrogen peroxide (Figure 
4.11). From present results, it is likely that the up-regulation or maintenance of FOXO3A 
expression in hESC is due to the increasing FOXO1 expression/activity, and oxidative stress 
induces both FOXO3A and FOXO1 expression in hESC decidualisation. Further 
investigation is needed into the effect of oxidative stress on FOXO1 and FOXO3A 
expression during decidualisation. In the present study, hESC were treated with MM1 
medium for only 24 h to initiate decidual changes prior to examining the effect of FOXO 
knock-down and oxidative stress. Therefore, the cells should be treated in MM1 medium for 
longer periods up to 6 days before being exposed to oxidative stress to determine whether 
their response changes with decidualisation. 
 
4.3.5 SOD2 is regulated by FOXO1 in hESC 
SOD2 is another marker for decidualisation which is up-regulated by FOXO transcription 
factors to scavenge superoxide radicals and protect cells from damage during decidualisation 
(Suzuki et al., 1999; Kajihara et al., 2006). The knock-down of FOXO1 in hESC was 
reported to reduce SOD2 expression during decidualisation, but not in control proliferative 
cells (Kajihara et al., 2006) supporting my findings that SOD2 was dramatically up-
regulated during decidualisation (Figure 3.6B), and significantly decreased following 
FOXO1 knock-down. 
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4.3.6 FOXO1 and FOXO3A negatively regulate HOXA10 
HOXA10 is a member of the homeobox gene family known to be expressed in the uterus in 
response to oestrogen and progesterone, and its expression increases during the mid-
secretory phase of the menstrual cycle when the progesterone levels peak (Taylor et al., 
1998). The loss of HOXA10 is associated with endometriosis, polycystic ovarian syndrome 
(PCOS) and infertility (Cermik et al., 2003; Gui et al., 1999). HOXA10 was also reported 
to reduce IGFBP-1 expression in hESC decidualisation (Kim et al., 2007). In addition, a 
total of 494 genes were regulated by HOXA10 during hESC decidualisation by microarray 
analysis (Lu et al., 2008) and its deletion can lead to defective implantation and 
decidualisation impairment in mice (Lim et al., 1999). Interestingly, my results show that 
FOXO1 and FOXO3A knock-down up-regulates HOXA10 mRNA levels in hESC during 
decidualisation suggesting that HOXA10 may negatively regulated by FOXO1. This may 
explain the reduction of HOXA10 mRNA expression from day 3 to day 6 (Figure 3.8B) of 
stimulation due to increasing FOXO1 expression and activity in St-T1b cells (see Section 
3.2.3.1). Whilst the FOXO3A mRNA goes up but its protein levels remain unchanged during 
decidualisation. We do not know its relative activity during decidualisation. These 
experiments were performed in the St-T1b cell line only due to time constraints. So, future 
studies should explore this relationship in primary hESC to confirm these findings. 
Furthermore, FoxM1 has been reported to be directly regulated by HoxA10 during 
decidualisation in mice (Gao et al., 2015). In my study, FOXM1 expression was increased 
following FOXO1 and FOXO3A knock-down in proliferative hESC which may be due to 
the increase of HOXA10 expression. However, FOXM1 expression did not change 
following FOXO1 and FOXO3A knock-down under decidual conditions which suggests that 
not only HOXA10, other factors like C/EBPb and STAT3 may also regulate FOXM1 in 
hESC decidualisation. 





In summary (Figure 4.12), here provide evidence that highlights maintenance of FOXO3A 
expression in hESC during decidualisation and shows FOXO1 was shown to positively 
regulate FOXO3A expression. In addition, FOXO1 and FOXO3A were found to regulate 
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VEGF plays a crucial role in the female reproductive system (Girling and Rogers, 2009) and 
the level of VEGF in the endometrium around the time of implantation is a marker of 
endometrial receptivity and correlates with reproductive success (Houzi et al., 2009; El-
Zenneni et al., 2015; Jakovljevic et al., 2016; Bansal et al., 2017). Lower levels of VEGF 
expression are detected in the decidual vasculature of women with recurrent miscarriage 
compared to those who have had healthy pregnancies (Vuorela et al., 2000) and the 
dysregulation of VEGF can also lead to pathological conditions such as preeclampsia and 
IUGR (Fan et al., 2014). 
The up-regulation of VEGF in endometrium induces angiogenesis which is important for 
cyclical endometrial regeneration, implantation, regulating trophoblast migration/function 
and maintenance of maternal-fetal blood supply (Plaisier, 2011). During decidualisation, the 
endometrium undergoes extensive angiogenesis and vascular remodelling in preparation for 
implantation (Dunn et al., 2003). It is established that VEGF expression increases with in 
vitro decidualisation of primary hESC (Matsui et al., 2004; Lockwood et al., 2009) and 
decidual cells have been recognised as an important source of VEGF in the endometrium 
(Lin and Gu, 2005). However, the mechanisms underpinning VEGF up-regulation and the 
potential role of VEGFs on decidual hESC remained unclear. This is partly due to the fact 
that other cell types such as resident inflammatory cells also express VEGF. 
The major physiological driver of VEGF expression is hypoxia (Ferrara, 2009). VEGF is 
up-regulated by HIF-1a which is induced by hypoxia during menstrual and proliferative 
phases, however, low HIF-1a levels are detected during the mid-secretory phase of the cycle 
(Maybin et al., 2018). VEGF is reported to be up-regulated in response to E2 or progesterone 
treatment in hESC (Huang et al., 1998; Classen-Linke et al., 2000). However, others have 
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shown that VEGF expression in endometrial epithelial and hESC is not affected by E2 
treatment (Lockwood et al., 2002).   
Preliminary findings from our laboratory demonstrated that adenoviral-mediated over-
expression of wild-type or constitutively active FOXO1 in St-T1b cells results in a 
significant increase in VEGF production. Similarly, the over-expression of constitutively 
active FoxO1 in pancreatic islet cells in mice strongly up-regulated VEGF (Kikuchi et al., 
2012) and very recently, Jeon et al. (2018) reported that FOXO1 directly regulates VEGF 
expression in keratinocytes during wound healing.  
In this chapter, the regulation of VEGF expression and secretion in hESC decidualisation 
was characterised in primary hESC and the St-T1b cell line. The role of FOXO1 in VEGF 
up-regulation in hESC during decidualisation and the potential interplay between FOXO1 
and FOXO3A was also investigated. 
 
5.2 RESULTS 
5.2.1 VEGF expression in human ESCs during decidualisation  
Endometrial VEGF mRNA levels increase during ESC decidualisation (Matsui et al., 2004; 
Lockwood et al., 2009). In order to characterise the up-regulation of VEGF in hESC during 
decidualisation, primary hESC and St-T1b cells were grown to confluence and then 
incubated with E2 or MM1 medium over 6 days. Fresh medium was added to the cells 24 h 
prior to harvesting cell lysates and supernatants at 3 and 6 days. VEGF mRNA and protein 
levels were assessed by real-time qPCR and ELISA respectively. There was a significant 
increase in VEGF mRNA expression in primary hESC during decidualisation (Figure 5.1A). 
Surprisingly, although VEGF mRNA expression increased in St-T1b cells at 3 and 6 days of 
stimulation, it did not reach significance (Figure 5.2A). VEGF protein secretion was 
significantly increased with decidualisation in both primary hESC (Figure 5.1B) and St-T1b 
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cells (Figure 5.2B) which is consistent with the protein array data shown in Chapter 3 
(Section 3.2.4). Shorter-term stimulation with E2 or MM1 medium was also examined in 
St-T1b cells. Rapid induction of VEGF secretion was observed following stimulation with 
MM1 medium which was detected as early as 5 h onwards whereas, the level of VEGF 




























Figure 5.1: Up-regulation of VEGF expression and secretion in primary 
hESC during decidualisation. Primary hESC isolated from 5 individuals were incubated 
in E2 or MM1 medium, and RNA and cell supernatants were harvested after 3 and 6 days. (A) 
Real-time qPCR analysis of VEGF mRNA expression normalised to b-actin. (B) VEGF 
protein secretion determined by ELISA. Results are the mean (+/- SEM) of 5 independent 

























5.2.2 The effect of progesterone on VEGF expression in hESC 
Progesterone has been reported to either increase (Shifren et al., 1996), or have no effect on 
VEGF expression (Okada et al., 2011) in primary hESC. In order to determine the effect of 
progesterone on VEGF expression in hESC, St-T1b cells were grown to confluence in 24-
well plates and then incubated with different concentrations of MPA (0.1, 1, and 100 µM) 




























Figure 5.2: Up-regulation of VEGF expression in St-T1b cells during 
decidualisation. St-T1b cells were incubated in E2 or MM1 medium, RNA and cell 
supernatants were harvested after 3 and 6 days. (A) Real-time qPCR analysis of VEGF expression 
normalised to b-actin. The VEGF protein secretion was determined by ELISA (B) over 6 days and 
(C) 24 h time course (30 min, 3, 5, 7, 11 and 24 h). Results are the mean (+/- SEM) of 4 independent 
experiments and analysed using an unpaired t-test; *p<0.05; **p<0.01; ***p<0.001. 
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concentrations of MPA and significantly reduced at high MPA concentrations (100 µM) in 
hESC (Figure 5.3).  
 
 
5.2.3 The effect of oestrogen on VEGF expression in hESC 
17b-Oestradiol (E2) has been reported to either stimulate VEGF production in hESC 
(Classen-Linke et al., 2000; Okada et al., 2010) or have no effect (Lockwood et al., 2002). 
To determine the effect of E2 on VEGF expression in St-T1b cells, confluent monolayers 
grown on 24-well plates were incubated with different concentrations of E2 (1, 100 and 
10,000 nM) over 6 days. The 24 h supernatants were collected, and VEGF levels were 



























Figure 5.3: Effect of progesterone on VEGF secretion in hESC. St-T1b cells were 
plated in 24-well plates (1.2 x 105 cells/well) overnight and incubated with various concentrations 
of MPA in duplicates for 24 h on various days. The supernatants were collected at different time 
points and VEGF secretion assessed by ELISA. Results are the mean (+/- SEM) of 3 experiments 
and analysed using two-way ANOVA with Dunnett test; **p<0.01. 





5.2.4 The effect of MPA and cAMP on VEGF expression 
As shown in Figure 5.3, high concentrations of MPA suppressed VEGF expression in hESC. 
In order to determine whether the MPA present in the MM1 decidualising medium affects 
VEGF expression in hESC, St-T1b cells were plated in 24-well plates overnight and 
incubated in DMEM/F12 with 2% FBS (control) containing 0.5 mM 8-Br-cAMP and/or 1 
µM MPA over 3 days. Cell culture supernatants were collected every 24 h and VEGF levels 
assessed by ELISA. VEGF secretion increased in the cells treated with 8-Br-cAMP, or the 
combination of 8-Br-cAMP and MPA. Cells treated with both 8-Br-cAMP and MPA 
produced less VEGF than the cells treated with 8-Br-cAMP alone (Figure 5.5). MPA alone 
did not affect VEGF expression which is consistent with the earlier findings in this study 


























Figure 5.4: 17b-Oestradiol (E2) does not affect VEGF secretion in hESC. St-T1b 
cells were plated on 24-well plates (1.2 x 105 cells/well) overnight and incubated in various 
concentrations of E2 in duplicates. The 24 h supernatants were collected at different time points 
and VEGF secretion assessed by ELISA and expressed relative to the control. Results are the 
mean (+/- SEM) of 3 experiments and analysed using two-way ANOVA with Dunnett test. 





5.2.5 FOXO1 and FOXO3A regulate VEGF expression and release in hESC 
5.2.5.1 Effect of FOXO1 or FOXO3A knock-down on VEGF expression and secretion 
in hESC 
To determine whether FOXO1 is driving VEGF expression and release during hESC 
decidualisation, FOXO1 was knocked-down in hESC using siRNA to determine the effect 
on VEGF mRNA and protein levels. Primary hESC and St-T1b cells were transfected with 
siRNAs targeting FOXO1 (siFOXO1), FOXO3A (siFOXO3A), or control (siControl) using 
Viromer Blue for 24 h followed by 24 h stimulation with E2 or MM1 medium. Real-time 
qPCR and Western blotting were used to confirm FOXO1 and FOXO3A knock-down (refer 
to Chapter 4). VEGF mRNA expression was significantly suppressed when FOXO1 was 
knocked-down in both primary hESC (Figure 5.6A) and St-T1b cells (Figure 5.7A) during 
decidualisation. Consistent with these findings, VEGF protein secretion was also suppressed 
Figure 5.5: Effect of MPA and cAMP on hESC VEGF secretion. St-T1b cells were 
plated in 24-well plates (1.2 x 105 cells/well) overnight and incubated with DMEM/F12 
supplemented with 2% FBS (control) containing 0.5 mM 8-Br-cAMP and/or 1 µM MPA over 3 
days. The supernatants were collected every 24 h and VEGF secretion assessed by ELISA. Results 
are the mean (+/- SEM) of 3 experiments and analysed using two-way ANOVA with Dunnett test; 
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by FOXO1 knock-down (Figure 5.6). Conversely, VEGF expression and protein secretion 
were significantly increased with FOXO3A knock-down in primary hESC following 
decidualisation (Figure 5.6A&B). VEGF protein secretion was also determined in 24 h 
supernatants by ELISA. In contrast, FOXO3A knock-down in St-T1b cells did not affect 























Figure 5.6: VEGF expression and secretion following FOXO1 and FOXO3A 
knock-down in proliferative and decidualised primary hESC. Primary hESC were 
plated on 6-well plates overnight and transfected with siRNAs targeting FOXO1 (siFOXO1), 
FOXO3A (siFOXO3A), or control (siControl) overnight followed by stimulation with E2 or 
MM1 medium for 24 h prior to harvesting. (A) Real-time qPCR analysis of VEGF mRNA 
expression normalised to β-actin levels. (B) VEGF protein secretion in 24 h culture supernatants 
measured by ELISA. Results are the mean (+/- SEM) of 3 experiments and analysed using two-





























5.2.5.2 FOXO1 over-expression increases VEGF expression in hESC 
St-T1b cells were plated at a density of 2.5 x 105 cells/well on 6-well plates, incubated 
overnight, transduced with adenovirus encoding HA-tagged murine FoxO1 (Ad-FoxO1) or 
empty control virus (Ad-CMV) for 24 h and incubated in E2 medium for 24 h prior to 
harvesting. Successful viral infection was confirmed by qPCR and Western blotting for HA-
tagged FoxO1. A large increase of both FoxO1 mRNA and protein was detected in cells 
treated with Ad-FoxO1 (see Section 4.3.3.2). VEGF mRNA expression was up-regulated 
with FOXO1 over-expression (Figure 5.8A). VEGF protein levels were also increased in 
Ad-FoxO1 treated St-T1b cells (Figure 5.8B). Collectively, these results show that FOXO1 























Figure 5.7: VEGF expression and secretion following FOXO1 and FOXO3A 
knock-down in proliferative and decidualised St-T1b cells. St-T1b cells were plated 
on 6-well plates and transfected with siRNAs targeting FOXO1 (siFOXO1), FOXO3A 
(siFOXO3A), or control (siControl) overnight followed by stimulation with E2 or MM1 medium 
for 24 h prior to harvesting. (A) Real-time qPCR analysis of VEGF mRNA expression normalised 
to β-actin levels. (B) VEGF protein secretion in 24 h culture supernatants measured by ELISA. 





















Chapter 5: VEGF Regulation in hESC Decidualisation 
 
 140 
addition, FOXO3A appears to suppress FOXO1 activity suggesting that it is able to compete 
with FOXO1 to regulate VEGF gene expression. 
 
5.2.6 VEGF promoter activity increases during hESC decidualisation 
VEGF protein secretion was found to increase at 5 h following stimulation with MM1 
medium (Section 5.2.1) suggesting de novo synthesis. Various transcription factors have 
been reported to regulate the VEGF promoter (Pages and Pouyssegur, 2004) as shown in 
Figure 1.11. Therefore, VEGF promoter activity was examined using VEGF promoter-
firefly luciferase reporter constructs (pGL-VEGF-Luc). St-T1b cells were co-transfected 
with VEGF promoter (pGL-VEGF-Luc-1.8, -2.9, -4.7 kb) and pRL-CMV, a Renilla 
luciferase control plasmid (see Section 2.14.1). The cells were stimulated with E2 or MM1 
medium for 24 h and the readings normalised to pRL-CMV Renilla activity to determine 
relative firefly luciferase activity. Incubation of St-T1b cells in MM1 medium increased the 





Figure 5.8: FoxO1 over-expression in hESC promotes VEGF production. St-T1b 
cells were transduced with an adenovirus encoding HA-tagged murine FoxO1 (Ad-FoxO1) or 
empty control virus (Ad-CMV) overnight and incubated in fresh E2 medium for another 24 h 
prior to harvesting. (A) Real-time qPCR analysis of VEGF mRNA normalised to b-actin. (B) 
VEGF protein secretion assessed in cell supernatants by ELISA. Results are the mean (+/- SEM) 
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the pGL-VEGF 2.9 kb construct showed the greatest activity change between proliferative 
and decidual conditions, its activity increased by 50% in the decidualised cells. Whereas, 
cells transfected with the 4.7 kb construct had the lowest luciferase activity compared to 
cells transfected with 1.8 kb and 2.9 kb constructs (Figure 5.9). 
 
5.2.7 VEGF expression is regulated by FOXO transcription factors 
Due to the strong up-regulation of both FOXO1 and VEGF expression in decidualisation 
and previous preliminary findings in our laboratory and others (Vasquez et al., 2015), we 
hypothesised that VEGF transcription was being driven directly by FOXO1 in hESC 
decidualisation. In addition, a number of FHRE sites were identified within 2.5 kb of 5 kb 
human VEGF promoter sequences. In order to determine the effect of FOXO1 on VEGF 
expression, St-T1b cells were co-transfected with pGL-VEGF-Luc-1.8 kb or -2.9 kb 
constructs with constitutively active FOXO1 (caFOXO1) or FOXO3A (caFOXO3A) mutant 
plasmids (Ramaswamy et al., 2002), or the pcDNA3.1 parent plasmid as a control with pRL-





































Figure 5.9: VEGF promoter activity increases hESC decidualisation. St-T1b cells 
were co-transfected with pGL-VEGF-Luc-1.8, -2.9 and -4.7 kb and pRL-CMV control plasmids 
overnight followed by stimulation with E2 or MM1 medium for 24 h. Firefly luciferase readings 
were normalised to Renilla luciferase activity. Results are the mean (+/- SEM) of 3 experiments 
and analysed using unpaired t-test; *p<0.05. 
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CMV. Firefly luciferase readings were normalised to pRL-CMV Renilla activity. The 
activity of both the pGL-VEGF-Luc-1.8 kb and -2.9 kb constructs increased with the over-
expression of caFOXO1 (Figure 5.10). Although the activity of the pGL-VEGF-Luc-1.8 kb 
construct was lower than that of cells transfected with pGL-VEGF-Luc-2.9 kb, both 
increased by a similar amount with caFOXO1 over-expression. In contrast, caFOXO3A 
over-expression strongly suppressed activity in cells transfected with both VEGF promoter 
constructs.  
 
To determine the effect of loss of endogenous FOXO1 or FOXO3A activity on VEGF 
promoter activity, St-T1b cells were co-transfected with either pGL-VEGF-Luc-1.8 kb or -
2.9 kb and FOXO1, FOXO3A or control siRNAs overnight and subsequently stimulated for 
24 h with E2 or MM1 medium. VEGF promoter activity in cells transfected with pGL-
VEGF-Luc-1.8 kb and -2.9 kb constructs was significantly reduced following FOXO1 
knock-down in both E2 medium and MM1 medium conditions (Figure 5.11A). Whereas, 



































Figure 5.10: Over-expression of FOXO transcription factors regulates VEGF  
promoter activity in hESC. St-T1b cells were plated on 12-well plates overnight and co-
transfected with pGL-VEGF-Luc-1.8 kb or -2.9 kb and constitutively active mutant FOXO1 
(caFOXO1) or FOXO3A (caFOXO3A) mutant plasmids or pcDNA3.1 as a control for 24 h. The 
firefly luciferase readings were normalised to Renilla activity. Results are the mean (+/- SEM) of 
3 experiments and analysed using two-way ANOVA; *p<0.05; **p<0.01; ***p<0.001. 
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VEGF promoter activity increased upon FOXO3A knock-down under both proliferative and 
decidualised conditions (Figure 5.11B). 
 
5.2.8 FoxO1 drives Vegf expression in MEFs 
In order to extend our findings and confirm FoxO regulation of VEGF more broadly in 
fibroblasts, MEFs isolated from floxed FoxO mice (Paik et al., 2007) were transduced with 







































Figure 5.11: FOXO1 and FOXO3A regulate VEGF promoter activity in hESC. 
St-T1b cells were plated on 12-well plates overnight and co-transfected with pGL-VEGF-Luc-
1.8 kb or -2.9 kb and siRNAs targeting (A) FOXO1 (siFOXO1), (B) FOXO3A (siFOXO3A), or 
control (siControl) for 24 h followed by 24 h treatment with E2 or MM1 medium. The firefly 
luciferase readings were normalised to Renilla activity. Results are the mean (+/- SEM) of 3 
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a recombinant adenovirus encoding Cre recombinase (Ad-Cre) to induce Cre-mediated 
knock-out of FoxO in the cells. MEFs were grown to confluence and infected with MOI 50 
Ad-Cre, or Ad-CMV empty vector (control) for 24 h prior to being seeded onto 6-well-
plates. The expression of Cre-recombinase in the Ad-Cre transduced cells was confirmed by 
RT-PCR (Figure 5.12A) and the loss of FoxO1 and FoxO3a protein by Western blotting 
(Figure 5.12B). A significant increase in FoxO1 expression was observed in the Ad-CMV 
treated MEFs following 24 h stimulation with 0.25 mM 8-Br-cAMP compared to the control. 
Vegf expression was increased by more than 2-fold at 24 h following treatment with 8-Br-
cAMP (Figure 5.12D).  Whereas, in MEFs pre-treated with Ad-Cre for 24 h, FoxO1 mRNA 
expression was dramatically reduced indicating that FoxO1 had been deleted from the 
majority of the Ad-Cre transduced MEFs (Figure 5.12B). There was no cAMP-mediated 
increase in Vegf mRNA expression following FoxO1 knock-out indicating that FoxO1 
regulates Vegf expression in these cells (Figure 5.12D).  
Floxed FoxO MEFs were co-transfected with pGL-VEGF-Luc-2.9 kb and either caFOXO1 
or caFOXO3A plasmids, or the pcDNA3.1 were used as a control plasmid. The MEFs 
behaved like the St-T1b cells and the VEGF promoter activity was increased with FOXO1 
over-expression and suppressed by FOXO3A (Figure 5.13A). 
In addition, the Ad-Cre and Ad-CMV transduced MEFs were plated on 12-well plates 
overnight and transfected with pGL-VEGF-Luc-2.9 kb followed by stimulation with or 
without 0.25 mM 8-Br-cAMP for 24 h. VEGF promoter activity was increased in 8-Br-
cAMP treated control cells which is consistent with the earlier Vegf mRNA expression 
results following cAMP stimulation. VEGF promoter activity was suppressed in the Ad-Cre 
pre-treated FoxO knock-out MEFs stimulated with cAMP (Figure 5.13B). 
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Figure 5.12: FoxO1 drives cAMP-stimulated Vegf expression in MEFs.  MEFs 
isolated from 3 different mice were plated on 6-well plates overnight and infected with adenovirus 
encoding Cre recombinase (Ad-Cre), or empty adenovirus (Ad-CMV, control) for 24 h followed 
by stimulation with, or without, 0.5 mM 8-Br-cAMP. Cell lysates were harvested after 24 h. (A) 
Detection of Cre-recombinase in Ad-Cre transduced MEFs by RT-PCR. (B) Representative 
Western blot of FoxO1 and FoxO3a in MEF whole-cell lysates. Tubulin was used as loading 
control. Real-time qPCR was used to determine the expression of (C) FoxO1, and (D) VEGF 
mRNA normalised to β-actin mRNA levels. Results are the mean (+/- SEM) of 3 experiments and 























































5.3.9 FOXM1 regulates FOXO3A and VEGF expression in hESC 
FOXM1 transcription factor plays important roles in cell proliferation and differentiation 
(Zhang et al., 2013) and was reported to up-regulate VEGF in breast carcinoma cells 
(Karadedou et al., 2012). FOXM1 transcription factor is up-regulated in hESC following 
decidualisation (Figure 3.6E) and its deletion is reported to impair the differentiation of 
hESC through a loss of STAT3 activity (Jiang et al., 2015). In order to determine the 
consequences of FOXM1 inhibition on VEGF expression in hESC, sub-confluent St-T1b 
cells were incubated with E2 or MM1 medium for 3 days and then treated with thiostrepton 
(3 µM), which inhibits FOXM1 expression, overnight prior to harvesting. FOXM1 mRNA 
expression was significantly decreased in decidualised cells as was STAT3 mRNA 
Figure 5.13: FOXO1 is required for cAMP-stimulated VEGF promoter activity 
in MEFs. (A) MEFs isolated from 3 different mice were plated on 12-well plates overnight and 
co-transfected with pGL-VEGF-Luc-2.9 kb and constitutively active FOXO1 (caFOXO1), 
FOXO3A (caFOXO3A) or pcDNA3.1 plasmids as a control for 24 h. (B) Floxed FoxO MEFs were 
transduced with adenovirus encoding Cre recombinase (Ad-Cre), or Ad-CMV (control), overnight 
and transfected with pGL-VEGF-Luc-2.9 kb for 24 h followed by incubation in DMEM medium 
supplemented with 2% FBS (control), and 0.25 mM 8-Br-cAMP for a further 24 h. VEGF promoter 
activity was determined using the dual luciferase assay. Results are the mean (+/- SEM) of 3 
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expression (Figure 5.14A&B). There was an increase of FOXO3A mRNA (Figure 5.14C) 
and protein expression (Figure 5.14G) following the inhibition of FOXM1 in hESC whereas 
there were no changes in FOXO1 mRNA (Figure 5.14D) and protein levels (Figure 5.14F). 
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Figure 5.14: Inhibition of FOXM1 increases FOXO3A and suppresses VEGF 
expression in decidualised hESC St-T1b cells were treated with E2 or MM1 medium for 
3 days and followed by thiostrepton (3 µM) treatment overnight prior harvesting cell lysates and 
supernatants Real-time qPCR analysis of (A) FOXM1, (B) STAT3, (C) FOXO3A, (D) FOXO1, 
and (E) VEGF mRNA expression normalised to b-actin following FOXM1 inhibition. (F) 
Representative Western blots showing FOXO1 and FOXO3A expression with tubulin as a 
loading control. (G) Densitometry analysis of relative FOXO3A protein levels normalised to 
tubulin. Results are the mean (+/- SEM) of 3 experiments and analysed using unpaired t-test; 
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5.2.10 FOXO1 directly regulates VEGF promoter activity in hESC 
We have shown that FOXO1 stimulates VEGF promoter activity. However, it is not known 
whether FOXO1 can bind directly to the VEGF promoter to regulate its expression in hESC. 
In order to address this question, ChIP assays were performed on proliferative and 
decidualised St-T1b cells. The cells were treated with E2 or MM1 medium for 6 days and 
then harvested. The cross-linked protein-chromatin material was then sonicated to obtain 
200-500 bp DNA fragments for each cell type which were then immunoprecipitated with 
specific antibodies to obtain protein-DNA complexes of interest. Immunoprecipitation with 
anti-FOXO1 (H-128, Santa Cruz) antibodies was used to determine the FOXO1 binding to 
the FHRE sequences identified in the VEGF promoter in St-T1b incubated with E2 or MM1 
medium with rabbit IgG (sc2027) as a negative control and anti-Pol II (RNA polymerase II) 
antibody was also used as a positive control to optimise the ChIP conditions. 
The VEGF promoter sequence was analysed using UCSC gene browser, Genomatix 
MatInspector and rVISTA to look for putative FOXO binding-sites (Figure 5.15). As we 
had evidence from the VEGF promoter reporter assay that the 2.9 kb region upstream from 
the transcriptional start site was regulated by FOXO1, we focused our efforts on this 
sequence. Both FOXO1 and FOXO3A have very similar DNA binding sites as shown in 
Figure 5.16. Various sets of the primers were designed from the human VEGF promoter 
DNA sequence using Primer3 and Primer-BLAST (Koressaar and Remm, 2007) (Figure 
5.17). Each primer set amplifies a DNA fragment of 150 to 170 bp nucleotides in length. In 
addition, a set of primers amplifying a non-transcribed intergenic region (NegC) was used 
as an internal background control. All the primers were tested on human genomic DNA to 
ensure efficient amplification of the target sequence before running on the ChIP material. 
The results were expressed as a percentage of the ‘input’ DNA to normalise them according 
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to the amount of chromatin input used (see Section 2.16) and the relative fold enrichment to 
NegC was calculated. 
In order to ensure that the conditions for ChIP were optimal, ChIP assays were run using an 
anti-Pol II antibody. This showed strong enrichment of Pol II binding near to the VEGF 
transcriptional start site confirming that the VEGF gene was actively transcribed in these 
cells (Figure 5.20). An anti-isotype matched IgG antibody was used as a negative control. 
Three different ChIP grade anti-FOXO1 antibodies were trialled, but only one (Santa Cruz, 
H128) successfully precipitated chromatin-associated FOXO1. Initially the endothelial cell 
line, HMEC-1, which constitutively expresses higher levels of FOXO1 than ESC was used 
to examine FOXO1 binding sites in the VEGF promoter (Appendix B1) prior to using 
proliferative and decidualised St-T1b cells.  
To confirm that the ChIP had been successful in the St-T1b cells, a well characterised 
FOXO1 binding site in IGFBP-1 promoter was used as a positive control. There was 
significant enrichment of FOXO1 binding at this site (Appendix B2) in decidualised hESC 
which is consistent with previous reports (Vasquez et al., 2015). Enrichment of FOXO1 
binding was also detected at VEGF ChIP-1-to-3. Notably, the level of enrichment increased 
significantly with decidualisation corresponding to the rise in FOXO1 expression in hESC 
and was negligible under proliferative conditions (Figure 5.18 A-D). Collectively, these 
results indicate that FOXO1 binds directly to the VEGF promoter.  
 




Figure 5.15: Human VEGF promoter and 5’ UTR sequences showing potential 
FOXO consensus binding sites. The human VEGF-A reference gene sequence 
(NM_001025366) was analysed using UCSC genome browser, Genomatix MatInspector and 
rVISTA for the presence of FHRE consensus sequences highlighted (yellow) with potential FOXO 
core binding sites underlined. The sequence of the previously identified FOXM1 (M1) binding site 
is highlighted in green (Karadedou et al., 2012). The primer binding sites designed to amplify 
regions containing the FHRE sites are underlined and in italics. The transcription start site is 
highlighted in red and 5’ UTR sequences are in capitals. The relative position of the start codon and 
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Figure 5.17: Schematic representation of the human VEGF promoter indicating 
the relative positions of the four candidate FHRE sequences. The position and 
sequence of the previously identified FOXM1 (M1) binding site is shown in red 







Figure 5.16: Weblogo representation of the preferred FOXO1, FOXO3A and 
FOXO4 motifs (from JASPER http://jasper.binf.ku.dk). 
 
Table 5.1: Potential FOXO sites within 3 Kb in human VEGF promoter by rVISTA search 







































































































Figure 5.18: FOXO1 binds directly to VEGF promoter in decidualised hESC. ChIP 
assays were performed in proliferative and decidualised St-T1b cells and immunoprecipitated with 
anti-FOXO1, or control IgG antibodies. The % Input was used to determine the enrichment of 
VEGF binding. The fold enrichment of FOXO1 binding to the VEGF (A) ChIP-1, (B) ChIP-2, (C) 
ChIP-3, and (D) ChIP-4 sites to the NegC regions determined by real-time qPCR. Results are mean 
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5.3.11 FOXO3A binds directly to FHRE in the human VEGF promoter in hESC 
To determine whether FOXO3A binds at the same FHREs as FOXO1 in the VEGF promoter, 
we performed ChIP assays in St-T1b proliferative and decidualised cells. The cells were 
treated with E2 or MM1 medium for 6 days and the cells were harvested for ChIP. 
Immunoprecipitation with ChIP-grade anti-FOXO3A (ab12162, Abcam) antibody was used 
to determine the FOXO3A binding sites in the VEGF promoter. The results were calculated 
as a percentage of the ‘input’ DNA to normalise them according to the amount of chromatin 
input that was used in the experiment and the fold enrichment at the individual putative 
FHRE compared to the NegC regions was subsequently calculated (see Section 2.16). The 
fold enrichment of VEGF ChIP-1-to-3 were significantly increased compared to the IgG 
control antibody indicating FOXO3A enrichment at these sites mainly in proliferative cells 
(Figure 5.19). This is consistent with greater FOXO3A activity and very low FOXO1 
activity in the proliferative hESC whilst, only the VEGF ChIP-1 and -3 sites bound 
FOXO3A in the decidualised St-T1b cells (Figure 5.19C). Similar to the FOXO1 results, 
no enrichment was detected at VEGF ChIP-4 confirming that this is not a binding site for 
FOXO transcription factors (Figure 5.19D). Collectively the data show that FOXO3A binds 
to the same binding sites as FOXO1 in this 2.9 kb region of the VEGF gene promoter. 

















































Figure 5.19: FOXO3A binds directly to FHRE in the VEGF promoter in hESC. 
ChIP assays were performed in St-T1b proliferative and decidualised St-T1b cells 
immunoprecipitated with anti-FOXO3A, or isotype specific IgG control antibodies to determine 
the enrichment of binding to the VEGF promoter region. The % Input was used to determine the 
enrichment of VEGF binding. The fold enrichment of FOXO3A binding to VEGF (A) ChIP-1, (B) 
ChIP-2, (C) ChIP-3, and (D) ChIP-4 compared to NegC regions by real-time qPCR. Results are 
















































































































































5.3.1 Up-regulation of VEGF expression and secretion in hESC decidualisation. 
VEGF expression and secretion were found to be up-regulated during hESC decidualisation 
in both primary hESC and St-T1b cells which is consistent with earlier findings (Matsui et 
al., 2004, Lockwood et al., 2009). VEGF expression was induced rapidly, and increased 
VEGF secretion detected after 5 h stimulation in MM1 medium-treated cells. This indicates 
VEGF is being produced de novo and not being released from intracellular stores. Indeed, 










































Figure 5.20: FOXO1 and FOXO3A do not bind to VEGF-FOXM1 site in 
decidualised hESC.  ChIP assays were performed in proliferative and decidualised St-T1b cells 
and immunoprecipitated with anti-FOXO1, anti-FOXO3A antibodies or control IgG antibodies and 
Pol II antibodies as a positive control to determine the enrichment of binding to the VEGF promoter 
region. The % Input was used to determine the enrichment of VEGF binding. The fold enrichment 
of VEGF-FOXM1 binding normalised to NegC regions by real-time qPCR. Results are mean (+/- 
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mRNA. This is consistent with the majority of studies which show that VEGF is not stored 
significantly in most cell types (Ferrara, 2010). 
 
5.3.2 VEGF secretion in hESC decidualisation is regulated by a cAMP-stimulated 
pathway 
VEGF secretion in hESC has been reported to be regulated by E2 (Classen-Linke et al., 
2000) and progesterone (Shifren et al., 1996), but their effects are still controversial as other 
studies have reported that E2 and progesterone do not affect VEGF expression in hESC 
(Lockwood et al., 2002; Okada et al., 2011). In the present study, VEGF secretion was not 
stimulated by E2 even at high concentrations and progesterone reduced VEGF secretion at 
high concentrations in hESC. These findings also indicated that the concentration of E2 (1 
nM) in the E2 growth medium does not significantly affect VEGF levels in the present 
experiments. VEGF secretion is mediated by the cAMP-PKA pathway during hESC 
decidualisation and cAMP treatment alone was found to increase VEGF secretion. 
Progesterone (MPA; 1 µM) reduced the level of VEGF secretion stimulated by cAMP. This 
is likely to be due to the increased PI3K/Akt signalling stimulated by progesterone (Yoshino 
et al., 2003; Fabi et al., 2017), which promotes FOXO phosphorylation and translocation 
from nucleus to cytoplasm decreasing FOXO activity.  
 
5.3.3 FOXO1 and FOXO3A positively and negatively regulate VEGF transcription in 
hESC during decidualisation 
In the present findings demonstrated that over-expression of FOXO1 stimulates VEGF 
expression and secretion, while, FOXO1 knock-down reduces VEGF expression and 
secretion in hESC under decidual conditions. Furthermore, the present results have identified 
that FOXO3A antagonises VEGF expression. Three fragments of the human VEGF 
promoter (pGL-VEGF-Luc-1.8 kb, -2.9 kb and -4.7 kb) were used to define the role of 
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FOXO1 in VEGF transcription. The activity of all three VEGF promoter reporter constructs 
was significantly increased during hESC decidualisation. The 4.7 kb fragment was found to 
have the lowest relative activity which may indicate the presence of negative regulator 
regions. Although the -1.8 kb construct had lower overall activity than 2.9 kb fragment, 
caFOXO1 increased the activity of both constructs which indicates that there are FOXO1 
binding sites within the 1.8 kb region. Consistent with VEGF expression and protein data, 
over-expression of caFOXO1 increased VEGF promoter activity, whereas caFOXO3A 
suppressed it. FOXO1 knock-down also reduced VEGF promoter activity whilst FOXO3A 
knock-down increased its activity. The role of FOXO1 in up-regulating VEGF expression 
was also confirmed in MEFs isolated from the floxed FoxO mice. The FoxOF/F mutant mice 
possess loxP sites flanking exon 2 of the FoxO genes which are inactivated by Cre 
recombinase treatment (Paik et al., 2007). VEGF secretion increased with the 8-Br-cAMP 
stimulation in floxed FoxO MEFs which again shows that VEGF is expressed through 
activation of the PKA pathway leading to increased FOXO activity in fibroblasts. Following 
Cre recombinase-mediated FoxO deletion, Vegf expression decreased. FOXO3A was 
reported to reduce VEGF expression in breast carcinoma cells (Karadedou et al., 2012). 
 
5.3.4 FOXO1 and FOXO3A directly regulate VEGF in hESC 
We demonstrated that FOXO1 is important in the transcriptional regulation of VEGF gene 
expression. It was therefore, necessary to determine whether FOXO1 binding elements exist 
within the promoter and, if so, which putative FHRE is critical for promoter activity during 
hESC decidualisation. ChIP was used to determine whether FOXO1 and FOXO3A bind 
directly to FHRE identified VEGF gene promoter in hESC. The decidual markers, IGFBP-
1 which were reported to be direct targets of FOXO1 in hESC decidualisation (Vasquez et 
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al., 2015), were used as positive control sites to confirm the validity of the ChIP assays (see 
Appendix B2).  
Four potential FHRE binding sites were identified in a 2.9 kb region upstream of the VEGF 
start codon using various programs. All FOXO proteins recognise two FHRE consensus 
sequences: 5′-GTAAA(T/C)AA-3′ known as Daf-16 family member-binding element 
(DBE) and 5’-(C/A)(A/C)AAA(C/T)AA-3’ which is the insulin-responsive element (IRE) 
(Obsil et al., 2011). There are also several alternative binding sites (Weigelt et al., 2001) 
which make FOXO binding sites harder to predict. Four sites containing FOXO consensus 
binding sequences were examined by ChIP assays. There was an enrichment of FOXO1 
binding at three of the sites – VEGF ChIP-1-to-3. Importantly, the enrichment of FOXO1 
binding to the VEGF promoter was only significantly detected in decidualised St-T1b cells 
corresponding to the up-regulation of FOXO1 expression and activity. The VEGF ChIP-1 
site is located ~ 700 bp up-stream of the VEGF transcription start site and was reported in a 
very recent study to bind to FOXO1 during wound healing to promote VEGF expression in 
keratinocytes (Joen et al., 2018). As shown in Figure 5.21, VEGF ChIP-3 site showed the 
greatest enrichment for FOXO1 in decidualised hESC. These results are consistent with 
ChIPseq data deposited by Vasquez et al. (2015), which are available through the Cistrome 
Project (http://www.cistrome.org/), and when interrogated in UCSC gene browser and 
indicate a peak of FOXO1 binding to VEGF approximately around ~2.0 kb upstream of the 
transcriptional start site in decidual hESC. The VEGF ChIP-4 site which is a 100 % sequence 
match with the IRE-binding site showed no enrichment of FOXO1. Water-mediated 
interactions are one of the important factors for DNA recognition by FOXO proteins, the 
imbalance in the network of the hydrogen-bonds and water-mediated interactions may lead 
to the low binding affinity for the IRE sequence (Brent et al., 2008).  




There is no evidence in the literature of the competitive binding of FOXO3A to regulate 
FOXO1 transcriptional activity. Consistent with our expression data, we found enrichment 
in FOXO3A binding at three (ChIP-1-3) of the FHRE sites in VEGF promoter sequences. 
The degree of enrichment at these sites was greater in proliferative St-T1b cells, with the 
exception of VEGF ChIP-3. By in silico sequence analysis, the ChIP-3 site was predicted to 
be a FOXO1/3/4 site. The VEGF ChIP-3 site was found to have higher FOXO3A enrichment 
compared to the other three sites. In contrast, the enrichment of FOXO3A at the ChIP-2 site 
was low compared to ChIP-1 and ChIP-3 sites (Figure 5.22). Collectively, the expression 
and ChIP data indicate that VEGF is directly regulated positively and negatively by FOXO1 
and FOXO3A respectively in hESC as summarised in Figure 5.23.  















Figure 5.21: FOXO1 binding sites identified by ChIP analysis in human VEGF 
promoter in hESC. Graph showing the degree of enrichment of FOXO1 binding 





































5.3.5 FOXM1 and FOXO3A compete to regulate VEGF expression in hESC 
FOXM1 plays a critical role in hESC decidualisation (Jiang et al., 2015) and is regulated by 
E2 and progesterone (Xie et al., 2014). It was shown in breast carcinoma cells that FOXM1 
positively regulates VEGF expression through binding to the ChIP-M1 site (Figure 5.17) 
and this was inhibited by competitive FOXO3A binding at the same site (Karadedou et al., 
2012). However, both FOXO1 and FOXO3A were found to negatively regulate FOXM1 
Figure 5.22: FOXO3A binding sites identified by ChIP analysis in the human 
VEGF promoter. Graph shows the degree of enrichment of FOXO3A binding 
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expression in hESC (see Figure 4.8C). In agreement with Karadedou et al. (2012), the 
present findings have shown increased FOXO3A and reduced STAT3 and VEGF mRNA 
expression following FOXM1 inhibition with thiostrepton in hESC. The observed reduction 
in VEGF may be due to the up-regulation of FOXO3A leading to increased FOXO3A 
binding to the VEGF promoter. However, the present results did not detect FOXO3A or 
FOXO1 enrichment at this site in hESC. Further research would be required to determine 
whether FOXM1 is binding directly to the VEGF promoter in hESC, or simply acting 
indirectly via up-regulation of FOXO3A and STAT3. This could be determined by 
performing knock-down of FOXM1 to confirm the results obtained with thiostrepton and 
over-expression of FOXM1 in combination with FOXO3A knock-down as well as the 
appropriate ChIP experiments. 
 
5.3.6 Conclusion 
In conclusion, the present study shows that the VEGF gene is directly regulated by FOXO1 
and FOXO3A in hESC in a positive and negative manner. Furthermore, these results were 
confirmed in MEFs which indicate that this may be a more general mechanism regulating 
the angiogenesis promoting response in stromal cells. Moreover, both FOXO1 and FOXO3A 
bind to the VEGF promoter at the same FHRE sites, which leads us to propose that FOXO1 
and FOXO3A directly compete to regulate VEGF in hESC. Thus, the up-regulation of VEGF 
in hESC during decidualisation may be due to an overall shift in the balance from FOXO3A 
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Multiple soluble splice variants of Flt-1 have been reported (Thomas et al., 2009; Heydarian 
et al., 2009; He et al., 1999). sFlt-1-i13 is the predominant splice variant in endothelial cells 
and is expressed in most human tissues, whereas sFlt-1-e15a is thought to be a primate-
specific isoform mainly expressed in placenta, with much lower concentrations in other 
tissues (Jebbink et al., 2011). Interestingly, sFlt-1-i13 is the predominant isoform in the 
rhesus monkey placenta (Rajakumar et al., 2009). 
Up-regulation of Flt-1 (Andraweera et al., 2012; Nishizawa et al., 2011; Chung et al., 2004) 
and sFlt-1 (Muy-Rivera et al., 2005; Maynard et al., 2003) are associated with preeclampsia 
and unexplained fetal growth restriction (Nikuei et al., 2015). sFlt-1 is over-expressed in the 
placentas of preeclamptic patients, and leads to the maternal syndrome, for example, 
hypertension and renal dysfunction, by hindering the physiological activity of VEGF in the 
maternal circulation (Kendall and Thomas, 1993; Maynard et al., 2003; Shibuya et al., 2011; 
Pang et al., 2013; Hod et al., 2015).  
There are only a few studies that report sFlt-1/Flt-1 in the context of the endometrium. 
Higher expression of sFlt-1 was detected in the mid to late proliferative phase compared to 
secretory phase in hESC isolated during different phases of the menstrual cycle (Krussel et 
al., 1999). It was also reported that the Flt-1 receptor exhibited strong expression throughout 
the secretory phase but decreased in the late secretory phase in hESC (Krussel et al., 1999; 
Jee et al., 2009). Very recent studies show that sFlt-1 expression is down-regulated during 
decidualisation at both the protein and mRNA level in hESC and is negatively correlated 
with PRL and VEGF expression (Cottrell et al., 2017). However, the mechanisms regulating 
Flt-1 expression and production of its soluble isoforms during hESC decidualisation is still 
unknown.  
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In this chapter, changes in the expression of Flt-1 receptor and sFlt-1 production during in 
vitro decidualisation of hESC are investigated. The Flt-1 receptor was previously reported 
to be regulated by FOXO1 in endothelial cells (Potente et al., 2005; Furuyama et al., 2004). 
Therefore, we also determined whether FOXO1 regulates Flt-1 gene activity during hESC 
decidualisation. These findings may have important implications in pregnancy 
complications, such as preeclampsia that involve abnormal decidualisation, implantation and 
angiogenesis at the maternal-fetal interface. 
 
6.2 RESULTS 
6.2.1 Changes in sFlt-I expression in hESC during decidualisation 
In order to characterise the expression of sFlt-1 in hESC during decidualisation, primary 
hESC and St-T1b cells were grown to confluence and then incubated with E2 or MM1 
medium at different time points over 6 days. Fresh medium was added to the cells 24 h prior 
to harvesting of RNA lysates and collection of cell supernatants at 3 and 6 days. sFlt-1 
mRNA and protein levels were assessed by real-time qPCR and ELISA respectively. 
Relatively high levels of total sFlt-1 were detected in proliferative cells incubated in E2 
medium and there was significant (p<0.01) down-regulation of sFlt-1 secreted levels during 
decidualisation in both primary hESC, isolated from five individuals at passage 3, (Figure 
6.1A) and St-T1b cells (Figure 6.2A). Consistent with these results, the sFlt-1 protein levels 
in the cells also decreased with decidualisation from day 3 to day 6 of stimulation by Western 
blotting in primary hESC (Figure 6.1B) and St-T1b cells (Figure 6.2B) and were nearly 
undetectable on day 6 of stimulation with MM1 medium. Total sFlt-1 secretion in 
proliferative cells also found to increase as early as 11 h, while the sFlt-1 levels in 
decidualised cells remained unchanged (Figure 6.2C). 






Figure 6.1: Decidualisation leads to a decrease in sFlt-1 release in primary hESC. 
Primary hESC were incubated in E2 or MM1 medium and protein lysates and supernatants were 
harvested after 3 and 6 days. (A) The sFlt-1 secretion in supernatants was determined by ELISA in 
primary hESC. (B) Representative Western blotting analysis of sFlt-1 protein with tubulin as loading 
control. Densitometric analysis of relative (C) sFlt-1-e15a and (D) sFlt-1-i13 protein levels 
normalised to tubulin. Results are the mean (+/- SEM) of 5 experiments and analysed using an 
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Figure 6.2: Decidualisation leads to a decrease in sFlt-1 release in St-T1b cells.  St-
T1b cells were incubated in E2 or MM1 medium and protein lysates and supernatants were harvested 
over 6 days. The sFlt-1 secretion in supernatants was determined by ELISA in St-T1b cells treated (A) 
over 6 days and (B) 24 h. (C) Representative Western blotting analysis of sFlt-1 protein with tubulin 
as loading control. (D) Densitometric analysis of relative (D) sFlt-1-e15a and (E) sFlt-i13 protein levels 
normalised to tubulin. Results are the mean (+/- SEM) of 3 experiments and analysed using an unpaired 
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The mRNA expression of the two major isoforms, sFlt-1-i13 and sFlt-1-e15a mRNA was 
also determined. sFlt-1-e15a mRNA was also significantly suppressed in decidualised 
primary hESC consistent with the ELISA results in primary hESC (Figure 6.3A). However, 
the sFlt-i13 isoform mRNA was surprisingly found to increase in decidualisation in primary 
hESC on day 3 but was found to be similar to the proliferative controls at day 6 of stimulation 
(Figure 6.3B). Similarly, sFlt-1-e15a mRNA expression in St-T1b cells was found to be 
significantly decreased from 24 h of stimulation with MM1 medium (Figure 6.4A) and at 3 
and 6 days compared to control (Figure 6.4B), whereas, the sFlt-1-i13 mRNA expression 
significantly increased (p<0.01) at day 3 and day 6 of in vitro decidualisation in St-T1b cells 
(Figure 6.4 C&D). Collectively, these results indicate that sFlt-1 secretion is significantly 








Figure 6.3: Changes in sFlt-1 mRNA isoform expression in primary hESC during 
decidualisation. Primary hESC were incubated in E2 or MM1 medium, over 6 days and RNA 
lysates were harvested after 3 and 6 days. Real-time qPCR analysis showing relative (A) sFlt-1-e15a 
and (B) sFlt-1-i13 mRNA expression normalised to β-actin. Results are the mean (+/- SEM) of 5 


















































6.2.2 Does FOXO1 regulate sFlt-1 expression and release in hESC? 
6.2.2.1 Effect of FOXO1 knock-down on sFlt-1 expression and secretion in hESC 
FOXO1 is known to regulate Flt-1 in endothelial cells (Potente et al., 2005). To determine 
whether FOXO1 or FOXO3A regulate sFlt-1 expression and release during hESC 
decidualisation, primary hESC and St-T1b cells were transfected with FOXO1, FOXO3A or 









Figure 6.4: Changes in sFlt-1 mRNA isoform expression in St-T1b cells during 
decidualisation.  St-T1b cells were incubated in E2 or MM1 medium, over 6 days and RNA 
lysates were harvested within 24 h and longer term (3 and 6 days). Real-time qPCR analysis showing 
relative (A, B) sFlt-1-e15a and (C, D) sFlt-1-i13 mRNA expression normalised to β-actin. Results 
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or MM1 medium. sFlt-1-e15a mRNA expression was significantly suppressed following 
FOXO1 knock-down in both primary hESC (Figure 6.5A) and St-T1b cells (Figure 6.6A) 
following 24 h stimulation with MM1 medium. Surprisingly, there were no significant 
changes in sFlt-1-i13 isoform mRNA in either primary hESC (Figure 6.5B) or St-T1b cells 
(Figure 6.6B) following FOXO1 knock-down. In primary hESC following FOXO3A 
knock-down, sFlt-1-e15a mRNA expression increased (Figure 6.5A) in the proliferative 
cells. In contrast, sFlt-1-e15a and sFlt-1-13 mRNA expression did not change in St-T1b cells 
following FOXO3A knock-down (Figure 6.6 A&B). Furthermore, levels of total sFlt-1 
secretion, assayed by ELISA, were also suppressed in the primary hESC (Figure 6.5C) and 
St-T1b cells (Figure 6.6C) following FOXO1 knock-down. Consistent with these findings, 
sFlt-1-e15a protein expression was also significantly decreased in primary hESC (Figure 
6.5E) and St-T1b cells (Figure 6.6E) following FOXO1 knock-down, whereas, FOXO3A 
knock-down did not affect the sFlt-1 protein levels. 
 




























































































Figure 6.5: Effect of FOXO1 knock-down on sFlt-1 expression in primary hESC 
decidualisation. Primary hESC were plated on 6-well plates overnight and transfected with 
siRNAs targeting FOXO1 (siFOXO1), or FOXO3A (siFOXO3A), or control (siControl) overnight 
followed by stimulation with E2 or MM1 medium for 24 h. Real-time qPCR analysis of (A) sFlt-1-
e15a and (B) sFlt-1-i13 mRNA normalised to β-actin. (C) Total sFlt-1 protein secretion in hESC 
supernatants by ELISA. (D) Representative Western blots showing sFlt-1 protein with tubulin as a 
loading control. Densitometric analysis of relative (E) sFlt-1-e15a and (F) sFlt-i13 protein levels 
normalised to tubulin. Results are the mean (+/- SEM) of 3 experiments and analysed using two-
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Figure 6.6: Effect of FOXO1 knock-down on sFlt-1 expression in St-T1b cell 
decidualisation. St-T1b cells were plated on 6-well plates overnight and transfected with siRNAs 
targeting FOXO1 (siFOXO1), FOXO3A (siFOXO3A), or control (siControl) overnight followed by 
stimulation with either E2 or MM1 medium for 24 h. Real-time qPCR analysis of (A) sFlt-1-e15a and 
(B) sFlt-1-i13 mRNA normalised to β-actin. (C) Total sFlt-1 protein secretion in St-T1b cell 
supernatants by ELISA. (D) Representative Western blots of FOXO1, FOXO3A and sFlt-1 protein 
with Tubulin as control. Densitometric analysis of relative (E) sFlt-1-e15a and (F) sFlt-1-i13 protein 
levels normalised to tubulin. Results are the mean (+/- SEM) of 3 experiments and analysed using 
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6.2.2.2 FOXO1 over-expression increases sFlt-1 expression  
St-T1b cells were plated at a density of 2.5 x 105 cells per well on a 6-well plate overnight. 
The cells were then transduced with recombinant adenovirus expressing HA-tagged murine 
FoxO1 (Ad-FoxO1) or empty control virus (Ad-CMV) for 24 h and incubated in E2 medium 
for another 24 h prior to harvesting. The cell lysates were harvested for real-time qPCR and 
Western blotting. Successful viral transduction was confirmed by real-time qPCR and 
Western blotting as described previously for the HA-tagged FoxO1 (see Figure 4.6B) which 
showed a large increase of mouse FoxO1 mRNA and protein expression in cells treated with 
Ad-FoxO1 (see Section 4.2.3.2). We found that sFlt-1-e15a mRNA was significantly 
increased following FoxO1 over-expression (Figure 6.7A). Interestingly, no significant 
change of sFlt-1-i13 isoform mRNA expression was observed in FoxO1 over-expressing 
cells (Figure 6.7B). Total sFlt-1 protein secretion was also measured by ELISA in the cell 
supernatants. Consistent with the sFlt-1-e15a mRNA results, total sFlt-1 protein secretion 
was increased with Ad-FoxO1 transduction of hESC (Figure 6.7C). 
 




6.2.3 Changes in Flt-1 expression in hESC during decidualisation 
To determine whether full-length Flt-1 was expressed in hESC, qPCR was used to determine 
the presence of Flt-1 mRNA during hESC decidualisation. Primary hESC and St-T1b cells 
were stimulated with E2 or MM1 medium over 6 days and RNA was purified. Levels of Flt-
1 mRNA were significantly increased in both primary hESC (Figure 6.8A) and St-T1b cells 
(Figure 6.8B) after 6 days decidualisation.  
Figure 6.7: FOXO1 over-expression in hESC promotes sFlt-1 expression and 
secretion. St-T1b cells were transduced with recombinant adenoviruses encoding FoxO1 (Ad-
FoxO1), or empty virus control (Ad-CMV) overnight and incubated in fresh E2 medium for another 
24 h prior harvesting. Real-time qPCR was used to measure the mRNA expression of (A) sFlt-1-
e15a, and (B) sFlt-1-i13 normalised to b-actin. (C) The sFlt-1 protein secretion on FoxO1 over-
expression was assessed by sFlt-1 ELISA in cell supernatants. Results are the mean (+/- SEM) of 3 
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Indirect flow cytometry was used to determine the presence of Flt-1 receptor on the surface 
of hESC; St-T1b cells were grown to confluence and treated with E2 or MM1 medium for 6 
days. The cells were fixed without permeabilisation followed by staining with anti-Flt-1 
antibody, or an irrelevant IgG control antibody staining. Propidium iodide was used to 
counterstain the DNA. Surface Flt-1 receptor was detected in both proliferative and 
decidualised cells (Figure 6.9 A&B). There was a slight shift of the peaks indicating the 







Figure 6.8: Flt-1 expression increases in decidualised hESC.  Primary hESC and St-
T1b cells were incubated in E2 or MM1 medium and RNA lysates harvested after 3 and 6 days. 
Real-time qPCR was used to determine the Flt-1 mRNA expression normalised to β-actin in (A) 
primary hESC and (B) St-T1b cells, respectively. Results are the mean (+/- SEM) of 3 experiments 















































6.2.4 Flt-1 promoter activity during hESC decidualisation 
In order to determine whether the Flt-1 gene transcription is activated by decidualisation, 
Flt-1 promoter activity was examined by dual luciferase assays. St-T1b cells were co-
transfected with a 1.8 kb Flt-1 promoter luciferase-reporter construct (pFlt-1-Luc) and the 
pRL-CMV control plasmid. The cells were stimulated with E2 or MM1 medium for 24 h 
and the firefly luciferase activity normalised to pRL-CMV Renilla activity to determine the 
Figure 6.9: Expression of Flt-1 on hESC by FACS. St-T1b cells were grown to 
confluence and stimulated with E2 or MM1 medium, for 6 days. The cells were fixed and stained 
with anti-Flt-1 or control IgG antibodies and then incubated with either Alexa Fluor 488 (Flt-1) 
antibody or Alexa Fluor 594 (control antibody). Representative scans of surface Flt-1 expression 
on (A) proliferative, and (B) decidualised St-T1b cells as indicated. (C) Representative overlay 
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relative Flt-1 promoter activity. Incubation of St-T1b cells in MM1 medium containing 8-
Br-cAMP was found to increase the activity of Flt-1-Luc by 2-fold which is consistent with 
the Flt-1 mRNA results (Figure 6.10). 
 
 
6.2.5 Flt-1 expression is regulated by FOXO1 transcription factors 
FOXO1 has been shown to regulate the Flt-1 promoter in endothelial cells (Roupé et al., 
2014; Potente et al., 2005). Therefore, the binding of FOXO1 to the Flt-1 promoter in hESC 
was examined. St-T1b cells were co-transfected with pFlt-1-Luc with constitutively active 
FOXO1 plasmids (caFOXO1) or FOXO3A (caFOXO3A) (Ramaswamy et al., 2002) or the 
pcDNA3.1 parent plasmid as a control. The pFlt-1-Luc readings were normalised to the 
pRL-CMV Renilla activity to determine the relative Flt-1 promoter activity. Flt-1 promoter 
Figure 6.10: Activity of Flt-1 promoter increases in hESC during 
decidualisation. Relative Flt-1 promoter activity determined by using a 1.8 kb Flt-1 promoter 
luciferase-reporter construct (pFlt-1-Luc). Following transfection cells were stimulated with E2 or 
MM1 medium for 24 h and the firefly luciferase readings normalised to Renilla activity. Results 
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activity increased in cells over-expressing caFOXO1 whilst, there was no significant change 
in cells co-transfected with caFOXO3A (Figure 6.11A).  
To further explore the effect of FOXO1 and FOXO3A transcription factors on Flt-1 
expression, St-T1b cells were co-transfected with pFlt-1-Luc with either FOXO1 or 
FOXO3A siRNAs. FOXO1 knock-down significantly decreased the Flt-1 promoter activity 
in both proliferative and decidualised cells, however, loss of FOXO3A did not affect the 
pFlt-1-Luc promoter activity (Figure 6.11B). 
 
 
6.2.6 FoxO1 drives Flt-1 expression in MEFs 
In order to extend our findings and confirm FoxO1 regulation of Flt-1 in fibroblasts, MEFs 
isolated from the floxed FoxO transgenic mice were transduced with a recombinant 
Figure 6.11: FOXO1 transcription factor regulates Flt-1 promoter activity in 
hESC. (A) St-T1b cells were plated on 12-well plates overnight and co-transfected with a 1.8 kb 
Flt-1 promoter luciferase-reporter construct (pFlt-1-Luc) and constitutively active FOXO1 
(caFOXO1), FOXO3A (caFOXO3A) plasmids or pcDNA3.1 as a control for 24 h. (B) The St-T1b 
cells were co-transfected with pFlt-1-Luc and siRNAs targeting FOXO1 (siFOXO1), or FOXO3A 
(siFOXO3A), or control (siControl) for 24 h followed by 24 h treatment with E2, or MM1 medium. 
The firefly luciferase readings were normalised to Renilla activity. Results are the mean (+/- SEM) 
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adenovirus encoding Cre recombinase (Ad-Cre) to induce Cre-mediated knock-out of FoxOs 
in the cells. MEFs were grown to confluence and infected with Ad-Cre, or Ad-CMV 
(control) at MOI of 50 for 24 h prior to being seeded onto 6-well-plates. The expression of 
Cre-recombinase in the Ad-Cre treated cells were confirmed by RT-PCR and the deletion of 
FoxO1 and FoxO3a were confirmed by PCR and Western blotting as shown previously in 
Figure 5.10. Flt-1 expression increased by more than 2-fold at 24 h following treatment with 
8-Br-cAMP (Figure 6.12A). However, the cAMP-mediated increase in Flt-1 mRNA was 
blunted following FoxO1 knock-out indicating that FoxO1 regulates Flt-1 expression in 
these cells (Figure 6.12A).  
In addition, MEFs were co-transfected with pFlt-1-Luc and caFOXO1, caFOXO3a 
plasmids, or the pcDNA3.1 as a control. The MEFs were found to behave like the St-T1b 
cells, as the Flt-1 activity was increased with caFOXO1 over-expression, while no effect 
was observed with caFOXO3a (Figure 6.12B). 





6.2.7 FOXO1 directly regulates sFlt-1/Flt-1 promoter activity in hESC 
We have shown that FOXO1 can activate Flt-1 promoter reporter activity; however, it is not 
known whether FOXO1 can bind directly to Flt-1 promoter to regulate its expression in 
hESC. In order to address this question, ChIP assays were performed in decidualised St-T1b 
cells. The cells were treated with MM1 medium for 6 days and then harvested for ChIP. The 
chromatin was fragmented by sonication and immunoprecipitated with anti-FOXO1 (H-128, 
Santa Cruz) and anti-FOXO3A (ab12126, Abcam) antibodies or an irrelevant rabbit IgG 
control antibody to determine the FOXO1 and FOXO3A binding to potential FHRE 
sequences in the Flt-1 promoter in St-T1b incubated with E2 or MM1 medium. 
The Flt-1 promoter sequence was analysed using the UCSC genome browser, Genomatix 
MatInspector and rVISTA to look for putative FHRE binding-sites (Figure 6.13). The 
Figure 6.12: FoxO1 increases Flt-1 promoter activity in MEFs. (A) MEFs were 
transduced with adenovirus encoding Cre recombinase (Ad-Cre) or empty control virus (Ad-
CMV) overnight and then transfected with a 1.8 Kb Flt-1 promoter luciferase-reporter 
construct (pFlt-1-Luc) overnight followed by stimulation with DMEM medium supplemented 
with 2% FBS (control), or 0.25 mM 8-Br-cAMP for 24 h. (B) MEFs were plated on 12-well 
plates overnight and co-transfected with pFlt-1-Luc and with constitutively active mutant 
FOXO1 (caFOXO1) or FOXO3A (caFOXO3A) plasmids or pcDNA3.1 as a control for 24 h. 
The firefly luciferase readings were normalised to Renilla activity. Results are the mean (+/- 
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degree of conservation of the identified sites was analysed following alignment of a ~3 kb 
of the Flt-1 gene sequence upstream of the start codon of several species using CLUSTAL 
Omega (Sievers et al., 2011) (Figure 6.14). Various sets of primers were designed from the 
human Flt-1 promoter sequence using Primer3 and Primer-BLAST (Figure 6.13). Each 
primer set amplifies a PCR fragment approximately 120 bp nucleotides in length flanking 
the FHRE site (Figure 6.14). In addition, a set of primers amplifying a non-transcribed 
intergenic region (NegC) was used as an internal background control. All the primers were 
tested on the genomic DNA to ensure efficient amplification of the target sequence before 
use on the ChIP material. The results of the ChIP were expressed as a percentage of the 
‘input’ DNA to normalise them according to the amount of chromatin input used in each 
experiment and the fold enrichment was calculated by normalising it to the NegC result. We 
found that all the three sequences containing the potential FOXO sites were enriched relative 
to the input chromatin (Figure 6.15), indicating FOXO1 binds directly to the Flt-1 promoter 
at all three sites. Whereas, there was no enrichment of FOXO3A binding to these regions 
supporting our results showing that unlike VEGF, Flt-1 is not regulated by FOXO3A 
(Figure 6.15). 





Figure 6.13: Human Flt-1 promoter and 5’ UTR sequences showing potential 
FOXO consensus binding sites.  Human Flt-1 reference sequence (NM_002019) was analysed 
using the UCSC genome browser, Genomatix MatInspector and rVISTA for the presence of FHRE 
consensus sequences and the potential FOXO binding sites are highlighted (yellow) and HIF-1a 
binding site (blue). The transcription start codon (ATG) and coding region is in bold and the 5’ UTR 
untranslated sequences from the transcription start site (red) are in capitals. The position of the 

































CGGGCACCGGGCGAGCAGGCCGCGTCGCGCTCACC ATG GTC AGC TAC TGG 
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Figure 6.14: FHRE consensus sites in the Flt-1 gene promoter. Schematic 
representation of the human Flt-1 promoter showing the candidate putative FHRE 
consensus sequences and other characterised transcription factor binding sites identified 
previously (Takeda et al., 2004; Jin et al., 2009). The boxes show the degree of 
conservation of the FHRE sites determined using multiple sequence alignment with 
CLUSTAL-Omega. 





Figure 6.15: FOXO1 binds directly to Flt-1 promoter in decidualised hESC. ChIP 
assays were performed in St-T1b cells decidualised for 6 days and immunoprecipitated with rabbit 
anti-FOXO1 antibody, FOXO3A antibody or, control IgG and the % Input was used to determine 
the enrichment of Flt-1 binding at (A) ChIP-1, (B) ChIP-2, and (C) ChIP-3 binding regions 
normalised to NegC region by real-time qPCR. Results are mean (+/- SEM) of 2 independent of 
ChIP experiments and analysed using one-way ANOVA; *p<0.05; **p<0.01. 
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The level of sFlt-1 expression in ESC may potentially influence fertility, embryo 
implantation, placentation and early pregnancy. sFlt-1 acts to block VEGF activity and so 
may affect angiogenesis and other functions such as trophoblast and leukocyte migration (Li 
et al., 2015) into the endometrium that are required for establishing a normal pregnancy. 
Little is known of the expression and regulation of Flt-1/sFlt-1 in the hESC. Krussel et al. 
(1999) found peak sFlt-1 mRNA expression was detected in endometrial epithelial and 
stromal cells isolated from the mid- to late- proliferative phase of the menstrual cycle. sFlt-
1 production was reported to be inhibited by E2 in proliferative hESC (Okada et al., 2010) 
and thrombin has been shown to induce sFlt-1 expression during stromal cell decidualisation 
(Lockwood et al., 2007).  
 
6.3.1 Down-regulation of sFlt-1 in hESC decidualisation 
In the present study, proliferative hESC are capable of producing relatively high levels of 
sFlt-1 and that total sFlt-1 production was markedly reduced in decidualised hESC compared 
to proliferative cells supporting the earlier studies in hESC isolated from an endometrial 
tissues from healthy women in different phases of the menstrual cycle showing that sFlt-1 
mRNA expression peaks during mid-proliferative phase and decreases in secretory phase 
(Krussel et al., 1999). While the present studies were being performed, a study was published 
showing sFlt-1 is produced by hESC and reduced by decidualisation (Cottrell et al., 2017). 
Cottrell et al. (2017) showed that total sFlt-1 expression both at the RNA and protein level 
is down-regulated with hESC decidualisation. However, Cottrell et al. (2017) did not look 
into the regulation and expression of sFlt-1 mRNA splice variants. The two predominant 
sFlt-1 isoforms, sFlt-1-i13 and sFlt-1-e15a, were investigated in the present study. sFlt-1-
e15a is a primate-specific sFlt-1 isoform, mainly produced by non-endothelial cells types, 
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for example, smooth muscle cells, dendritic cells and epithelial cells (Thomas et al., 2009; 
Sela et al., 2009; Jebbink et al., 2011). Sela et al. (2009) showed that endothelial cells 
produce mainly sFlt-1-i13. Furthermore, Jebbink et al. (2011) investigated sFlt-1 mRNA 
splice variant expression in 21 different human tissues, including HUVEC and human brain 
microvascular endothelial cells, and showed that the sFlt-1-e15a isoform is the predominant 
isoform expressed in placenta. Both sFlt-1-e15a and sFlt-1-i13 were found to be produced 
in both primary hESC and St-T1b cells. Consistent with the sFlt-1 ELISA results, Western 
blotting showed that sFlt-1-i13 and sFlt-1-e15a decreased with decidualisation in hESC. 
However, sFlt-1-i13 mRNA expression was found to increase during decidualisation in 
primary hESC and St-T1b cells. Furthermore, sFlt-1-i13 mRNA expression also increased 
in primary hESC stimulated with MM1 medium for 3 days but remained at similar levels as 
proliferative hESC on day 6 of stimulation. This difference in the sFlt-1-i13 mRNA and 
protein expression results may be due to the action of miRNAs which have been shown to 
be up-regulated during decidualisation (Aoyagi et al., 2017, Tochigi et al., 2017).  
Fan et al. (2014) demonstrated that endometrium-specific over-expression of VEGF in 
mouse ESC, using viral vectors, triggers excess production of sFlt-1 (Fan et al., 2014). 
Furthermore, Xiao et al. (2018) also showed that VEGF regulates sFlt-1 and sFlt-1-e15a 
mRNA and protein expression in human choriocarcinoma (JEG3) and human trophoblast 
(HTR-8/SVneo) cell lines. According to these findings, it is also a possibility that up-
regulation of the sFlt-1-i13 isoform mRNA is driven in an autocrine manner by increased 
VEGF expression during hESC decidualisation. The preliminary results showed that both 
sFlt-1-e15a and sFlt-1-i13 mRNA were decreased following VEGF knock-down St-T1b 
cells (Appendix F) which would be consistent with the previous studies (Fan et al., 2014; 
Xiao et al., 2018). We also do not know the effect of exogenous VEGF or PIGF on sFlt-1-
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i13 isoform expression in hESC during decidualisation, therefore, further investigation of 
the effect of VEGF on sFlt-1-i13 expression in hESC decidualisation is needed.  
 
6.3.2 Regulation of sFlt-1/Flt-1 during hESC decidualisation 
sFlt-1-e15a and sFlt-1-i13 protein levels were consistent with the total secreted sFlt-1 and 
found to decrease in hESC decidualisation. Whereas, sFlt-1-i13 isoform mRNA expression 
was more variable but increased at day 3 of decidualisation in both primary hESC and St-
T1b cells. The oxygen-sensing jumonji domain containing protein 6 (JMJD6) is known to 
directly affect the splicing pattern of Flt-1 to produce sFlt-1 in endothelial cells (Palmer et 
al., 2016; Boeckel et al., 2011). JMJD6 hydroxylates U2AF65, a component of the splicing 
machinery, under normal conditions to produce the full-length membrane bound Flt-1 
transcript (Boeckel et al., 2011). However, hypoxia was found to decrease JMJD6 activity 
reducing its ability to hydroxylate U2AF65 splicing factor directing the transcription of sFlt-
1 mRNA (Palmer et al., 2016). Interestingly, there are different regulation patterns in sFlt-1 
production by JMJD6 between endothelial and trophoblast cells. JMJD6 knock-down in 
endothelial cells increased both sFlt-1-i13 and sFlt-1-e15a isoforms, in contrast with sFlt-1-
e15a is the only isoform significantly produced from trophoblast cells that are affected by 
JMJD6 knock-down (Palmer et al., 2016). Also, decidualisation is a complex event with 
various biochemical changes and regulated by various hormones, growth factors and 
cytokines which may potentially affect the JMJD6 factor subsequently influencing the 
splicing conditions. There are no studies on the activity of JMJD6 in hESC decidualisation, 
therefore, further studies are needed to examine the role of JMJD6 on sFlt-1 isoforms 
expression in hESC.  
Apart from differential JMJD6 expression affecting Flt-1 mRNA splicing, post-
transcriptional regulation, or microRNAs (miRNA) might also be a factor leading to sFlt-
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1/Flt-1 splicing and expression in hESC during decidualisation. miRNA are small, 
endogenous, and non-coding RNAs that are key regulators of gene expression, either 
mediating translational repression, or direct mRNA degradation (Pillai, 2005). The gain or 
loss of miR-221/222 function in human endothelial cells leads to changes VEGF, Flt-1 and 
VEGFR-2 expression (Poliseno et al., 2006). A number of studies have identified the 
expression of miRNAs in the reproductive tract tissues including endometrial tissue in both 
healthy and diseased states (Chegini, 2010; Filigheddu et al., 2010; Myatt et al., 2010; Qian 
et al., 2009). In addition, a number of studies have reported the expression of miRNAs in 
hESC during in vitro decidualisation (Wang et al., 2016; Aoyagi et al., 2017; Tochigi et al., 
2017). These findings raise the possibility that sFlt-1/Flt-1 mRNA expression might be 
differentially affected by miRNAs in hESC decidualisation. As mature miRNAs bind to their 
target mRNAs typically in the 3’-untranslated region (3’UTR) miRNA (Felekkis et al., 
2010), the alternative 3’UTRs of the Flt-1/sFlt-1 mRNAs may, therefore, represent selective 
targets for miRNAs. Therefore, the effect of decidual-related miRNAs on the sFlt-1 isoform 
expression should be investigated. 
 
6.3.3 FOXO1 regulates sFlt-1-e15a in hESC decidualisation 
The present findings found that sFlt-1-e15a isoform expression in hESC is regulated by 
FOXO1. The reduction of FOXO1 suppressed total sFlt-1 protein secretion and the 
expression of sFlt-e15a mRNA and protein. As discussed earlier, the sFlt-1 production was 
decreased and FOXO1 expression was increased in decidualisation. However, FOXO1 
knock-down only affected sFlt-1 expression in proliferative hESC. FOXO1 activity is 
strongly up-regulated during decidualisation whilst sFlt-1 secretion and sFlt-1-e15a mRNA 
expression decreases suggesting other mechanisms are clearly responsible for the 
suppression of sFlt-1 during decidualisation.  
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6.3.4 Flt-1 receptor expression in hESC 
In the present study, the Flt-1 receptor was detected on the cell surface in both proliferative 
and decidualised hESC. Flt-1 mRNA expression and promoter activity was found to increase 
initially with hESC decidualisation, but the expression level then decreased from day 3 to 
day 6 of stimulation supporting an earlier study in human epithelial and stromal cells isolated 
from a endometrial tissues from healthy women in different phases of the menstrual cycle 
showing that Flt-1 mRNA expression peaks during the secretory phase and then decreases 
to the late secretory phase (Krussel et al., 1999; Jee et al., 2009). Overall the fact that the 
Flt-1 receptor is maintained at the cell surface and sFlt-1 levels dramatically decrease 
suggests that decidual hESC may be more responsive to VEGF and PIGF. Although little is 
known about the expression of Flt-1 receptor during hESC decidualisation, there are many 
studies reporting the up-regulation of Flt-1 expression in the placenta leading to 
preeclampsia in pregnancy (Nikuei et al., 2015; Andraweera et al., 2012; Nishizawa et al., 
2011; Chung et al., 2004). Therefore, it will be important to understand how changes of Flt-
1 expression in hESC during decidualisation may be associated with the onset of pregnancy 
complications like preeclampsia. 
 
6.3.5 FOXO1 regulates Flt-1 in hESC 
The knock-down of FOXO1 by siRNA suppressed the Flt-1 promoter activity in hESC, 
whereas, no effect was observed in hESC following FOXO3A knock-down which supports 
previous studies in endothelial cells showing FOXO1, but not FOXO3A, regulates Flt-1 
gene expression (Potente et al., 2005). Furthermore, MEFs were also used in this study to 
determine the effect of FOXO1 on Flt-1 expression and we found that Flt-1 promoter activity 
increased in MEFs over-expressing caFOXO1, while over-expression of caFOXO3A had no 
effect. Consistent with these results, the Flt-1 promoter activity decreased following global 
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FoxO knock-out in MEFs. These results are also in agreement with previous studies in 
FoxO-deficient mice which show that FoxO deletion reduced the Flt-1 expression in 
endothelial cells and led to the failure of angiogenesis (Furuyama et al., 2004). 
FOXO1 activity also affected sFlt-1 levels. Knock-down of FOXO1 reduced sFlt-1-e15a 
mRNA expression, whereas over-expression of FOXO1 increased sFlt-1-e15a mRNA 
expression consistent with the Flt-1 promoter activity in hESC. FOXO3A had no effect on 
Flt-1 promoter activity or full-length Flt-1 and sFlt-1 expression.  
 
6.3.6 FOXO1 directly binds to Flt-1 promoter 
Overall, FOXO1 knock-down decreased the Flt-1 promoter activity and over-expression of 
FOXO1 increased Flt-1 promoter activity in St-T1b cells. Therefore, ChIP was used to 
determine whether FOXO1 directly bound to the Flt-1 promoter. There was FOXO1 
enrichment at three potential FHRE binding sites identified in the Flt-1 promoter sequence 
with the greatest binding at the Flt-1 ChIP-1 site in decidualised hESC (Figure 6.16). These 
sites appear with marks in the FOXO1 ChIP-seq data in hESC decidualisation (Vasquez et 
al., 2015). Interestingly, when ChIP was performed in human microvessel endothelial cell 
(HMEC-1) there was no FOXO enrichment at ChIP site 1 and the greatest binding was found 
at the ChIP-3 site which may reflect cell-specific differences in Flt-1 gene regulation 
(Appendix B4). Combined with the mRNA and protein expression data these results suggest 
that FOXO1 promotes Flt-1 gene expression in decidualised hESC, but that is also subject 
to regulation by other decidual factors that negatively impact on its expression.  






First, the predominant sFlt-1 isoform, sFlt-1-e15a mRNA and protein expression are down-
regulated with hESC decidualisation. Despite increases in sFlt-i13 mRNA, the protein levels 
of this isoform also declined dramatically with hESC decidualisation reflecting the decline 
in the overall level of sFlt-1 secreted by the cells. Second, the Flt-1 gene promoter activity 
and relative full-length Flt-1 receptor mRNA expression were also increased, and the 
receptor maintained on the cell surface with hESC decidualisation (Figure 6.17). This 












Figure 6.17: Summary of Flt-1/sFlt-1 expression in hESC during decidualisation. 














Figure 6.16: FOXO1 binding sites identified by ChIP analysis in the Flt-1 
promoter. Graph shows the degree of enrichment of FOXO1 binding normalised 
to input DNA and negative control region.  
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The human endometrium is a dynamic organ that undergoes cyclic changes of periodic 
growth, breakdown, regeneration and remodelling. Endometrial tissue remodelling is 
regulated by ovarian hormones as well as various cytokines and growth factors that are 
produced locally and act in an autocrine and paracrine manner (Okada et al., 2017). 
Angiogenesis is crucial for human endometrial development and differentiation in 
preparation for implantation and maintenance of any subsequent pregnancies (Gordon et al., 
1995). 
VEGF has pleiotropic activities on endothelial cells playing a crucial role in physiological 
neo-vascularisation via VEGFR-2/KDR (Terman et al., 1991) and VEGFR-1/Flt-1 (Shibuya 
et al., 1990) and co-receptors such as NRP-1 (see Figure 1.11). In addition, it also has many 
effects on non-endothelial cell types, such as inflammatory and neuronal cells in many cases 
acting through VEGFR-1/Flt-1 (Dewerchin and Carmeliet, 2012). VEGF activates key cell 
signalling pathways such as MAPK and Akt (Claesson-Welsh, 2016). Although the pro-
angiogenic properties of VEGF are well characterised, the effect of VEGF on hESC function 
has yet to be investigated. 
In this chapter, the pro-angiogenic activity of decidual hESC is examined to determine the 
relative contributions of VEGF activity and sFlt-1. In addition, as the Flt-1 receptor 
identified on the surface of hESC and maintained in decidual cells, the action of VEGF on 










7.2.1 Angiogenic activity of decidual hESC conditioned medium 
In order to determine the relative angiogenic activity in decidualised and proliferative hESC 
CM, cell supernatants were collected, and their activity assessed in scratch-wound, tube 
formation, and spheroid sprouting assays. St-T1b cells were seeded on 10 cm Ø culture 
dishes. Cells were grown to confluence and incubated with E2 or MM1 medium for 6 days. 
The cells were re-stimulated with fresh medium 24 h prior to harvesting the CM. The cell 
supernatants were collected, aliquoted and stored at -20oC for use in functional assays.  
 
7.2.1.1 Decidual hESC conditioned medium promotes HUVEC migration 
Wound healing assays were performed with HUVEC grown to confluence on the 12-well 
plates. A scratch-wound was created using the end of a 200 µl tip after starving the cells for 
4 h in DMEM/F12 medium. The cells were then incubated with DMEM/F12 supplemented 
with 1% FBS (control), proliferative hESC CM, decidual CM or VEGF (50 ng/ml) as a 
positive control. Images of eight fields for each condition were captured at 0 h and 24 h with 
an EVOS inverted phase microscope under the 10 X objective as shown in Section 2.17.1. 
Cells incubated in decidual CM migrated significantly faster than those in the proliferative 
CM and controls (Figure 7.1B). Assays were also performed with CM diluted with 
DMEM/F12 medium in ratio 1:4 and 2:3 (DMEM/F12 medium: hESC CM). Similarly, 
HUVEC incubated in 60% or 80% decidual CM migrated faster than those in the same 
concentration of proliferative cell CM (Figure 7.2B).  
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7.2.1.2 Effect of decidual hESC conditioned medium on in vitro endothelial tube 
formation 
Matrigel tube formation assays were performed in 12-well plates. HUVEC were resuspended 
in control medium, proliferative CM or decidual hESC CM, or VEGF (50 ng/ml) as a 
positive control and added on top of a layer of growth factor-reduced Matrigel as described 
in Section 2.17.2. Images of capillary-like endothelial tubes were taken every 6 h up to 24 
h using an IncuCyte ZOOMÒ  (Essen Bioscience) with 4 X objective. The number of meshes 
and branches were analysed with the Angiogenesis Analyser, ImageJ plugin software. VEGF 
promoted tube formation at all time points relative to the control medium. The meshes started 
to break up and number of branch points reduced from 12 h under all conditions (Figure 
7.3B) therefore tube formation was measured at 6 h. Decidual hESC CM induced 
significantly greater mesh formation than proliferative CM (Figure 7.3 B&C). However, 
the proliferative CM showed reduce tube formation compared with the control medium 
(Figure 7.3 B&C). Overall, the decidual CM was more angiogenic compared to the 
proliferative CM measured either by mesh or branch formation (Figure 7.3 B&C).  


















Figure 7.1: Decidual cell conditioned medium (CM) promotes endothelial cell 
migration.  Confluent HUVEC monolayers were scratch-wounded and with various VEGF or 
hESC CM. (A) Representative images taken at time 0 and 24 h of HUVEC treated with VEGF 
(50 ng/ml), proliferative CM, decidual CM or DMEM/F12 containing 1% FBS (control). (B) 
Graph showing the mean relative migrated area normalised to the control. Images were taken at 
time 0 and 24 h of 8-fields using an EVOS phase-contrast microscope under the 10 X objective 
and the mean area of wound closure measured using ImageJ software and normalised to control. 
Results are the mean (+/- SEM) of 3 experiments performed in duplicate and analysed using one-
way ANOVA; ***p<0.001. 
210 µm 




Figure 7.2: Diluted decidual cell conditioned medium (CM) promotes endothelial  
cell migration.  Confluent HUVEC monolayers were scratch-wounded and treated with 60% or 
80% of decidual or proliferative hESC CM. (A) Representative images taken at time 0 and 24 h. 
(B) Analysis of the relative mean migrated area normalised to the control. Images were taken at 
time 0 and 24 h of 8-fields using an EVOS phase-contrast microscope under the 10 X objective 
and the mean area of wound closure measured using ImageJ software and normalised to control. 
Results are the mean (+/- SEM) of 3 experiments performed in duplicate and analysed using one-


















































































Figure 7.3: Decidual hESC conditioned medium (CM) stimulates in vitro 
endothelial tube formation. HUVEC (180,000 cells/well) were seeded on growth factor-
reduced Matrigel in a 12-well plate. (A) Representative images taken at 6, 12 and 24 h following 
treatment with VEGF (50 ng/ml), proliferative and decidual hESC CM, or control (DMEM/F12 
containing 1% FBS). Graphs showing the mean number of (B) meshes and (C) branches formed 
at the indicated time points. Images were taken using an IncuCyte ZOOMÒ system under 4 X 
objective. Results are the mean (+/-SEM) of 3 independent experiments performed in duplicate 
and analysed using two-way ANOVA; *p<0.05; **p<0.01; ***p<0.001. 
 
Figure 7.3: Decidual conditioned medium (CM) stimulates in vitro endothelial tube 
C 
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7.2.1.3 Decidual hESC conditioned medium stimulates multicellular spheroid 
sprouting 
In order to further characterise the effect of decidual CM on angiogenesis, multicellular 
(HUVEC and St-T1b) spheroid sprouting assays were performed. Mixed spheroids formed 
from HUVEC and St-T1b cells were embedded into the growth factor-reduced Matrigel on 
24-well plates as described in Section 2.17.3 and incubated with proliferative or decidual 
hESC CM, VEGF (50 ng/ml) or DMEM/F12 supplemented with 1% FBS as a control. 
Images of the spheroids were taken after 24 h with an EVOS microscope under the 10 X 
objective. VEGF induced a significant increase in spheroid sprouting compared with control 
medium. Spheroids treated with decidual CM sprouted significantly more than those with 
proliferative CM, which were found to be similar to the control (Figure 7.4).  
 
7.2.2 FOXO1 knock-down in hESC reduces pro-angiogenic activity 
In Chapter 5, I demonstrated that FOXO1 directly regulates VEGF in hESC (Figure 5.7B). 
To further investigate this, we conducted wound healing and tube formation assays using 
CM harvested from hESC following FOXO1 or FOXO3A knock-down. Scratch-wounds 
were created in confluent HUVEC monolayers and the cells treated with CM harvested from 
proliferative St-T1b, or St-T1b cells stimulated to decidualise for 24 h following FOXO1, 
FOXO3A, or control knock-down. CM collected from FOXO1, or FOXO3A knock-down 
ESC did not significantly affect HUVEC migration compared to the cells treated with control 
CM (Figure 7.5 A-B). 
Matrigel tube formation assays were performed with HUVEC resuspended in proliferative 
CM or decidual hESC CM, control medium or VEGF (50 ng/ml) and added on top of a layer 
of growth factor-reduced Matrigel as described in Section 2.17.2. Images of capillary-like 
endothelial tube formation were taken every 6 h up to 24 h. CM collected following FOXO1 
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knock-down in hESC significantly reduced the number of meshes and branches formed 
(Figure 7.6) whereas FOXO3A knock-down in hESC had no significant effect on mesh and 
branch formation induced by CM (Figure 7.6).  
Figure 7.4: Decidual hESC conditioned medium (CM) promotes mixed 
endothelial/St-T1b cell spheroid sprouting. HUVEC and St-T1b cells were mixed in 
a 1:1 ratio and seeded in 96-well rounded bottom plates in 0.25% methylcellulose overnight. 
The spheroids were embedded in growth factor-reduced Matrigel and incubated in DMEM/F12 
supplemented with 1% FBS (control), VEGF (50 ng/ml), proliferative CM, or decidual hESC 
CM. (A) Representative images taken after 24 h incubation under 10 X objective. (B) Graph 
showing mean of sprout lengths relative to control analysed using ImageJ. Results are mean (+/- 
SEM) of 2 independent experiments performed in duplicate (12 replicates per well) and 










































































Figure 7.5: FOXO1 knock-down in hESC does not affect CM-driven endothelial  
cell migration. St-T1b cells were transfected with siRNAs targeting FOXO1 (siFOXO1), 
FOXO3A (siFOXO3A), control (siControl) overnight and incubated with E2 or MM1 medium 
for 24 h. The CM was collected and used in endothelial wound healing assays. (A) Representative 
images taken at time 0 h and 24 h following addition of CM. (B) Graph showing relative mean 
migrated area normalised to the control. Results are the mean (+/-SEM) of 2 independent 


































Figure 7.6: FOXO1 activity in hESC is critical for their pro-angiogenic effect 
during decidualisation. St-T1b cells were transfected with siRNAs targeting FOXO1 
(siFOXO1), FOXO3A (siFOXO3A), or control (siControl) overnight and incubated with E2 or 
MM1 medium for 24 h. The CM was collected and used in endothelial tube formation assays. (A) 
Representative images taken at 6 h following addition of CM using the IncuCyte ZOOMÒ  system 
under 4 X objective. Graph showing the mean number of (B) meshes and (C) branches quantified 
using Angiogenesis Analyser in ImageJ. Results are the mean (+/-SEM) of two independent 
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7.2.3 VEGF activity in decidual hESC CM 
In order to determine the relative activity of VEGF in decidual hESC supernatants, 
functional assays were performed following the blockade of VEGF activity with 
recombinant sFlt-1 in hESC CM. Decidual CM was incubated with 0.5, 1.5 or 3.0 ng/ml of 
recombinant sFlt-1 for an hour at room temperature. Scratch-wounds were created (as 
described in Section 2.17.1) in confluent HUVEC monolayers. The migration in HUVEC 
was found to be significantly slower with hESC CM pre-treated 1.5 ng/ml and 3.0 ng/ml of 
sFlt-1 (Figure 7.7 B-C). Subsequently, 1.5 ng/ml of recombinant sFlt-1 was used for tube 
formation assays due to the limited amount of CM that could be readily collected. Consistent 
with the wound healing assay results, sFlt-1 blocked the pro-angiogenic effect of decidual 
CM in tube formation assays (Figure 7.8). These results confirm that VEGF contributes the 
majority of the angiogenic secreted by decidual hESC.  






Figure 7.7: VEGF activity in decidual hESC conditioned medium (CM) drives 
endothelial cell migration.  HUVEC were grown on 12 well-plates until they reached 
confluence and then scratch-wounded and treated with various CM. (A) Representative images 
taken at time 0 and 24 h of HUVEC treated with decidual hESC CM in the absence, or presence, 
of recombinant sFlt-1. (B) Graph showing relative mean migrated area normalised to the control. 
Results are the mean (+/-SEM) of 3 experiments performed in duplicate and analysed using two-
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Figure 7.8: VEGF activity in decidual hESC conditioned medium (CM) drives 
in vitro endothelial tube formation. HUVEC (180,000 cells/well) were seeded on growth 
factor-reduced Matrigel and treated with CM or VEGF. (A) Representative images taken at 6 h 
using the IncuCyte ZOOMÒ system under 4 X objective. Analysis of the mean number of (B) 
meshes, and (C) branches using the ImageJ Angiogenesis Analyser plug-in. Results are the mean 
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7.2.4 Immunoprecipitation of sFlt-1/Flt-1 from decidual-derived CM reveals the 
presence of shed micro-vesicles but does not promote VEGF activity in CM 
To further investigate, the significance of VEGF in both proliferative and decidual CM, 
VEGF was immunoprecipitated with anti-Flt-1 antibody, or an irrelevant control antibody 
and protein A/G beads overnight on a rotary stirrer at 4oC. The supernatant was collected in 
new tubes after magnetic separation and stored at -20oC for wound healing assays. The beads 
were then washed few times with serum-free medium and resuspended in SDS lysis buffer 
separated by SDS-PAGE and Western blotted as described in Section 2.15. Western blotting 
confirmed the precipitation of sFlt-1 (Figure 7.9A). Surprisingly, full-length Flt-1 receptor 
was also strongly detected in the medium, suggesting the presence of membrane bound 
vesicles shed into the CM. More sFlt-1/Flt-1 was detected in proliferative CM than decidual 
CM. In addition, an ELISA was run to confirm the reduction of sFlt-1 levels in IP CM before 
angiogenesis assays were performed. The level of sFlt-1/Flt-1 in proliferative CM was 
significantly decreased (Figure 7.9B). The supernatants were used in scratch-wound assays 
and the anti-Flt-1 IP CM significantly reduced the migration in HUVEC (Figure 7.9 C&D). 
As the removal of sFlt-1 from CM did not show the expected increase in endothelial 
migration, VEGF levels were examined on CM following IP by ELISA. Surprisingly, the 
VEGF levels in CM decreased following Flt-1 IP in the decidual CM (Figure 7.10) 
indicating that the decrease in endothelial migration was potentially due to a reduction of 
VEGF in CM. 
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Figure 7.9: Presence and activity of sFlt-1/Flt-1 in decidual cell-derived hESC 
conditioned medium (CM). St-T1b cells were stimulated with E2 or MM1 medium for 6 
days and 24 h CM was collected. The CM were incubated with anti-Flt-1, or control (IgG) 
antibodies and protein A/G magnetic beads overnight. (A) The precipitated material was eluted 
and analysed by Western blot for Flt-1/sFlt-1 using anti-Flt-1 antibody. The supernatants were 
collected by magnetic separation and assessed for sFlt-1 in wound healing assays. (B) sFlt-1/Flt-
1 levels in CM measured by ELISA. (C) Representative images taken at time 0 and 24 h of 
HUVEC treated with control (DMEM/F12 medium supplemented with 2% FBS), and with 
proliferative, or decidual CM followed by anti-Flt-1 antibodies. (D) Graph showing relative mean 
migrated area normalised to the control. Results are mean (+/- SEM) of 2 independent experiments 











7.2.5 Expression of VEGF receptors in hESC 
As hESC express Flt-1 receptor at their cell surface (Figure 6.10), the presence of other 
VEGF receptors was investigated. The human microvascular endothelial cell line, HMEC-
1, was used as a positive control with VE-cadherin as an endothelial cell specific marker 
(Figure 7.11). VEGFR-2 was not detected in hESC during decidualisation by qPCR (data 
not shown) or Western Blotting (Figure 7.11). Interestingly, the VEGF co-receptor NRP-1 
was expressed and found to increase during hESC decidualisation (Figure 7.11 A&D) albeit 
at a lower level than in HMEC-1 (Figure 7.11 A&C). Surprisingly, sFlt-1/Flt-1 expression 
was detected at very low levels in HMEC-1. 
Figure 7.10: Removal of sFlt-1/Flt-1 in hESC conditioned medium (CM) reduces 
VEGF levels. The proliferative, and decidual hESC CM was incubated with anti-Flt-1, or control 
IgG antibodies with protein A/G beads overnight. The supernatants were collected by magnetic 

























Figure 7.11: VEGF receptor expression in hESC decidualisation. St-T1b cells and 
HMEC-1 as a control were plated on 6-well plates. St-T1b cells were stimulated with E2 or MM1 
medium over 6 days and protein lysates were harvested. (A) Representative Western blot showing 
VE-Cadherin, VEGFR-2, and NRP-1 expression with tubulin as a loading control. (B) Graph of 
densitometric analysis of NRP-1 expression in St-T1b cells during decidualisation. (C) Real-time 
qPCR of (C) NRP-1 mRNA expression in HMEC-1 and St-T1b cells and (D) NRP-1 expression 
in St-T1b cells stimulated with E2 or MM1 medium normalised to b-actin. Results are the mean 
(+/-SEM) of 3 experiments and analysed using unpaired t-test; *p<0.05; **p<0.01; ***p<0.001. 
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7.2.6 Effect of VEGF on hESC function 
7.2.6.1 VEGF increases hESC migration 
VEGF produced by hESC during decidualisation was shown to be a key regulator of 
endothelial cell migration and tube formation in previous section. As hESC express Flt-1 
receptor on their surface (Figure 6.10) and we have shown that Flt-1 receptor is shed into 
CM, the effect of VEGF on hESC function was examined. St-T1b cells were incubated with 
E2 or MM1 medium for 6 days and re-plated on 12-well plates for another 18 h in low-serum 
medium. The pre-treated St-T1b cell monolayers were then scratch-wounded and incubated 
in serum-free medium supplemented with 50 ng/ml of VEGF or PIGF and eight images of 
each conditions were taken of each condition at 0 h and 18 h. VEGF significantly increased 
both the proliferative and pre-decidualised hESC migration (Figure 7.12) whereas, 
unexpectedly, no significant effect of PIGF on pre-decidualised St-T1b cell migration was 
observed. The migratory activity of the decidual condition cells was significantly increased 
compared to the proliferative control cells (Figure 7.12). 




Figure 7.12: VEGF/PIGF activity increases hESC migration following 
decidualisation. St-T1b cells were incubated with either E2 or MM1 medium for 6 days and 
re-plated on 12-well plates in reduced-serum medium for 24 h. The cell monolayers were then 
wounded and incubated in serum-free medium supplemented with VEGF or PIGF. The wound 
closure was quantified using ImageJ as described in Section 2.17.1. (A) Representative images 
captured at 0 and 24 h using an EVOS microscope under 10 X magnification. (B) The mean of 
migrated area relative to the proliferative control cells. Results are the mean (+/- SEM) of 3 
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7.2.6.2 VEGF/PIGF promotes hESC invasion 
Spheroid sprouting assays were used to examine the invasive activity of hESC following 
decidualisation. St-T1b cells were incubated with E2 or MM1 medium for 6 days. The cells 
(5,000/well) were plated overnight in 96-well rounded bottom non-tissue culture-treated 
plates in DMEM/F12 medium supplemented with 2% FBS and 0.25% of methylcellulose. 
The spheroids were embedded in growth factor-reduced Matrigel on 24-well plates and 
DMEM/F12 basal medium supplemented with 50 ng/ml of VEGF, or PIGF as described in 
Section 2.17.3 was added. Images were taken after 24 h and the mean sprout length 
measured using ImageJ software. Strikingly, the spheroids formed from decidual St-T1b 
cells were found to sprout significantly more than those formed from proliferative St-T1b 
cells (Figure 7.13). In addition, VEGF increased the invasive activity of spheroids formed 
from both proliferative and decidualised St-T1b cells (Figure 7.13) whereas, no significant 
increase was observed with PIGF in proliferative or decidualised St-T1b cell spheroids 
(Figure 7.13). 
 
7.2.7 Knock-down of VEGF reduces ESC invasion  
Up-regulation of VEGF activity during hESC decidualisation was observed in previous 
chapters and it is considered the major angiogenic factor in endometrium (Girling and 
Rogers, 2009).  To further substantiate a role of VEGF in hESC, St-T1b cells were plated on 
6-well plates and transfected with VEGF, or control siRNAs overnight. The supernatants 
and RNA lysates were harvested, and spheroids were formed overnight, following VEGF 
knock-down, using 5,000 cells/well on round bottom non-tissue culture-treated 96-well 
plates in DMEM/F12 medium supplemented with 2% FBS and 0.25% methylcellulose. The 
spheroids were embedded in Matrigel and the formation of hESC sprouts was assessed.  The 
knock-down of VEGF was confirmed by qPCR (Figure 7.14C) and VEGF was significantly 
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reduced, by ELISA, in hESC supernatants (Figure 7.14D). VEGF knock-down hESC 
showed significantly reduced spheroid sprouting activity in Matrigel (Figure 7.14B) which 
indicates that VEGF is playing an autocrine stimulatory role on hESC invasion. 
As an alternative approach to block endogenous VEGF activity, St-T1b cells were 
transduced with an adenovirus encoding murine sFlt-1 Ig-like loops 1-3 (Ad-sFlt-1) (Tseng 
et al., 2002), or empty virus control (Ad-CMV) overnight before cells were used to form 
spheroids. Over-expression of sFlt-1 significantly reduced hESC spheroid sprouting (Figure 
7.15B). Endogenous sFlt-1-e15a mRNA expression did not significantly change following 
over-expression of sFlt-1 (Figure 7.15C). Surprisingly, over-expression of sFlt-1 reduced 
both VEGF mRNA expression (Figure 7.15D) and protein secretion (Figure 7.15D). 
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Figure 7.13: VEGF increases invasive activity in hESC. St-T1b cells were incubated 
in E2 or MM1 medium for 6 days and then plated on 96-well rounded bottom non-tissue culture 
plate in DMEM/F12 medium supplemented with 2% FBS and 0.25% methylcellulose overnight. 
The spheroids were then embedded in growth factor-reduced Matrigel and topped up with 
DMEM/F12 basal medium supplemented with VEGF or PIGF. (A) Representative images taken 
after 24 h using an EVOS microscope under 10 X objective and the mean sprout length 
determined using ImageJ. (B) Graph showing the mean of sprout length relative to the 
proliferative control cells. Results are the mean (+/- SEM) of 2 experiments performed in 
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Figure 7.14: VEGF knock-down reduces hESC invasion. St-T1b cells were transfected 
with siRNAs targeting VEGF (siVEGF), or control (siControl) overnight. Spheroids were formed 
and embedded in Matrigel with the DMEM/F12 basal medium. (A) Representative images were 
taken at 24 h using an EVOS inverted phase microscope under 10 X objective and the sprout length 
were analysed using ImageJ. (B) Graph showing the mean of sprout length relative to the control. 
(C) Real-time qPCR analysis of VEGF mRNA expression normalised to b-actin. (D) Mean VEGF 
secretion from St-T1b cells by ELISA. Results are the mean (+/-SEM) of 2 experiments performed 


































































Figure 7.15: Over-expression of sFlt-1 reduces hESC invasion. St-T1b cells were 
transduced with adenovirus encoding murine sFlt-1-IgG-loops 1-3 (Ad-sFlt-1), or empty virus 
control (Ad-CMV) overnight. Spheroids were formed and embedded in Matrigel with the 
DMEM/F12 basal medium. (A) Representative images were taken using an EVOS inverted phase 
microscope under 10X objective and the sprout lengths were analysed using ImageJ. (B) Graph 
showing the mean of sprout lengths relative to the control. (C) Real-time qPCR analysis of VEGF 
mRNA expression. (D) Mean VEGF secretion from St-T1b cells by ELISA. (E) Real-time qPCR 
analysis of sFlt-1-e15a mRNA expression normalised to b-actin in the cells following VEGF 
knock-down. Results are the mean (+/-SEM) of from 2 experiments performed in duplicate (12 















































































7.2.8 Effect of VEGF and PIGF on phosphorylation of AKT and ERK1/2 in St-T1b 
cells 
Although no changes of cell signalling protein activity were detected following 24 h 
stimulation for decidualisation (see Appendix H), it is well known that these pathways are 
stimulated by VEGF in endothelial cells (Takahashi et al., 2003). Furthermore, Tang et al. 
(2006) reported that VEGF activates the PI3K/Akt pathway, but not ERK1/2 in normal 
human lung fibroblasts. Therefore, we examined the effects of VEGF and PIGF on the 
phosphorylation of AktS473 and ERK1/2 kinases in hESC. St-T1b cells were starved 
overnight and treated for 0-60 mins with VEGF (50 ng/ml) or PIGF (50 ng/ml). Cell lysates 
were analysed by Western blotting with phospho-specific antibodies that recognise their 
phosphorylation at active sites of pAktS473, ERK1/2Thr-202/Tyr-204 (pERK1/2) respectively. We 
found that pAktS473 and pERK1/2 was rapidly activated by VEGF, or PIGF, in a time-
dependent manner, without altering the total protein levels (Figure 7.16A). Interestingly, 
unlike the PIGF-induced rapid increase in pAktS473 which declined after 15 min, VEGF-
induced Akt phosphorylation was less rapid and sustained up to 60 mins (Figure 7.16B). 
Unlike pAktS473, pERK1/2 was activated after 15 min with both VEGF and PIGF treatment 
(Figure 7.16C). 
 





Figure 7.16: VEGF and PIGF activate Akt and ERK in hESC. Cells were treated 
with 50 ng/ml of PIGF or VEGF for 0-60 min. (A) Representative Western blots showing total 
Akt, pAktS473, ERK1/2, and pERK with tubulin as a control. Densitometry analysis of relative (B) 
pAktS473 to total Akt and (C) pERK1/2 to total ERK1/2 normalised to tubulin. Results are the mean 
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7.2.9 Increased phosphorylation of Akt following Flt-1 knock-down 
As shown in Chapter 6, VEGFR-1/Flt-1 receptor expression increased with hESC 
decidualisation and Flt-1 expression is reported to be required for fibroblast migration 
stimulated by VEGF and PIGF (Jin et al., 2007). To determine whether the functional 
activity of Flt-1/sFlt-1 expression in hESC influences the expression of VEGF and other 
decidualisation related genes, Flt-1 was knocked-down with siRNAs targeting Flt-1 (siFlt-
1) or control (siControl) in St-T1b cells. Flt-1 knock-down significantly suppressed the sFlt-
1 isoforms in the St-T1b cells (Figure 7.17A). Interestingly, no significant change was 
observed in VEGF expression following Flt-1 knock-down (Figure 7.17B).  
Protein expression in the cells with Flt-1 knock-down was also determined by Western 
blotting. Interestingly, we found increased FOXO1 protein expression (Figure 7.18B), but 
no changes in FOXO3A protein levels with Flt-1 knock-down (Figure 7.18D). pAktS473 
levels were found to increase following Flt-1 knock-down (Figure 7.18E) with no changes 
in total Akt expression (Figure 7.18F).  
 
Figure 7.17: Knock-down of Flt-1 in St-T1b does not affect VEGF expression.  
The St-T1b cells were plated on 6-well plates and transfected with siRNAs targeting Flt-1 (siFlt-
1), or control (siControl) overnight, followed by 24 h stimulation with E2 or MM1 medium. Real-
time qPCR was used to measure the expression of (A) Flt-1 and (B) VEGF mRNAs. Results are 
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Figure 7.18: Knock-down of Flt-1 in St-T1b effects on decidualisation markers. 
The St-T1b cells were plated on 6-well plates and transfected with siRNAs targeting Flt-1 (siFlt-
1), or control (siControl) overnight, followed by 24 h stimulation with E2 or MM1 medium. (A) 
Representative Western blot showing Flt-1, total Akt, pAktS473, FOXO1, pFOXO1S256, FOXO3A 
with tubulin as a loading control. Graph of densitometry analysis of relative (B) FOXO1; (C) 
pFOXO1S256, (D) pAktS473 / total Akt, and (E) FOXO3A normalised to tubulin. Results are the 






















































































7.3.1 VEGF is the major angiogenic factor produced during hESC decidualisation  
Angiogenesis is essential for endometrial repair and regeneration and is a critical event 
during decidualisation for successful pregnancy (Maybin and Critchley, 2009). Endothelial 
function and angiogenesis assays were carried out using St-T1b cell CM. The cells were re-
stimulated with fresh medium 24 h prior to harvesting for consistency and trying to minimise 
the effects of nutrient depletion and accumulated waste products. Overall, decidual CM was 
more angiogenic than proliferative CM in endothelial cell migration, tube formation and also 
mixed spheroid sprouting. The angiogenic activity in proliferative CM was not significantly 
different from the control medium. This finding indicates that the increase in endogenous 
VEGF and other angiogenic factors and decrease in inhibitors produced by decidualised 
hESC are sufficient to stimulate endothelial cell migration, tube formation and sprouting. 
Furthermore, this angiogenic activity was blocked in the decidual CM by using recombinant 
sFlt-1, a natural inhibitor of VEGF. Endothelial cell migration and tube formation was 
significantly, but not fully, inhibited by the addition of recombinant sFlt-1 showing that 
although VEGF is the major angiogenic factor produced by decidual hESC other angiogenic 
factors are also produced. A range of concentrations of recombinant sFlt-1 (0, 1.0, 2.0, 3.0, 
4.0 and 6.0 ng/ml) were incubated with hESC CM and VEGF levels measured by ELISA. I 
found a significant reduction of VEGF detected following recombinant sFlt-1 treatment 
(Appendix D). This may be due to the VEGF binding to sFlt-1 so that it is not accessible to 
the VEGF capture antibody. Indeed, R&D systems report that the presence of sFlt-1 can 
affect ELISA readings indicating that the ELISA is largely reading “free VEGF”.  
In order to investigate activity of sFlt-1 in CM, sFlt-1/Flt-1 was also immunoprecipitated 
from the hESC CM using an anti-Flt-1 antibody. Surprisingly, CM where Flt-1 was removed 
by IP lead to decreased HUVEC migration in wound healing assays. Further investigation 
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revealed that removing sFlt-1 had also co-immunoprecipitated and removed VEGF from the 
CM which could be detected by ELISA (Figure 7.10). This was perhaps to be expected as 
Flt-1 has high affinity for VEGF (Shibuya, 2011). In addition, full-length Flt-1 receptor was 
also immunoprecipitated from CM and found to be released more in proliferative than 
decidual hESC which is a very surprising result. Full-length Flt-1 receptor was found on the 
surface of hESC (Figure 6.10). This suggests that the receptor is shed on micro-vesicles 
released into the medium. Although there are no studies in the literature characterising the 
release of micro-vesicles in hESC decidualisation, Tong et al. (2017) reported the up-
regulation of Flt-1 expression on micro- and nano-vesicles in placenta from preeclampsia 
women compared to normal placenta. In my findings, there were higher levels of Flt-1 
receptor immunoprecipitated from proliferative hESC CM suggesting proliferative hESC 
may produce more Flt-1 containing micro-vesicles. Taken together with the findings in 
Chapter 6, decidual hESC express more Flt-1 receptor, but they shed less from their cell 
surfaces and express less sFlt-1 leading to increased VEGF activity and potentially greater 
responsiveness of hESC themselves to VEGF during decidualisation.  
Tong et al. (2017) also showed that micro-vesicle removal did not affect the total sFlt-1 
secretion. Furthermore, vesicle-bound VEGF was also detected shed by placenta and 
removal of micro-vesicles significantly reduced VEGF levels. In decidual hESC CM there 
was reduced VEGF with no significant change of total sFlt-1 detected. This may be 
explained by the fact that Flt-1/sFlt-1 immunoprecipitation from decidual CM differentially 
removed vesicle-associated Flt-1 and subsequently removing vesicle-associated VEGF did 
not greatly affecting the already suppressed sFlt-1 levels. Total sFlt-1/Flt-1 levels were also 
found to significantly decrease in proliferative hESC CM, which contains significantly more 
sFlt-1 prior to IP than decidual hESC and suggests that micro-vesicle bound Flt-1 is being 
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detected in the ELISA. Therefore, further investigation is required to determine the role of 
micro-vesicle shedding in hESC and to examine whether VEGF and Flt-1 are vesicle-
associated. Probing the Western blotted IP material for VEGF would confirm whether VEGF 
is co-precipitated with Flt-1. 
Collectively, VEGF produced during hESC decidualisation was the main factor contributing 
to the pro-angiogenic activity in decidual hESC CM. This is consistent with a recent study 
by Wheeler et al. (2018) showing that VEGF in decidual primary hESC CM is one of the 
major factors contributing to macrophage, migration and polarisation. 
 
7.3.2 Angiogenesis assays and mixed cell spheroid sprouting 
To investigate sprouting from matrix embedded spheroids, I initially tested spheroids formed 
from HUVEC alone, but they did not form well and were found to break up in sprouting 
assays as shown in Appendix C, making them difficult to analyse. Therefore, mixed 
spheroids composed of HUVEC and St-T1b cells were used in this study. Good sprouting 
results were obtained with multicellular spheroids in the present study, but due to time 
limitations, I was not able to investigate the nature of the sprouting fully and subsequently I 
do not know whether the sprouts contain both endothelial or St-T1b cells. In order to answer 
this question, the cells could be labelled with fluorescent dyes prior to mixing for spheroids 
formation with cell tracer dyes visualise them under the fluorescence microscope.  
 
7.3.3 FOXO1 and FOXO3A, pro-angiogenic factors in endothelial cell function 
FOXO1 and FOXO3A have distinct roles in human endometrium, activation of FOXO3A 
upon prolonged oxidative stress triggers oxidative cell apoptosis, whereas FOXO1 
stimulates differentiation and oxidative stress resistance during hESC decidualisation 
(Kajihara et al., 2006). As discussed in Chapter 5, FOXO1 and FOXO3A were found to 
positively and negatively regulate VEGF expression in hESC during decidualisation. In the 
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present study, the CM collected from the FOXO1, or FOXO3A knock-down St-T1b cells 
were used to examine the role of FOXO1 and FOXO3A in the overall angiogenic activity of 
hESC using endothelial migration and in vitro tube formation assays. FOXO1 knock-down 
CM was found to decrease tube formation, but not migration. In contrast to FOXO1, there 
was no significant change in HUVEC migration and tube formation with FOXO3A knock-
down CM.  
Therefore, FOXO1 appears to be a key regulator of hESC pro-angiogenic activity during 
decidualisation. In addition to VEGF, the angiogenic factor, HGF was found to be up-
regulated in decidual CM (Chapter 3) and is reported to be regulated by FOXO1 (Vasquez 
et al., 2015; Potente et al., 2005). Further investigation is needed to determine changes in 
hESC secreted angiogenic factors following FOXO1 or FOXO3A knock-down.  
 
7.3.4 VEGF increases hESC function 
In the present study, VEGF was found to increase hESC migration and invasion in both 
proliferative and decidual hESC. These findings are in direct contrast with previous findings 
by Schwenke et al. (2013) who reported VEGF and PIGF do not enhance hESC chemotactic 
and chemokinetic migration. This may be because lower concentrations of VEGF (20 ng/ml) 
were used for their studies compared to 50 ng/ml of VEGF in my study. VEGF activity is 
reported to be a highly concentration-dependent when examined in tissue environment, with 
different threshold concentrations required dependent on function (Ozawa et al., 2004). In 
addition, the production of saturating amounts of VEGF, or sFlt-1, by the cultured cells 
might also lead to these differences between studies. PIGF was found to increase 
proliferative hESC migration, but not in decidual hESC. This may be due to PIGF binding 
to sFlt-1 and displacing VEGF in proliferative hESC and therefore promoting migration. 
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Decidual hESC produced lower levels of sFlt-1 therefore is less potential for VEGF 
displacement from sFlt-1.  
Furthermore, decidualisation was found to stimulate hESC migration and invasion 
suggesting potential autocrine activity of VEGF in hESC function. The migration and 
invasion in decidual hESC was higher compared to proliferative hESC. However, a recent 
study in human immortalised ESC (HIESC), Fabi et al. (2017) found that decidual HIESC 
showed significantly reduced cell motility and failed to close the scratch-wounds. This may 
be because of differences in the decidualisation method used. In this study, St-T1b cells were 
decidualised with cAMP and MPA for 6 days and then re-plated before performing the 
wound healing assays. Whereas, Fabi et al. (2017) performed the wound healing assay by 
treating with cAMP and MPA directly on the wounded hESC without pre-decidualising the 
cells. One possibility is that there are differences in hESC function during decidualisation, 
which are not expressed within 24 h. In addition, the presence of progesterone, which has 
been reported to inhibit endometrial cell migration, could inhibit wound closure in hESC 
(Gentilini et al., 2007). Furthermore, cAMP has also been reported to inhibit MEF migration 
(Chen et al., 2008). We performed the assays in DMEM/F12 basal medium, so they were 
not directly influenced by the presence of oestrogen, progesterone, or high levels of 
exogenous cAMP. 
A recent study reported that isolated human eutopic mesenchymal stem cells transduced with 
adenovirus encoding sFlt-1 had significantly reduced VEGF expression and lead to 
endometriotic lesions (Gopalakrishnan et al., 2016) supporting my finding that hESC 
transduced with Ad-sFlt-1 show decreased VEGF mRNA expression and subsequently 
reduced invasion/migration. siRNA-mediated VEGF knock-down St-T1b cell and over-
expression of sFlt-1 St-T1b cell spheroids using adenovirus was found to reduce the hESC 
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invasion activity. These findings suggest that VEGF may promote hESC invasion in an 
autocrine manner which needs further investigation to determine whether this is an intracrine 
or extracrine effect on hESC function. This could be examined through the knock-down, or 
over-expression of VEGF and Flt-1 and/or NRP-1 receptors and analysis of ESC function.  
 
7.3.5 Induction of Akt and ERK1/2 phosphorylation by VEGF in ESC 
In the present study, we demonstrated that VEGF stimulates the migration and invasion of 
hESC. Although the precise mechanism by which VEGF induces hESC migration and 
invasion are unknown, Gentilini et al. (2007) demonstrated that growth factors like PDGF-
BB, and EGF are an important promoter of the dynamic behaviour of ESC and stimulate 
migration by activation of both PI3K/Akt and ERK1/2 pathways. Previous studies have also 
reported that Akt plays an important role in endometrium (Veillette et al., 2013; Fabi et al., 
2017). In addition, the PI3K/Akt pathway was reported to be involved in the control of 
invasion, and chemotaxis in hESC (Schwenke et al., 2013; Li et al., 2012; Gentilini et al., 
2007).  
In the present study, the level of pAktS473 was found to be decreased in decidualisation, this 
is consistent with previous studies showing that Akt is activated by PI3K in response to 
growth factors, and that PI3K/Akt signalling pathway activity is reduced during 
decidualisation (Yoshino et al, 2003; Fabi et al., 2017). However, we failed to detect changes 
in protein phosphorylation using phospho-kinase arrays (Appendix H). This is likely to be 
due to the sensitivity of the arrays or the fact that cells were stimulated over 24 h rather than 
over shorter time periods. This needs to be investigated further in the future. The pAktS473 
and pERK1/2 (Thr202/Tyr204) was rapidly activated by exogenous VEGF and PIGF 
stimulation in a time-dependent manner in hESC. Our findings suggest that PI3K/Akt and 
ERK1/2 may mediate VEGF and PIGF-stimulated migratory responses in hESC. Further 
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studies are needed to determine the signalling pathways responsible for VEGF-mediated 
hESC migration through the use of selective PI3K/Akt and ERK1/2 pathway inhibition. 
Furthermore, sFlt-1/Flt-1 knock-down was found to increase pAktS473 suggesting that Flt-1 
activity in hESC suppresses the Akt pathway. Furthermore, knock-down of Flt-1 also 
increased FOXO1 activity through FOXO1 up-regulation and insignificantly decreased 
FOXO1 phosphorylation. Although the role of Flt-1 signalling during hESC decidualisation 
remains unclear, these findings suggest that Flt-1 may play a role in hESC decidualisation 
via suppression of the Akt pathway promoting decidualisation in hESC. This suggests that 
VEGF-induced migration and invasion of hESC may mediated, at least in part, through Flt-
1 and not VEGFR-2/KDR as we could not detect VEGFR-2 expression in hESC. The hESC 
did however express the VEGF co-receptor neuropilin-1.  
 
7.3.6 VEGF receptors in ESC 
As discussed in chapter 6, Flt-1 was maintained in hESC during decidualisation consistent 
with the earlier studies showing that Flt-1 is expressed in ESC in the secretory phase and 
decreases in the late secretory phase of the menstrual cycle (Krussel et al., 1999; Perrot-
Applanat et al., 2000; Jee et al., 2009). There are many studies on VEGFR-2 expression in 
endometrium, but it is controversial. Sugino et al. (2002) isolated hESC from proliferative 
phase endometrium followed by in vitro decidualisation with oestrogen and MPA for 18 
days and showed that VEGFR-2 mRNA was significantly increased, with no changes 
detected in Flt-1 mRNA expression. In the present study, VEGFR-2 mRNA and protein was 
not detected in hESC. A study in isolated mouse endometrial epithelial cells and ESC 
showed that only low mRNA levels of VEGFR-2 detected in ESC (Fan et al., 2008).  
NRP-1 was also found to be expressed in both epithelial and stromal cells with much higher 
expression in ESC (Fan et al., 2008). My results showed that NRP-1 protein was expressed 
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in hESC and its expression increased with decidualisation. In contrast, one histological study 
in human endometrial samples obtained from healthy women in proliferative and secretory 
phase of menstrual cycle showed that NRP-1 expression was higher in proliferative hESC 
than in secretory cells (Hess et al., 2009). Furthermore, a study of proliferative and secretory 
phase human endometrial tissue from healthy women showed a high but stable expression 
of NRP-1 mRNA throughout the menstrual cycle (Germeyer et al., 2005). In addition, NRP-
1 has been shown to interact with Flt-1 in mouse embryonic fibroblasts (NIH3T3) (Fuh et 
al., 2000) leading to the possibility that NRP is regulating Flt-1 activity in hESC. Flt-1 also 
been reported as negative regulator of angiogenesis by competing with NRP-1 (Fuh et al., 
2000). There is also some evidence which suggests that NRP-1 may act as signalling receptor 
for VEGF (Becker et al., 2005), however other studies dispute this fact. NRP-1 deletion in 
transgenic mice led to in utero death due to severe cardiovascular defects and defective 
vascular remodelling (Kawasaki et al., 1999; Kitsukawa et al., 1997). Further investigation 




In summary, I have demonstrated increased pro-angiogenic secretions of decidual hESC 
confirming that VEGF is the main angiogenic factor in these cells and concomitant changes 
in sFlt-1 contribute to increased VEGF activity. The angiogenic activity of decidualised CM 
was found to be significantly greater than proliferative CM. Furthermore, using well-
established in vitro model systems, we demonstrate that both endogenous and exogenous 
VEGF can stimulate hESC migration and invasion. Akt and ERK1/2 signalling pathways 
were shown to be involved in VEGF-induced signal transduction in hESC decidualisation. 
Moreover, Flt-1 may play an important role in regulating hESC decidualisation.   
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8.1 General discussion  
The initial aim of my thesis was to characterise the in vitro decidualisation of the St-T1b cell 
line. My results clearly demonstrate that the St-T1b line behaved in a very similar manner 
to primary hESC and was therefore a suitable model system to investigate the underlying 
mechanisms regulating VEGF expression and activity during decidualisation.  
 
8.1.1 Regulation of VEGF expression and activity in hESC decidualisation 
VEGF is essential for vascular remodelling, regeneration and maturation of the 
endometrium, implantation and maintenance of pregnancy. This is highlighted by the fact 
that inappropriate expression of sFlt-1 may disrupt implantation or lead to miscarriage or 
fetal growth restriction in mice (Zenclussen et al., 2014). Preeclampsia remains one of the 
most serious complications of pregnancy (Duley, 2009; Hutcheon et al., 2011) and although 
the underlying aetiology of the disease is unknown, high levels of sFlt-1 produced by the 
placenta enter the maternal circulation and reduce VEGF activity, disrupting vascular 
homeostasis and precipitating the symptoms of preeclampsia. As decidual hESC are an 
important source of VEGF in the endometrium, the balance of VEGF and sFlt-1 expression 
in these cells is likely to be critical for a successful pregnancy.  
Various transcription factors have been reported to regulate VEGF gene transcription such 
as Sp1/3, AP-2, EGR-1, STAT3 and HIF-1a (Pages and Pouyssegur, 2005). Hypoxia is the 
major physiological regulator of VEGF expression leading to increased HIF-1a  binding to 
the VEGF promoter up-regulating VEGF mRNA expression and stabilisation (Sharkey et 
al., 2000). In the absence of pregnancy progesterone levels decline as the corpus luteum 
degenerates during the late secretory phase and menstrual phase of the cycle. This triggers 
the inflammatory response in the endometrium to initiate menstruation (Critchley et al., 
1999; Maybin and Critchley, 2009). There is an increase of endometrial prostaglandin 
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synthesis (PGE2) following progesterone withdrawal (Sugino et al., 2004), which causes 
intense vasoconstriction of endometrial spiral arterioles, subsequently leading to hypoxia 
increasing HIF-1a stabilisation (Sharkey et al., 2000; Maybin et al., 2011; Maybin et al., 
2018). This results in up-regulation of VEGF during the menstrual and early proliferative 
phases (Maybin et al., 2011; Maybin et al., 2018). However, low HIF-1a levels were 
detected during the early and mid-secretory phase (Maybin et al., 2018), which indicates 
that the up-regulation of VEGF during the secretory phase is not driven by HIF-1a.  
Progesterone was reported to directly regulate VEGF in mouse primary stromal cells via 
progesterone receptors (Kim et al., 2013). Additionally, two PREs have been identified in 
the VEGF promoter within a 1.9 kb fragment upstream of the transcription start site (Figure 
1.10) which positively regulate VEGF expression in endometrial adenocarcinoma cells 
(Mueller et al., 2003). However, my results contradict this, and progesterone alone did not 
induce VEGF in primary hESC or the St-T1b cell line even following long-term stimulation. 
 
8.1.1.1 FOXO1 and FOXO3A regulate VEGF expression in hESC 
FOXO transcription factors were found to regulate VEGF expression during hESC 
decidualisation in vitro. FOXO1 positively regulated VEGF expression, while FOXO3A 
negatively regulated VEGF expression during decidualisation. Thus, the balance of FOXO1 
and FOXO3A activity in hESC is important for appropriate VEGF expression during 
decidualisation. High progesterone levels are important for establishing the decidual 
phenotype during the secretory phase and its maintenance during pregnancy. Progesterone 
signalling is important in hESC for survival through induction, translocation and inactivation 
of FOXO1 during decidualisation (Labied et al., 2006). During decidualisation, 
progesterone levels up-regulate relaxin, prostaglandins and subsequently increase 
intracellular cAMP, activating the PKA pathway inducing the expression of FOXO1 
Chapter 8: General Discussion 
 
 233 
(Christian et al., 2002) (see Figure 1.8). Phosphorylation of FOXO proteins by Akt inhibits 
their transcriptional activity by retaining them in the cytoplasm. Since progesterone is crucial 
for FOXO1 activity, the effect of progesterone on VEGF regulation is important. Although 
progesterone did not directly affect VEGF expression and secretion in hESC, VEGF was 
strongly induced by cAMP indicating that the PKA pathway is important in regulating 
VEGF expression through FOXO1 up-regulation in hESC. This could be further explored 
through the use of PKA inhibitors or knock-down approaches. This is consistent with a 
recent RNAseq and ChIPseq study which looked at global FOXO1-dependent changes in 
hESC (Vasquez et al., 2015). VEGF is one of the 437 genes that was identified to be 
regulated by FOXO1 by RNAseq although not confirmed by qPCR or Western blotting. 
Three FOXO binding sites were identified in a 3 kb region of the VEGF promoter up-stream 
from the start site (see Figure 5.21). Of these sites, the greatest enrichment, indicating 
occupancy of FOXO1, in hESC was at the VEGF ChIP-3 site (see Figure 5.21). 
Interestingly, when we performed ChIP experiments in endothelial cells, FOXO1 bound to 
all three sites with the greatest enrichment at VEGF-ChIP-1 site (see Appendix B1). Our 
results are consistent with a recent study which showed that FOXO1 binds directly to the 
same site in the VEGF promoter in keratinocytes (Jeon et al., 2018). In addition, Kikuchi et 
al. (2012) reported that FoxO1 binds in the same region of the mouse VEGF promoter in the 
b-cells of the pancreas. 
FOXO3A bound to the same sites in the VEGF promoter as FOXO1 and the ChIP-3 site was 
also showed the greatest enrichment of FOXO3A (Figure 5.22). Karadedou et al. (2012) 
reported that FOXO3A negatively regulates VEGF expression by binding to the ChIP-M1 
FHRE site by competing with FOXM1 in the breast carcinoma cells. Interestingly, there was 
no enrichment of FOXO1 or FOXO3A at this site in hESC or the HMEC-1 microvascular 
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endothelial cell line (see Appendix B3). My findings showed that FOXO3A knock-down 
increased FOXM1 expression in hESC, and FOXM1 inhibition up-regulated FOXO3A 
expression which may subsequently decrease VEGF expression. This could be investigated 
by examining the effect of over-expression, or knock-down, of FOXM1 on VEGF and 
FOXO3A mRNA and protein expression followed by ChIP assays to determine if there is 
an enrichment of FOXM1 to the VEGF promoter in hESC. This antagonistic relationship 
between FOXO1 and FOXO3A may have implications for the level of VEGF expressed in 
the endometrium in various pathologies which are characterised by increased oxidative 
stress.  
 
8.1.2 Regulation of sFlt-1/Flt-1 expression in hESC 
The sFlt-1-e15a isoform is predominantly produced by non-endothelial cells and the 
placenta, whereas endothelial cells express sFlt-1-i13 almost exclusively (Sela et al., 2009; 
Jebbink et al., 2011). In agreement with these studies, sFlt-1-e15a was found to be the 
predominant isoform produced by decidual hESC (Appendix J). sFlt-1 secretion was 
strongly down-regulated in decidual hESC consistent with a recent study (Cottrell et al., 
2017). Interestingly, sFlt-1-i13 and sFlt-e15a mRNAs were differentially expressed during 
hESC decidualisation with sFlt-1-e15a being strongly down-regulated. However, the 
molecular steps leading to the alternative splicing of Flt-1 mRNA to produce sFlt-1 during 
decidualisation have yet to be elucidated. Therefore, it is important to research this further 
and examine the activity of factors involved in mRNA splicing such as JMJD6 in hESC 
decidualisation (Palmer et al., 2016). This could be investigated by determining changes in 
JMJD6 expression with hESC decidualisation and assessing sFlt-1 isoform expression 
following over-expression or knock-down of JMJD6 expression in these cells. 
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Flt-1 was found to be regulated by FOXO1, but not FOXO3A in hESC which is consistent 
with the study of Potente et al. (2005) performed in endothelial cells. Vasquez et al. (2015) 
also showed that Flt-1 expression is positively associated with FOXO1 activity by RNAseq 
in hESC (Vasquez et al., 2105). However, although the full-length Flt-1 receptor is 
maintained during decidualisation, the level of sFlt-1, and in particular sFlt-1-e15a, 
decreased with FOXO1 knock-down, which indicates that FOXO1 activity is also affecting 
the splicing of Flt-1 mRNA.  
Taken together, FOXO1 and FOXO3A play a key role in regulating VEGF levels in hESC. 
It will be important to confirm this activity in vivo using a selective endometrial FOXO1 
knock-out mouse model. This could be achieved by crossing the floxed FOXO1 mice 
(Tanaka et al., 2009) with a suitable Cre driver line such as progesterone receptor Cre mice 
(Hawkins et al., 2012). Similar studies could then be performed using FOXO3A floxed mice. 
In addition to changes in VEGF and sFlt-1 levels the impact of the loss of endometrial 
FOXO1 and FOXO3A could then be examined on fertility, litter size and placental and fetal 
weight. Several attempts were made to isolate ESC from the floxed FoxO mice to extend 
these studies and confirm the same pattern of regulation in the mouse. Unfortunately, once 
isolated these cells did not proliferate in culture beyond the first passage. Recent reports 
have suggested a requirement for specific culture medium supplemented with growth factors 
to maintain mouse ESC culture (De Clercq et al., 2017). In the present study, MEFs isolated 
from floxed FoxO mice were also used which were easy to isolate in large numbers and 
could be cultured for 2 to 3 passages before they started to senesce. FoxO1 was found to 
regulate both VEGF and Flt-1 in MEFs confirming the data obtained in hESC and 
underlining the broader significance of FoxO1 in regulating these genes in cells of the 
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fibroblast lineage. Similar MEF studies should be used for FOXO3A. This would then lead 
on to the examination of FOXO3A on the VEGF and sFlt-1 regulation in hESC. 
 
8.1.3 VEGF angiogenic activity in hESC secretions 
VEGF was found to be the main angiogenic factor produced by decidual hESC as the 
angiogenic activity in CM was almost completely blocked by sFlt-1 in in vitro angiogenesis 
assays. The CM of hESC following FOXO1 knock-down also showed reduced endothelial 
cell tube formation suggesting that FOXO1 up-regulation in hESC is the key factor in 
promoting their pro-angiogenic activity. Indeed, a number of angiogenic factors such as 
HGF were identified that were up-regulated in decidual hESC, and are reported to be 
associated with angiogenesis and wound repair driven by FoxO1 (Mori et al., 2014).  
 
8.1.4 VEGF and hESC function 
I have shown that the Flt-1 receptor is present on the surface of hESC and its promoter 
activity up-regulated/maintained in hESC during decidualisation. Exogenous VEGF 
stimulated intracellular signalling and migratory activity of hESC. As I could not detect 
VEGFR-2 expression in hESC, Flt-1 and NRP-1 that are present must be mediating hESC 
migration and invasion driven by VEGF and PIGF. Flt-1 has also been reported to be 
expressed in other types of fibroblast, for example, human corneal fibroblasts (Berthaut et 
al., 2009) and gingival fibroblasts (Ohshima et al., 2016). Although there are many studies 
on the activity of Flt-1 and NRP-1, there are only limited reports in the endometrium. In 
agreement with my findings, Flt-1 and NRP-1 were detected in stromal cells by 
immunohistochemistry and up-regulated during the secretory phase (Krussel et al., 1999; 
Fan et al., 2008). The PI3K/Akt and ERK1/2 signalling pathways were found to stimulated 
by VEGF and PIGF in hESC. However, their full role in hESC function and decidualisation 
remain to be determined.  
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VEGF can activate many critical signalling pathways such as ERK1/2 and Akt in endothelial 
cells (Gerber et al., 1998; Gupta et al., 1999; Dimmeler and Zeiher, 2000; Dellinger et al., 
2011), Tang et al. (2006) reported that VEGF regulates via PI3K/Akt pathway in normal 
human lung fibroblasts. In the present study, VEGF was found to activate Akt and ERK1/2 
in a time-dependent manner consistent with previous studies in many cell types, for example, 
porcine trophectoderm cells and hESC (Schwenke et al., 2013). VEGF increased 
phosphorylation of both Akt and ERK1/2 in a time-dependent manner which was blocked 
by the PI3K inhibitor (LY294002) (Jeong et al., 2014). While Schwenke et al. (2013) 
demonstrated that inhibition of PI3K/Akt pathway with Wortmannin inhibits the 
chemokinesis and chemotaxis in hESC. Many studies have demonstrated that the PI3K/Akt 
signalling pathway plays a central role in mesenchymal cell proliferation, migration, 
differentiation and angiogenesis (Chen et al., 2013). VEGF was found to regulate hESC 
migration and sprouting/invasion. However, its direct effect on hESC function and 
decidualisation remains to be determined. Therefore, it is important to selectively inhibit the 
PI3K/Akt or ERK1/2 pathway to determine which signalling pathway is involved in hESC 
migration and sprouting.  
Surprisingly, both Akt and ERK1/2 activity were found to be up-regulated in unstimulated 
hESC following Flt-1 knock-down in hESC demonstrating that activation of these signalling 
pathways is mediated by Flt-1. Moreover, Akt activity rapidly decreased after 5 min of 
VEGF treatment. ERK1/2 activity also decreased slightly after 15 min of VEGF treatment 
and this suppression was only sustained until 30 min of treatment. These results suggest that 
Flt-1 signalling may be important in hESC function. However, further studies are needed to 
determine whether Flt-1 mediates these effects on cell signalling alone or requires the 
presence of NRP-1. NRP-1 has been shown to interact with Flt-1 in mouse embryonic 
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fibroblasts (NIH3T3) (Fuh et al., 2000) leading to the possibility that NRP-1 is regulating or 
contributing to Flt-1 activity in hESC. Furthermore, Flt-1 has been proposed to act as a 
negative regulator of angiogenesis in NIH3T3 by preventing NRP-1 binding to VEGF165 
(Fuh et al., 2000). To access this, experiments should be performed examine VEGF-
mediated signalling and function in hESC following Flt-1 receptor or NRP-1 knock-down. 
 
8.2 Limitations and future directions 
8.2.1 Complexity of cellular interactions in cycling human endometrial tissue and 
models for research  
Endometrial tissue homeostasis, cellular proliferation, metabolism and reproductive 
function are mediated by the orchestrated crosstalk between these diverse cell populations 
via paracrine and endocrine pathways (Kurita et al., 1998; Chen et al., 2013; Li et al., 2005). 
Histologic analysis of the cycling endometrial microenvironment consistently reveals 
luminal and glandular epithelial cells supported by ESC, and a complex vascular bed 
composed primarily of spiral arterioles and capillaries that undergo remodelling processes 
during the menstrual cycle to provide the nutrition and oxygen to the tissue maintaining 
homeostasis (Herington et al., 2011). Although ESC represent a large component of human 
endometrium, there are epithelial cells and a dynamic flux of resident or infiltrating immune 
cells. The immune cell component of the endometrium is composed of both resident and 
recruited leukocytes that primarily include macrophages, uNK cells, T cells and neutrophils 
(Russell et al., 2011). The relative numbers of these immune cell types is hormonally 
regulated within the endometrium throughout the menstrual cycle and the withdrawal of P4 
induces a sharp increase in immune cell infiltration during menstruation (Russell et al., 
2011). The immunological axis of endometrial function plays a critical role in protecting this 
open tissue from infectious pathogens, while being permissive to the invasion of an allogenic 
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embryo. Thus, the relative somatic cell numbers, proliferative states, architectural 
complexity and immune cell ratios within the endometrium vary significantly across each 
phase of the menstrual cycle further adding another level of complexity to endometrial 
research related to health and disease. Unfortunately, much of current knowledge of the 
human endometrial microenvironment relies on histological analysis of the endometrium 
and an analytical bandwidth that limits ability to fully understand the complex multi-cellular 
interactions and intrinsic molecular signatures that are necessary to maintain reproductive 
health.  
Appropriate tissue acquisition and characterisation protocols are essential for clinical and 
basic science research settings and coupled with accurate histological examination, allows 
researchers to obtain specific cell populations for designing in vitro studies. Clinical 
endometrial research has focused almost exclusively on the histological and pathological 
analysis of biomarkers of disease from examination of ex vivo tissues (Aplin, 1989). 
Alternatively, isolated human cells can be used prospectively for in vitro culture studies. 
Several protocols to obtain primary human endometrial cells (e.g. epithelial glands and 
stroma), as well as endothelial cells, from endometrial biopsies using enzyme digestion of 
the tissue have been established. The ability to culture hESC in vitro culture has greatly 
advanced our understanding of implantation. However, the technical simplicity of current 
cell culture models often fails to recapitulate the complex tissue microenvironment to which 
cells are exposed in vivo. The intra-patient variability between tissue samples has hindered 
the reproducibility of many studies and therefore investigations are often limited to single 
cell type in vitro studies, typically focusing on either the biology of epithelial cells or stromal 
fibroblasts, and to a much lesser extent the vascular and immune components (Albrecht, 
2003; Sha et al., 2007). Specifically, current models fail to mimic fully the physiological 
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changes that occur within the endometrium within a typical 28-day menstrual cycle in 
response to endocrine signals and the complex inter-cellular communication that regulate 
endometrial function. These experimental constraints have limited our understanding of the 
cellular and molecular mechanisms that drive reproductive function.  
Due to ethical considerations and the complexity of interspecies in vivo studies, experiments 
with endometrial implants and explants or in vitro culture of isolated ESC would be 
preferable. The most informative experimental set up, in my opinion, would involve human 
and mouse ESC, which should identify any interspecies variability and provide 
complimentary results. Future studies would aim to validate the findings of this thesis in 
hESC decidualisation in vitro using mouse decidualisation models. Mouse models have been 
widely utilised to investigate the process of decidualisation in vivo. However, the 
reproductive cycles of non-human mammals vary widely, particularly in the murine species 
which do not have a menstrual cycle, but rather an oestrous cycle (Ramathal et al., 2010). 
This issue with rodent models is a point of concern because they are the most widely used 
as in vivo models throughout drug development and toxicology. One of the reasons why 
human menstruation is not fully understood is the fact that this process has proved difficult 
to model experimentally. Menstruation only occurs in a few species including old world 
monkeys, apes and, of course, humans (Cameron et al., 1998). The most similar in vivo 
model to human endometrium is currently the macaque, but high costs, low throughput and 
ethical issues have limited the use of these animals for advancing reproductive biology 
(Greaves et al., 2017). In contrast, the relative low cost, easy maintenance and utility of 
murine models has been essential to the growth of biomedical research. Although mice do 
not menstruate and are not susceptible to endometrial conditions like endometriosis, the 
regulation of uterine function essentially mirrors that in women with cell proliferation during 
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an E2-dominated phase (proestrous) and functional maturation during a P4-dominated phase 
leading to development of a “window of uterine receptivity” stimulated by the action of E2 
on the P4 primed uterus (Paria et al., 2002; Bruner-Tran et al., 2018). To accomplish murine 
to human translation it is critically important to replicate and validate murine findings using 
murine models which better recapitulate the human condition in vivo. The development of 
humanized murine models or robust in vitro human models may each provide an alternative 
to overcome the issues discussed above. The ease of genetic manipulation in the mouse and 
commercial availability of genetically engineered murine models provides a clear advantage 
for in vivo research. Specifically, the grafting of human tissues or cells in immunodeficient 
mice and the ability to selectively control sex steroids provides suitable in vivo models for 
studying human endometrial processes.  
 
8.2.2 Further investigation of the regulation of VEGF and implications for endometrial 
and pregnancy-related disorders 
Total VEGF mRNA expression and protein secretion was observed in this thesis. The pattern 
of total VEGF mRNA expression differed from that of VEGF protein secretion in hESC 
under some conditions. This may be a result of alternative VEGF isoform expression. For 
example, if relative VEGF121 and VEGF165 mRNA increased and VEGF189 mRNA 
decreased, this may result in no significant overall change in total VEGF mRNA levels, but 
increased VEGF protein secretion may be detected by ELISA due to the relative increase in 
soluble isoforms which the ELISA assay detects in cell supernatants and a decrease in the 
largely cell/ECM associated VEGF189. Moreover, the primers for total VEGF will detect the 
inhibitory VEGFxxxb isoforms (Gu et al., 2013) as well as the more common active 
VEGFxxxa isoforms. Therefore, if VEGFxxxa mRNA increased and VEGFxxxb mRNA 
decreased, no overall change in total VEGF mRNA and protein secretion would be observed, 
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although there may be greater overall VEGF activity. Therefore, to further our understanding 
of VEGF expression in ESC, VEGF isoform-specific changes should be investigated using 
real-time qPCR as previously published (Walter et al., 2010) and isoform specific ELISAs. 
Furthermore, ELISA assays were used to detect the VEGF, or sFlt-1 protein released into 
culture supernatants. Therefore, if VEGF121 and VEGF165 are bound to Flt-1 on ESC, or sFlt-
1 in solution, then the levels of VEGF detected would be lower than the total amount 
produced by the cells. To overcome this issue and gain a better understanding of total VEGF 
levels and isoforms present in the ESC during decidualisation, Western blotting using 
antibodies that detect all VEGF protein isoforms, as well as antibodies selective for each 
isoform should also be performed. 
In the current study, it was also demonstrated that FOXO1 and FOXO3A differentially 
regulate VEGF in hESC. Further confirmation of the regulation of VEGF on the ESC using 
rodent models complemented by studies on human samples could shed light on the 
mechanisms underlying their effects on decidualisation, infertility and pathologies such as 
endometriosis and preeclampsia. The first step would involve murine models of 
decidualisation to determine the pattern of expression of FoxO1, Vegf and Flt-1 in wild-type 
mice. The use of uterine-specific mouse CRE lines, such as the P4 Cre line (Hawkins et al., 
2012), to target and ablate the FoxO1 and/or FoxO3a genes in the endometrium would be 
required to fully elucidate the interplay of FoxO1 and FoxO3a in decidualisation in vivo. 
These models also can be used to determine the relationship of FoxO1 and FoxO3A, and its 
expression in VEGF and Flt-1 regulation in suitable models of pathology such as 
endometriosis, or the restricted uterine perfusion model of preeclampsia (Fushima et al., 
2016). 
Chapter 8: General Discussion 
 
 243 
The complex nature of infertility and pregnancy related complications (preeclampsia, IUGR, 
miscarriage)-associated infertility has been the focus of study for many years. For examples, 
treatments for the chronic pain suffered by women with endometriosis, such as progesterone 
analogues, may result in menstruation cessation and a contraceptive effect which will not be 
desirable for all women. As discussed earlier in Chapter 1, several reports have demonstrated 
a decreased of FOXO1, HOXA10 and VEGF expression during ESC decidualisation in 
women with infertility problems. VEGF is crucial for vascular remodelling in the 
endometrium and perturbation of VEGF activity can lead to infertility, recurrent miscarriage 
and preeclampsia (Maynard et al., 2003; Jakovljevic et al., 2016). While the level of sFlt-1 
was found to increase in preeclampsia and recurrent miscarriage (Jakovljevic et al., 2016). 
In this thesis, VEGF levels were found to increase during hESC decidualisation and 
concomitant decrease in sFlt-1 secretion. Therefore, it is important to understand the 
relationship between VEGF and sFlt-1 levels in the patients with disorders related to 
decidualisation impairment for example endometriosis, preeclampsia, recurrent miscarriage 
and IUGR which may help in the identification of novel therapeutics for the concomitant 
treatment of pain and infertility associated with this disorder. Therefore, a full understanding 
of the specific roles of this transcription factors and during ESC decidualisation would allow 
a better understanding of cellular cross-talk and the control of functional processes in 
reproductive function in health and disease and may provide a basis for the development of 
new treatment modalities.  
 
8.3 Conclusion 
The findings in this thesis contribute to our understanding of the mechanisms underlying the 
up-regulation of VEGF activity during hESC decidualisation. Importantly, they identify the 
significance of FOXO1 in driving VEGF expression and the concomitant decrease in sFlt-1 
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expression in hESC decidualisation, therefore, leading to a net increase in VEGF activity. It 
also identifies for the first time the antagonistic relationship of FOXO1 and FOXO3A in 
regulating VEGF expression during hESC decidualisation (Figure 8.1).  
 
 



















Appendix A: Plasmid transfection in St-T1b cells 
The hESC were found to be difficult to transfect limiting the approaches that could be used 
to determine the signalling pathways and transcriptional regulation leading to increased 
VEGF expression upon decidualisation. Various transfection reagents were tested to try to 
improve the transfection efficiency of the hESC (Table I). The St-T1b cell line was seeded 
on 12-well plates following manufacturer’s guidelines and pcDNA3-EGFP plasmid (1 
µg/well) was used to transfect cells in order to determine the transfection efficiency by 
counting GFP positive cells and the total number of cells following Hoescht 33342 nuclear 
counterstaining. Various transfection reagents and conditions were used, and TransIT-2020 
reagent was found to give the highest transfection efficiency (~24%) in the St-T1b cells 






DNA (µg): Reagent (µl) Percentage (%) 
LIPOFECTAMINE® 2000 
(INVITROGEN) 
1: 3 ~ 1% 
1:5 ~ 1% 
JETPRIME (POLYPLUS) 1:2 ~ 8% 
1:3 ~ 1% 
K2 (BIONTEX) 1:3 ~2% 
1:4 ~1.5% 




TRANSIT-X2 (GENEFLOW) 1:2 ~6% 
1:3 ~11% 













































































   








   






Figure I: Transfection of the St-T1b with GFP plasmids usin  various reagents. Cells 
were transfected with pcDNA3-EGFP (green) using TransIT-2020, TransIT-X2 and Viromer Blue, 
counterstained with Hoescht 33442 (blue) and the images taken of five random fields with a 




Appendix B: ChIP 









Figure II: FOXO1 binds directly to VEGF promoter in HMEC-1.  ChIP assays were 
performed in HMEC-1 and immunoprecipitated with anti-FOXO1 or control IgG antibodies. The 
% Input was used to determine the enrichment of VEGF binding. The fold enrichment of FOXO1 
binding to the VEGF (A) ChIP-1, (B) ChIP-2, (C) ChIP-3, and (D) ChIP-4 sites to the NegC 
regions was determined by real-time qPCR. Results are the mean (+/- SEM) of two independent 
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Figure III: FOXO1 binding sites identified by ChIP analysis in the human VEGF 
promoter in HMEC-1. Graph showing the degree of enrichment of FOXO1 binding 
normalised to input DNA and NegC regions in HMEC-1. 
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Figure IV: FOXO1 binds directly to IGFBP-1 promoter in hESC. (A) Schematic 
representative of IGFBP-1 promoter containing three FOXO1 binding sites. ChIP assays were 
performed in St-T1b cells with anti-FOXO1, anti-FOXO3A, or control IgG antibodies to 
determine binding to FHRE in the IGFBP-1 promoter region. (B) The % Input was used to 
determine the enrichment of IGFBP-1 binding. The fold enrichment of IGFBP-1 binding 
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Figure V: FOXO1 binds directly to HBP-1 promoter in HMEC-1.  ChIP assays 
were performed in HMEC-1 cells and immunoprecipitated with anti-FOXO1, or control IgG 
antibodies and Pol II antibodies as positive control to determine the enrichment of binding to 
the HBP-1 and VEGF promoter region. The % Input was used to determine the enrichment of 
FOXO1 or Pol II binding to (A) HBP-1 and (B) VEGF-FOXM1 binding normalised to NegC 








Figure VI: FOXO1 binds directly to Flt-1 promoter in HMEC-1. ChIP assays were 
performed in HMEC-1 and immunoprecipitated with anti-FOXO1, or control IgG antibodies. The 
% Input was used to determine the fold enrichment of FOXO1 binding to the Flt-1 (A) ChIP-1, 
(B) ChIP-2, and (C) ChIP-3 sites relative to the NegC regions determined by real-time qPCR. 



















































































































































































Figure VII: FOXO1 binding sites identified by ChIP analysis in human Flt-1 
promoter in HMEC-1. Graph showing the degree of enrichment of FOXO1 binding 
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Figure VIII: Formation of spheroid from different cell types.  Spheroids were formed 
using HUVEC and/or St-T1b cells (5,000 cells/spheroid) overnight and embedded into the growth 
factor-reduced Matrigel in DMEM/F12 medium consisting of 2% FBS and 50 ng/ml VEGF 24 h. 




































Figure IX: Decreased VEGF detection in hESC conditioned medium (CM) 
following incubation with recombinant sFlt-1. Proliferative hESC CM or decidualised 
hESC CM were incubated with relatively high levels of recombinant sFlt-1 for 1 h at room 
temperature and VEGF levels assessed by ELISA.  




















Figure XI: Time course of FOXO3A siRNA knock-down in St-T1b cells.  St-T1b 
cells were plated on 6-well plates and transfected with siRNA targeting FOXO3A (siFOXO3A) 
or control (siControl). The cell lysate was harvested every 24 h up to 4 days and relative FOXO3A 

































































































Figure XII: VEGF knock-down decreases sFlt-1 and FOXO1 expression in 
decidual hESC.  St-T1b cells were plated on 6-well plates and transfected with siRNA targeting 
VEGF (siVEGF) or control (siControl) overnight and stimulated with E2 or MM1 medium for 24 
h. Real-time qPCR analysis of (A) VEGF, (B) sFlt-1-e15a, (C) sFlt-1-i13 and (D) FOXO1 mRNA 
expression normalised to  b-actin. (E) VEGF and (F) sFlt-1 protein levels in the supernatant were 















































Appendix G: Effect of H2O2 on FOXO1/O3A and VEGF expression in hESC 
FOXO1 and FOXO3A expression was found to increase dramatically in St-T1b cells treated with H2O2 during 
decidual conditions. Therefore, the effect of H2O2 on VEGF expression was determined in the St-T1b cells 
under proliferative and decidual conditions. The cells were grown to confluence and incubated with E2 or 
MM1 medium for 24 h before treatment with 200 µM H2O2 for a further 24 h. Figure XIII shows that there 
was a significant increase of VEGF protein secretion in both proliferative and decidual cells. VEGF secretion 
in proliferative cells stimulated with H2O2 was significantly greater than decidualised cells treated with H2O2.  
 
 
Appendix H: Changes in signalling activity in hESC decidualisation 
The pAktS473 was reported to be reduced in decidualised hESC compared to control cells (Yoshino 
et al., 2003) as my results confirmed in Section 4.3.6. Therefore, I wanted to determine changes in 
other cell signalling pathways involved in hESC decidualisation. Confluent St-T1b cells were treated 
with DMEM/F12 containing 2% FBS for 24 h followed by 6 h of stimulation with E2 or MM1, 
medium. The cell lysates were harvested to test on a human phospho-kinase arrays as described in 
Section 2.11.2. However, there were no significant changes in target protein phosphorylation 





















Figure XIII: Effect of H2O2 on VEGF secretion in hESC during 
decidualisation. St-T1b cells were plated in 6-well plates overnight and incubated with E2 
and MM1 medium for 24 h followed by 24 h. Supernatants were collected after 24 h exposure to 
200 µM H2O2. VEGF protein levels in the supernatant were assessed by ELISA. Results are the 





Target Phosphorylation site St-T1b 
Proliferative Decidualised 
p38a T180/Y182 0.51 0.33 
ERK1/2 T202/Y204, T185/Y187 0.72 0.45 
JNK1/2/3 T183/Y185, T221/Y223 0.60 0.60 
GSK-3a/b S21/S9 0.65 0.67 
EGF R Y1086 0.53 0.44 
MSK1/2 S376/S360 0.70 0.53 
AMPKa1 T183 0.58 0.54 
Akt 1/2/3 S473 0.38 0.41 
TOR S2448 0.42 0.37 
CREB S133 0.54 0.55 
HSP27 S78/S82 0.51 0.42 
AMPKa2 T172 0.77 0.72 
b-Catenin - 0.75 0.41 
Src Y419 0.62 0.53 
Lyn Y397 0.55 0.43 
Lck Y394 0.27 0.17 
STAT2 Y689 0.93 0.89 
STAT5a Y694 0.36 0.34 
Fyn Y420 0.43 0.33 
Yes Y426 0.68 0.64 
Fgr Y412 0.25 0.22 
STAT6 Y641 0.84 0.71 
STAT5b Y699 0.47 0.44 
Hck Y411 0.51 0.48 
Chk-2 T68 0.67 0.57 
FAK Y397 0.73 0.68 
PDGFRb Y751 0.70 0.55 
STAT5a/b Y694/Y699 0.63 0.59 
PRAS40 T246 0.92 0.87 
P53 S392 0.14 0.19 
Akt 1/2/3 T308 0.31 0.25 
P53 S46 0.26 0.27 
P70 S6 kinase T389 0.11 0.05 
P53 S15 0.08 0.03 
c-Jun S63 0.40 0.28 
P70 S6 
Kinase 
T421/S424 0.22 0.17 
RSK1/2/3 S380/S386/S377 0.16 0.10 
eNOS S1177 0.10 0.01 
STAT3 Y705 0.24 0.14 
P27 T198 0.03 0.00 
PLC-g1 Y783 0.13 0.05 
STAT3 S727 0.12 0.05 
WNK1 T60 0.57 0.43 
PYK2 Y402 0.16 0.05 




Table II: List of human phosphor-kinase that expressed in St-T1b cells during decidualisation. 
Signal densities were quantified using ImageJ software after exposure to film. Integrated densities 





































































Figure XIV: Changes in cell signalling protein phosphokinase activity during 
decidualisation in St-T1b cells.  St-T1b cells (2.4 x106) were plated on 10 cm Æ tissue culture 
dishes for 24 h. The cells were then treated with (A) 2% FBS medium or (B) MM1 medium for 6 
h and the cell lysate was harvested and run on phospho-kinase protein arrays. The density was 
measured by densitometry using Image J and the results were normalised to positive control spots 
after the background was substracted. (C) Graph showing the results of target kinases that have 
been indicated with the numbered boxes on the membrane decidualisation. Results are the mean 


























































Figure XV: MPA does not affect the FOXO expression in decidual hESC.  St-T1b 
cells were plated on 6-well plates overnight and stimulated with E2 or MM1 medium with only 
0.5 mM 8-Br-cAMP up to 6 days. Real-time qPCR analysis of (A) FOXO1, (B) FOXO3A, and 
(C) PLZF mRNA expression normalised to  b-actin. Results are the mean (+/- SEM) of 3 










































































Figure XVI: sFlt-1-e15a is the predominant isoform expressed in decidual hESC. 
Percentage of sFlt-1-e15a and sFlt-1-i13 isoforms expression in (A) primary hESC and (B) St-T1b 
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